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I  |  Introduction
BLADDER CANCER
Bladder cancer (BC) is the most common malignancy of the urinary tract. A total of 
382,700 new BC cases and 150,300 cancer deaths were estimated to have occurred 
worldwide in 2008 (1). The incidence rises with age and peaks between 50 and 70 
years. The majority of BC occur in men (4:1) (2). However, the incidence of bladder 
cancer is rising in Dutch women (1). Most important risk factor is smoking, accounting 
for approximately 50% of the cases (3-5). Other important risk factors are chemical and 
environmental exposures such as aromatic amines (e.g. paint), and chronic irritation 
(4, 6). 
In the Western world more than 90% of BC is urothelial carcinomas, or transitional cell 
carcinoma. The remainder are squamous cell carcinomas (5%) and adenocarcinomas 
(<2%) (7). Since 2004 the histopathological grading of papillary urothelial carcinomas 
of the bladder is classified into three groups: papillary urothelial neoplasm of low 
malignant potential, low grade papillary urothelial carcinoma, and high grade papillary 
urothelial carcinoma (8). For staging the TNM-classification is used (Figure 1) (9). 
On average, 75% of BC presents as non-muscle-invasive disease (NMIBC) and 
the remainder as muscle-invasive disease. Among the NMIBC approximately 70% 
present as Ta-lesions (non-invasive papillary carcinoma), 20% as T1-lesions (invasion in 
subepithelial connective tissue), and 10% as carcinoma in situ (CIS, or Tis lesions; ‘high 
grade non-invasive flat tumor’) (11, 12). 
Figure 1  Bladder cancer staging. Source: (10)
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Most patients present with painless hematuria. NMIBC rarely present with irritative 
voiding symptoms. If so, CIS may be suspected (7). The diagnosis of BC mainly 
depends on cystoscopic examination of the bladder, urinary cytology and histology. 
Although urinary cytology has a high specificity, sensitivity is low especially in low 
grade tumor (12-14). Therefore, negative results cannot exclude the presence of a low 
grade tumor. Several BC-markers have been investigated as a screening tool for low-
grade tumors (12-15). Most of these markers have a better sensitivity for detecting 
BC than cytology, but have lower specificity. Moreover, the additional costs should be 
considered. Therefore, the use of urinary markers is not recommended for detection 
(12). 
RISK MANAGEMENT OF NMIBC
As mentioned above, smoking is a risk factor for the occurrence of bladder cancer. 
Smokers have an overall two- to fourfold increased risk of developing bladder cancer, 
and approximately 60% of all bladder cancer is the result of smoking (5). Therefore, we 
hypothesized that there might be a correlation between smoking and clinical outcome 
concerning recurrence and progression. And thus, we investigated the role of smoking 
status on the prognosis of NMIBC in a large group of patient. The results of this 
prospective study are being discussed in Chapter II.1 Smoking status is a risk factor 
for recurrence after transurethral resection of non–muscle-invasive bladder cancer. 
NMIBC presents itself in different ways: from low grade Ta-tumors with low chances 
of progression but high changes of recurrences, to high grade tumors with high 
malignant potential. The European Organization for Research and Treatment of 
Cancer trials (EORTC) has provided risk tables to calculate the short-term (1 year) and 
long-term (5 year) risks of recurrence and progression after transurethral resection, and 
has identified factors that predict the outcome. The most important prognostic factors 
for recurrence are the numbers of tumors, their size and the prior recurrence rate; the 
most important factors for progression are the T-category, grade and the presence 
of CIS (16). These prognostic factors have been used by the European Association of 
Urology (EAU) to divide NMIBC into low-, intermediate- and high-risk groups, based 
on which subsequent adjuvant therapy can be chosen (Table 1) (12). 
Another well-known scoring model was developed by Fernandez et al. to predict 
outcome after treatment specifically with BCG (17). The Club Urológico Español de 
Tratamiento Oncologico (CUETO) categorized 1062 patients into four groups and 
calculated 1-, 2- and 5- year recurrence and progression probabilities for each group. 
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An overview of the development of the EORTC risk tables and other prognostic models 
for NMIBC, including the CUETO scoring model, are being discussed in Chapter II.2 
NMIBC risk calculators: how useful are they for the practicing urologist and how 
can their clinical utility be improved? In this chapter we also discuss the problems 
clinicians encounter when using prognostics models and our opinion how to improve 
the use of prognostic models.
Treatment for low- and high risk NMIBC is extensively investigated and treatment 
advises in the guideline are clear (12). However, treatment for intermediate risk 
patients is more complex due to the heterogeneity of this group of patients, which 
is also reflected in the definition of intermediate risk patients (Table 1). In order to 
improve treatment and thus outcome in these patients, we developed a prediction 
model on recurrence outcome for patients with intermediate risk treated specifically 
with intravesical chemotherapy, including an external validation with data from the 
Fundació Puigvert institute in Barcelona, Spain. Results are presented in Chapter 
II.3 Prediction model for recurrence probabilities after intravesical chemotherapy 
in patients with intermediate-risk non-muscle-invasive bladder cancer, including 
external validation. 
Table 1  Risk group stratification according to EAU guideline 2013 (12)
Risk group Definition
Low risk tumors Primary, solitary, Ta, LG/G1, <3 cm, no CIS
Intermediate risk tumors All tumors not defined in the two adjacent categories 
(between the category of low and high risk)
High risk tumors Any of the following: 
T1 tumor 
HG/G3 tumor 
CIS  
Multiple and recurrent and large (>3 cm) Ta, G1/G2 tumors 
(all conditions must be presented in this point)
CIS = carcinoma in situ; HG = high grade; LG = low grade.
13
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TREATMENT OF NMIBC
After a bladder tumor is detected, the diagnosis and clinical stage is established by 
a complete transurethral resection of the bladder tumor (TURBT). Several techniques 
are currently available to improve the quality of the TURBT. Especially photodynamic 
diagnosis or fluorescence cystoscopy using violet light after intravesical instillation of 
5-aminolaevulinic acid or hexaminolaevulinic acid has proven to be of additional value, 
and is now recommended to be used in patients suspected of having a high grade / 
G3 tumor (12). 
After a complete TURBT, further treatment depends on the risk group of the patient. 
Treatment advises are provided by the EAU (12). Patients with low- or intermediate 
risk should receive an immediate, single, post-operative installation of chemotherapy, 
because it can reduce the risk for recurrence in the first few years by about 12%. Number 
needed to treat to prevent one recurrence is approximately 8.5 (18). In patients with 
low risk a single post-operative instillation of chemotherapy may be considered a 
sufficient treatment. Patients in the intermediate risk group should receive additional 
intravesical therapy with either mitomycin C (MMC) or with Bacillus Calmette-Guerin 
(BCG) for at least one year. High risk patients should, first of all, receive a re-TURBT 
as the tumor is often understaged. Re-TURBT should also be performed in patients in 
which the initial TURBT is incomplete or if there is no detrusor muscle in the specimen 
(with exception of Ta G1/low grade tumors and primary CIS). Further treatment for 
high risk patients is full dose intravesical BCG for 1-3 years. An immediate cystectomy 
can also be considered. 
In the United States the American Urological Association (AUA) have their own 
guideline (19), in which patients are characterized in ‘index patients’. Each guideline 
statement addresses a specific index patient. Most important differences are the use 
of a single postoperative instillation of chemotherapy (“may be administrated”), the 
less important role of intravesical chemotherapy, and cystectomy has a more important 
role.
As mentioned earlier, several risk models and guidelines are commonly used to 
predict outcome for NMIBC after treatment, and when comparing the AUA guideline 
to the EAU guideline one can find many differences. We compared the predicted 
recurrence and progression outcomes according to the AUA, EAU, EORTC and 
CUETO classification with the real outcomes of a cohort of patients in the Netherlands. 
Furthermore, we investigated if patients who were undertreated according to these 
risk models did have worse outcomes than adequately treated patients. Results are 
presented in Chapter III.1 Comparison of expected treatment outcomes, obtained 
14
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using risk models and international guidelines, with observed treatment outcomes 
in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with 
intravesical chemotherapy. 
Recurrences occur often and patients do experience side-effects of intravesical 
treatment. Therefore, a quest for new therapies remains. One of the products registered 
for the use of preventing NMIBC recurrences is keyhole limpet hemocyanin (KLH). 
KLH is a protein found in the hemolymph of the sea mollusk Megathura crenulata, 
where it acts as a non-specific immune response modifier that induces both a cell-
mediated and a humoral response (20). Several small studies suggested a possible 
advantage of KLH over currently used treatments and showed that the use of KLH is 
safe (21-24), but results of phase 3 studies confirming its efficacy were not available. 
Therefore, we conducted a multicenter, prospective randomized phase 3 trial in which 
MMC was compared with KLH. This study is described in Chapter III.2 Intracutaneous 
and intravesical immunotherapy with keyhole limpet hemocyanin compared with 
intravesical mitomycin in patients with non–muscle-invasive bladder cancer: results 
from a prospective randomized phase III trial. 
Besides developing new drugs, another possibility would be to adapt existing drugs 
and treatments. A method to amplify the efficacy of intravesical treatment is to 
increase the uptake of the therapeutic agent. One of the options is to use intravesical 
microwave induced chemohyperthermia (CHT), also known as Synergo®. Hyperthermia 
is generated via direct irradiation with an intravesical microwave applicator. During the 
last 15 years CHT has been tested in different (clinical) settings. A critical overview of 
the current literature concerning the role of CHT for the treatment of NMIBC, including 
meta-analyses, is presented in Chapter III.3 The role of a combined regimen with 
intravesical chemotherapy and hyperthermia in the management of non-muscle-
invasive bladder cancer: a systematic review.
In general, this thesis discusses some of the difficulties we have encountered in the 
risk management and treatment of NMIBC. However, there are still areas that need 
further research, and new treatments to be discovered. This is described in Chapter 
IV.1 Discussion and future perspectives. Finally, a summary of this thesis is presented 
in English and in Dutch, in Chapter IV.2 and Chapter IV.3, respectively. 
15
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Chapter II.1 
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for recurrence after transurethral 
resection of non-muscle-invasive 
bladder cancer
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ABSTRACT
Background
Cigarette smoking is the most well-established risk factor for developing bladder 
cancer.
Objective
To investigate the role of smoking status on the clinical outcome of patients with non-
muscle-invasive bladder cancer. 
Design, setting and participants
Data obtained during a prospective phase 3 study with three schedules of epirubicin 
were used for statistical analysis. Smoking status (obtained when entering the study), 
other prognostic variables and clinical outcome measures of 718 patients were analyzed. 
Mean follow-up was 2.5 years.
Measurements
The primary outcome measure was recurrence-free survival (RFS). 
Results and limitations
Demographics were similar for nonsmokers versus ex-smokers and current smokers, 
except for gender (p<0.001) and grade (p=0.022). In univariate analyses, RFS was 
significantly shorter in male patients (p=0.020), in patients with a history of recurrences 
(p<0.003), in patients with multiple tumors (p<0.004), in patients with a history of 
intravesical therapy (p=0.037), and in ex-smokers and current smokers (p=0.005). In 
multivariate analyses, a history of recurrences, multiplicity, and smoking status remained 
significant factors for predicting RFS. Gender and initial therapy were no longer a 
significant influence on RFS. 
Because progression was uncommon (n=25), follow-up was short and focused only on 
recurrences, no conclusion can be drawn on progression-free survival. A limitation of 
the study were the questionnaires. They were only used when entering the study, and 
there were no questions about passive smoking and other causal factors. 
Conclusions
In this prospective study, the significance of known factors (history of recurrences and 
number of tumors) in predicting RFS was confirmed. Another significant factor that 
appears to predict RFS is smoking status: ex-smokers and current smokers had a 
significant shorter RFS compared to nonsmokers. 
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INTRODUCTION
Bladder cancer is the 7th most common malignancy in men and the 17th in women 
worldwide (1). On average, 70% of bladder cancer present as non-muscle-invasive 
bladder cancer (NMIBC) and the remainder as muscle-invasive disease (2, 3). NMIBC 
runs the spectrum from low-grade Ta tumors with low risk of progression and high risk of 
recurrences to high-grade tumors with high malignant potential. Adjuvant intravesical 
instillations are standard treatment because they reduce the risk of recurrence (3, 4). 
The choice of adjuvant treatment depends on the chance of recurrences based on the 
European Organization for Research and Treatment of Cancer (EORTC) risk tables (5). 
Cigarette smoking is the most well-established risk factor for bladder cancer: smokers 
have an overall two- to fourfold increased risk of developing bladder cancer. An 
estimated 60% of all bladder cancers result from smoking (6). 
Because smoking has a well-known causal association with bladder cancer, one could 
hypothesize that there is also a relationship between smoking status and clinical 
prognosis concerning the chances of recurrence and progression. There are only a few 
studies on smoking and the prognosis of bladder cancer (7-9). Most evidence is weak 
because of the low number of patients. 
We investigated the role of smoking status on the prognosis of NMIBC in a large group 
of patients treated with three intravesical instillation schedules with epirubicin.
MATERIALS AND METHODS 
Data obtained during a multicenter prospective randomized phase 3 trial were used 
for these analyses. Ethical committees of all participating hospitals had approved the 
study protocol (10). 
Patient selection
Patients < 85 yr of age with a histological proven solitary pT1 tumor or multiple 
primary or recurrent Ta/1 G1-3 urothelial carcinoma (UC) of the bladder, in whom 
complete transurethral resection was possible, were considered eligible. Patients with 
pathologically confirmed primary solitary Ta tumors, carcinoma in situ (CIS), or tumors 
≥T2 were excluded. Other exclusion criteria were concurrent malignancy (except basal 
cell carcinoma or squamous cell carcinoma of the skin); history of another malignancy 
with a disease-free interval <5 yr; expected poor compliance; World Health Organization 
(WHO) performance status >2; uncontrollable urinary tract infection; any previous 
systemic cancer therapy or radiotherapy; localization of UC in prostatic urethra or upper 
24
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urinary tract; pregnancy, lactation or women of reproductive age who refuse to take 
adequate contraceptive measures; congenital or acquired immunodeficiency; known 
hypersensitivity to anthracycline; or simultaneous treatment with an investigational 
drug.
All patients underwent complete transurethral resection of the bladder tumor 
(TURBT). Afterwards they were randomized in a trial comparing three schedules of 
adjuvant intravesical epirubicin (either standard schedule with 4 weekly and 5 monthly 
instillations, or standard schedule plus an additional instillation within 48 h after TURBT, 
or standard schedule plus additional instillations at 9 and 12 mo). Hendricksen et al. (10) 
published the results. 
Objectives and statistical analysis
The database of the epirubicin trial was used to investigate a possible relationship 
between smoking status and the development of recurrences and progression. The 
physicians of patients who were randomized in this clinical trial were asked to answer 
a set of questions in which the smoking status of their patients was qualified and 
quantified (Appendix A). The primary outcome measure was recurrence-free survival 
(RFS). Recurrences were defined as recurrence during treatment period, recurrence after 
treatment period, and occurrence of CIS. Demographics were compared for smoking 
status. Then we performed a univariate log-rank analysis for RFS for the variables gender, 
age, tumor stage, tumor grade, primary or recurrent disease, number of tumors, tumor 
size, initial therapy and smoking status (pipe/cigar, number of cigarettes per day, age 
when started smoking, number of years smoking, pack years and years since quitting). 
Pack years was defined as number of cigarettes per year multiplied by number of 
years smoked. Both the EORTC (5) and the Club Urológico Español de Tratamiento 
Oncológico (CUETO) risk tables (11) are commonly used. Therefore, both definitions 
of prognostic factors were used in the analyses. For those variables which were found 
to be statistically significant, we performed a multivariate analysis with Cox regression 
and hazard ratios (HR) with their 95% confidence interval (CI) for RFS. Statistical analyses 
were done in SPSS v.16.0.01 (SPSS Inc. IBM Corp, Somers, NY, USA).
RESULTS
Cohort selection
Between April 1998 and April 2004, 1000 patients were randomized. Only patients for 
whom the questionnaire on smoking status was filled out were included in the analyses. 
Of all 718 patients suitable for analyses, 577 were male and 141 were female. Patients 
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were divided into two groups: those who never smoked (nonsmokers; n=121; 16.9%), 
versus those who used to smoke but stopped smoking prior to entering the study (ex-
smokers; n=359; 50%) and patients who still smoked when entering the study (current 
smokers; n=238; 33.1%). 
Demographics
Table 1 lists the baseline patient and tumor characteristics stratified by smoking 
status. There were no significant differences in baseline characteristics between ex-
smokers and current smokers versus nonsmokers, except for tumor grade and gender: 
nonsmokers had more high-grade (G2 or G3) tumors compared with ex-smokers and 
current smokers (p=0.022), and there were significantly more male ex-smokers and 
current smokers (p<0.001). Combining ex-smokers and current smokers did not change 
baseline characteristics.
Disease outcome
After a mean follow-up of 2.5 years (range: 0-6.3 yr), 284 recurrences were found 
(39.6%). Mean time to recurrence was 19.7 mo (median: 16.2 mo). A total of 32.7% of 
all recurrences occurred in the first year of follow-up. Table 2 shows the factors which 
significantly influenced RFS in the univariate analysis: male gender, history of intravesical 
therapy, and (history of) smoking (p=0.020, p=0.037, and p=0.005, respectively). 
Figure 1 shows the influence of smoking on RFS. Also a history of recurrences and 
number of tumors according to the definitions of both EORTC and CUETO were of 
significant influence on RFS (Table 2). The number of pack-years ≥35 almost significantly 
influenced RFS (p=0.057). None of the other factors influenced RFS significantly. 
A multivariate analysis was done for the factors which significantly influenced RFS in 
the univariate analyses. Results are indicated in Table 3, using the definitions according 
to the EORTC and the CUETO risk tables. In both analyses, history of recurrence and 
multiple tumors were associated with a significant shorter RFS (p<0.05). Also ex-smokers 
and current smokers had significant shorter RFS: with EORTC factors, smoking status 
had a HR of 1.47 (95% CI 1.00-2.15; p=0.048); with CUETO factors, smoking status had 
a HR of 1.57 (95% CI 1.06-2.31; p=0.022). Gender and initial therapy in both multivariate 
analyses were no longer of statistically significant influence on RFS. No significant 
differences were found between prognostic risk factors as defined by EORTC and 
CUETO. 
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Table 1  Demographic data of patients with non-muscle-invasive bladder cancer compared for 
smoking status (ex-smokers and current smokers versus nonsmokers)
Current and 
ex-smokers 
(%)
Nonsmokers 
(%)
P-value
No. of patients 597 121 N.A.
Gender
Male
Female
511 (85.6)
86 (14.4)
66 (54.5)
55 (45.5)
<0.001
Age, yr, mean ± SD 66.6 ± 9.8 66.2 ± 11.5 0.705
Primary tumor according to definition of EORTC
Yes
No, ≤1 recurrence / yr
No >1 recurrence / yr
284 (47.6)
114 (19.1)
199 (33.3)
65 (53.7)
23 (19.0)
33 (27.3)
0.169
Primary tumor according to definition of CUETO
Yes
No
284 (47.8)
313 (52.4)
65 (53.7)
56 (46.3)
0.217
Stage
Ta
T1 
470 (78.7)
127 (21.3)
95 (78.5)
26 (21.5)
0.958
Grade
1
2
3
Unknown
263 (44.1)
268 (44.9)
64 (10.7)
2 (0.3)
37 (30.6)
67 (55.4)
14 (11.6)
3 (2.5)
0.022
Tumor size
<3 cm
≥3 cm
Unknown
383 (64.2)
86 (14.4)
128 (21.4)
65 (53.7)
23 (19.0)
33 (27.2)
0.091
Number of tumors according to definition of EORTC
Single
2-7
8 or more
117 (19.6)
432 (72.4)
48 (8.0)
26 (21.5)
85 (70.2)
10 (8.3)
0.731
Number of tumors according to definition of CUETO
≤3
>3
389 (65.2)
208 (34.8)
71 (58.7)
50 (41.3) 
0.176
Initial therapy 
TURBT only
TURBT and adjuvant intravesical instillations
Primary tumor/NA
Unknown
210 (35.2)
87 (14.6)
284 (47.8)
16 (2.7)
34 (28.1)
18 (14.9)
65 (53.7)
4 (3.3)
0.417
FU, yr, mean ± SD 2.5 ± 1.7 2.7 ± 1.8 0.262
CUETO = Club Urológico Español de Tratamiento Oncológico; EORTC = European Organization 
for Research and Treatment of Cancer; FU = follow-up; NA = not applicable; SD = standard 
deviation; TURBT = transurethral resection of bladder tumor.
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Table 2  Univariate analysis of recurrence-free survival (RFS) by means of log-rank test in patients 
with non-muscle-invasive bladder cancer
Covariant No. of 
patients
Patients with 
RFS, %
P-value
Gender
Male
Female
577
141
46.9
59.5
0.020
Age according to definition of CUETO, yr
<60
60-70
>70
181
223
314
53.0
46.2
53.6
0.275
Stage
Ta
T1
565
153
48.7
51.1
0.911
Grade
1
2
3
Unknown
300
335
78
5
50.4
49.8
41.3
NA
0.584
Primary tumor according to definition of EORTC
Yes
No, ≤1 recurrence / yr
No >1 recurrence / yr
349
137
232
54.5
50.6
40.2
0.002
Primary tumor according to definition of CUETO
Yes
No
349
369
54.5
44.1
0.005
Tumor size 
<3 cm
≥3 cm
Unknown
448
109
161
50.9
50.5
NA
0.556
No. of tumors according to definition of EORTC
Single
2-7
8 or more
143
517
58
60.6
47.2
35.1
<0.001
No. of tumors according to definition of CUETO
≤3
>3
460
258
54.3
45.0
0.003
Initial therapy
TURBT only
TURBT and adjuvant intravesical instillation
Primary tumor/NA
Unknown
244
105
349
20
46.5
37.9
54.5
NA
0.037
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Table 2  (continued)
Covariant No. of 
patients
Patients with 
RFS, %
P-value
Pipe and/or cigar*
No
Yes
Unknown
423
155
19
47.8
46.5
NA
0.211
No. of cigarettes per day*
1-9
10-19
20-29
≥30
Unknown
121
193
200
50
33
35.6
51.3
48.3
53.7
NA
0.295
Age when started smoking, yr*
<14
14-16
16-18
>18
Unknown
60
259
132
122
24
47.4
49.7
45.2
45.9
NA
0.820
No. of years smoked*
<20
20-35
35-50
>50
Unknown
67
141
228
136
25
56.0
50.2
44.2
50.5
NA
0.253
No. of pack years*
<35
≥35
Unknown
169
171
257
55.1
46.3
NA
0.057
No. of years since stopping smoking*
<15
≥15
Unknown
181
176
240
52.5
46.0
NA
0.340
* include only ex-smokers and current smokers (n=597). CUETO = Club Urológico Español de 
Tratamiento Oncológico; EORTC = European Organization for Research and Treatment of Cancer; 
NA = not applicable; TURBT = transurethral resection of bladder tumor.
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Table 3  Multivariate analysis with (a) European Organization for Research and Treatment of 
Cancer (EORTC) and (b) Club Urológico Español de Tratamiento Oncológico (CUETO) risk factors 
for recurrence-free survival with Cox regression in patients with non-muscle-invasive bladder 
cancer
(a)
Covariant HR 95% CI P-value
Gender
Male
Female
1.34
1
0.96-1.88
NA
0.083
Primary tumor according to definition of EORTC
Yes
No, ≤1 recurrence / yr
No, > 1 recurrence / yr
1
1.17
1.59
NA
0.85-1.63
1.21-2.08
0.341*
0.001*
No. of tumors according to definition of EORTC
Single
2-7
8 or more
1
1.55
2.49
NA
1.11-2.15
1.52-4.10
0.009
Initial therapy
TURBT only 
TURBT and adjuvant intravesical instillation
Primary tumor/NA
Unknown
0.88
1
NA
NA
0.62-1.24
NA
NA
NA
0.455
Smoking status
Nonsmokers
Ex- and current smokers
1
1.47
NA
1.00-2.15
0.048
(b)
Covariant HR 95% CI P-value
Gender
Male
Female
1.31
1
0.93-1.85
NA
0.111
Primary tumor according to definition of CUETO
No
Yes
1.39
1
1.10-1.76
NA
0.006
No. of tumors according to definition of CUETO
<3
≥3
1
1.51
NA
1.18-1.92
0.001
Initial therapy
TURBT only 
TURBT and adjuvant intravesical instillation
Primary tumor/NA
Unknown
1
0.87
NA
NA
NA
0.62-1.23
NA
NA
0.428
Smoking status
Non-smokers
Ex- and current smokers
1
1.57
NA
1.06-2.31
0.022
* RFS is significant different for primary tumor versus more than one recurrence per year (p=0.001) 
but not for primary versus less than one recurrence per year (p=0.341). CI = confidence interval; 
HR = hazard ratio; NA= not applicable; TURBT = transurethral resection of bladder tumor. 
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Figure 1  Smoking status significantly influences the recurrence-free survival of patients with 
non-muscle-invasive bladder cancer
After a mean follow-up of 2.5 years 46.8% of the ex-smokers and current smokers were 
recurrence-free, compared to 62.3% of the nonsmokers (log-rank test, p = 0.005).
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DISCUSSION
This prospective study is one of the largest studies on NMIBC that investigated the 
influence of smoking status on the development of recurrences and progression. 
Combining ex-smokers and current smokers did not change baseline characteristics 
or clinical outcome, but the statistical impact on prognosis was stronger. Surprisingly, 
nonsmokers had significantly more high-grade tumors. No clear explanation can be 
given other than multiple statistical testing. 
A total of 284 recurrences were found (39.6%), which is less than other studies with 
intermediate- and high-risk patients (43-70%) (8, 12, 13). This could be due to excluding 
CIS-patients, to the relative short follow-up, and to the adjuvant epirubicin instillations, 
although no difference in RFS was found in those three treatment groups (10). 
Mean time to recurrence in this study was 19.7 mo, which is comparable with other 
studies (12-40 mo) (14-17). It is not surprising that patients who already had a history 
of recurrences had a higher HR for developing recurrences again than patients with 
primary NMIBC. The relationship between multiplicity and higher HR for developing 
recurrences was also not unexpected. Interestingly, in this study ex-smokers and 
current smokers had a significant shorter RFS compared to nonsmokers. There might 
be a relationship between smoking status and the efficacy of chemotherapy. Because 
all patients in this study were treated with epirubicin, we cannot draw any conclusions 
on this. 
Calculations on progression were problematic for several reasons: CIS patients 
were excluded in this study, but CIS is a very important reason for progression. The 
number of patients with progression was low (n=25, 3.9%), although comparable with 
the literature (3-7%) (17). Also the follow-up time was too short, and was focused on 
recurrences. In all, it leads to results sensitive for different kinds of bias, and therefore 
we canceled further analyses of PFS. 
In this study we compared EORTC risk factors to CUETO risk factors and found no 
difference in predicting RFS between the two risk tables. Comparison is interesting 
because the EORTC risk table has some limitations: the inclusion period was a long 
time ago (1979-1989). In that time a second resection in high-risk patients was not 
standard, as were maintenance instillations, and only a few patients received a single 
immediate postoperative instillation (11, 18). In all, the EORTC tables on recurrence 
only have a predictive accuracy of 66% at 1 and 5 years (19). For this reason the CUETO 
group also developed a risk table for progression and recurrence (11). The CUETO 
used data of 1062 patients treated exclusively with Bacillus Calmette-Guérin (BCG), 
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whereas in the EORTC only 171 patients were treated with BCG. The significant 
independent predictors for recurrence according to CUETO were gender, age, grade, 
tumor status, multiplicity and associated CIS. The calculated risks for recurrence using 
CUETO tables were lower than those obtained with the EORTC tables (11). 
Limitations of this study were the questionnaires. Smoking status was only measured 
when entering the study, and questions about passive smoking and other causal 
factors (20) were lacking. The questionnaires were not filled out by the patients 
themselves but by their physicians, and the validity of the results depend on the 
assumption that patients’ reported smoking status is stable over time. This probably 
holds for nonsmokers, but it is likely that some ex-smokers returned to smoking and 
that some current smokers stopped smoking. Not all questionnaires were filled out 
complete, which may have caused some bias. However, smoking status in this study is 
very comparable for the general Dutch population: in 2009 28% of Dutch population 
smoked, and 55% was ex-smokers (21). 
Furthermore, patients were followed until they developed a recurrence. For an accurate 
analysis of progression, patients need to be followed until they develop progression. 
Finally, in this study only intermediate- and high-risk patients were included, and so 
results might be different for low-risk patients. 
Only a few studies mention the relationship between smoking and clinical outcome 
in bladder cancer (8, 13, 22-25). Fleshner et al. found a significantly decreased RFS 
among current smokers compared with ex-smokers (HR 1.4, 95% CI 1.03-1.91; p=0.03). 
Moreover, current smokers tended to recur faster than ex-smokers (13). However, 
the group of ex-smokers was small, and the study did not specify smoking status. 
Garcia Mediero et al. found no statistical difference in recurrence, but did found more 
progression in smokers (p=0.03) (24). Chen et al. found a significant higher HR for RFS 
for smokers than for quitters (HR 2.0, 95% CI 1.0-3.7; p=0.04). The relationship between 
smoking status and PFS was inconsistent in this study (8). However, the number of 
patients with progression was low (32 patients; 18%), and there might have been a 
recall bias due to the use of post hoc questionnaires. In a study by Serretta et al., 
recurrences were more frequent in long-term smokers, independent of the number 
of cigarettes and smoking cessation (25). But smoking status was only analyzed when 
entering the study and there was no follow-up. 
Aveyard et al. reviewed 15 studies and found an overall higher risk of recurrence in 
ex-smokers and current smokers compared with nonsmokers, although this difference 
was significant in only three studies. This shows that it is difficult to draw conclusions 
because the overall quality of the articles is limited, and heterogeneity of the 
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populations and calculation methods is high (7). 
The relationship between smoking and recurrences is also found in other cancers (e.g. 
prostate cancer). Joshu et al. found more recurrences after prostatectomy in current 
smokers compared with ex-smokers and nonsmokers (HR 2.31, 95% CI 1.05-5.10) (26). 
In all, smoking remains an important clinical problem as it significantly influences the 
clinical prognosis of patients, and up to 50% of patients who smoke at the time of 
diagnosis continue to use cigarettes (13). As shown by Nieder et al., awareness of the 
relationship between smoking and bladder cancer in patients is low (27). Physicians 
also underestimate the effect of support in smoking cessation (9). Therefore, more 
attention should be paid to cessation of cigarette smoking after the initial diagnosis of 
NMIBC. A clinical implication of our study results might be to treat more aggressively 
those patients who (used to) smoke and have them under even closer follow-up 
schedules. 
It is also important that smoking status, especially current status and number of pack-
years, be added as a contributing factor in future studies. Moreover, smoking status 
should be evaluated properly (e.g., by using questionnaire in Appendix A), including 
questions on passive smoking and other causal factors, and it should be reevaluated 
during patient follow-up. In that way the effect of stopping smoking after initial TURBT 
could be investigated in future studies. 
CONCLUSIONS
In this prospective study, the significance of known prognostic factors (history of 
recurrences, number of tumors and history of intravesical therapies) in predicting 
RFS was confirmed. Another factor that appears to predict RFS is smoking status: ex-
smokers and current smokers had significant shorter RFS than nonsmokers. 
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Appendix A. Questionnaire for smoking behavior
1. Is the patient smoking regularly, or did the patient smoke regularly over a period of 
more than six months? (Regular means one cigarette/day, or at least five cigarettes/
week, or at least one package/month)
•	 No, never smoked
•	 Yes, smoked in the past but not now à please answer questions 2 and 3
•	 Yes, smokes now à please answer questions 2 and 4
2. For ex- and current smokers:
•	 At what age did patient start smoking?
•	 How many cigarettes on average did patient smoke per day in the past?
•	 Does the patient, or did the patient ever, smoke a pipe or cigars?
3. For ex-smokers only:
•	 At what age did patient stop smoking?
4. For current smokers only: 
•	 How many cigarettes on average does patient smoke per day now?
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KEY POINTS
•	 The natural history of non-muscle-invasive bladder cancer in individual patients 
can be unpredictable. 
•	 Although there are known clinical and molecular factors associated with tumor 
recurrence and progression, it is challenging to reconcile these data during a 
typical patient encounter within a busy clinic. 
•	 Prognostic models, such as risk tables and nomograms, aim to facilitate risk 
stratification, patient counseling, and treatment decision-making. 
•	 There are many prognostic models available for non-muscle-invasive bladder 
cancer, but they are not commonly used in daily practice because of their 
complexity and limited usefulness in treatment decision making. 
•	 To make prognostic models more useful, the focus should be on the clinical 
implications of the model for the patient, such as by focusing on negative and 
positive predictive value, rather than P values, sensitivity and specificity. The net 
benefit of the model should be compared with the standard model by means of 
classification tables and decision analytic techniques to test its additional clinical 
value. 
•	 Biomarkers do not have sufficient additional value, and markers undergoing 
investigation should first stand the test of time.
•	 Ultimately, even good models will not be translated into clinical practice unless 
they can be integrated into the standard clinical workflow.
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BACKGROUND
Overall, bladder cancer (BC) is the seventh most common malignancy in men and the 
17th in women (1). The incidence increases with age and is highest at 50 to 70 years of 
age. Eighty percent of patients with BC are men (2). Important risk factors are chemical 
and environmental exposures, such as smoking and aromatic amines, and chronic 
irritation (3, 4). In the Western world, more than 90% of BC are urothelial carcinomas or 
transitional cell carcinoma (5). 
On average, 70% of patients with BC present with non-muscle-invasive bladder 
cancer (NMIBC) and the remainder with muscle-invasive disease (MIBC). In the non-
muscle-invasive group, approximately 70% present as Ta lesions (noninvasive papillary 
carcinoma), 20% as T1 lesions (invasion into subepithelial connective tissue), and 
10% as carcinoma in situ (CIS, or Tis lesions; high-grade non-invasive flat tumor) (6). 
For grading, both the World Health Organization (WHO) 1973 and the WHO 2004 
classifications are advised. The WHO 1973 grading system recognizes 3 groups: grade 
1 to 3. The WHO 2004 classification defines 4 groups of papillary lesions: urothelial 
papilloma (benign), papillary urothelial neoplasm of low malignant potential, low-
grade papillary urothelial carcinoma, and high-grade papillary urothelial carcinoma (7). 
For staging, the TNM-classification is used (8).
Another way to stratify patients is by prognostic factors and, thus, outcome. The 
European Organization for Research and Treatment of Cancer (EORTC) developed 
a prognostic model for recurrence and progression for patients with NMIBC (9), 
which the authors discuss in this article. Other prognostic models with applications in 
urological practice have been created recently using other techniques: nomograms, 
neuro-fuzzy models, and artificial neural networks (ANN). 
The most well-known prognostic model is the risk table, which divides patients into 
risk groups based on their score. It gives the probability of an event (recurrence, 
progression) for patients within a given risk group. It assumes that all patients within 
a given risk group have a similar prognosis; however, the choice of cutoff values when 
stratifying patients into groups is somewhat artificial. It is unlikely that all patients within 
a given group will have the same prognosis, and patients with similar scores who fall 
into different risk groups might not have different prognoses. Furthermore, when one 
variable is missing it is not possible to calculate the probabilities. Nevertheless, risk 
tables can easily identify the very low- and very high-risk patients. 
A nomogram is a graphical device that is used to calculate an individual patient’s 
probability of an event based on a multivariable model with their specific prognostic 
factors and, hence, gives a more individualized risk calculation. Nomograms are based 
on a (continuous) score whereas risk tables subdivide patients into different categories 
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based on their score. They provide a more individualized probability of the event of 
interest, and software is usually developed to make them easy to use. Because the 
nomogram probabilities come directly from the multivariable model, it is important 
that the model is well calibrated, that is, it has an excellent goodness of fit. Otherwise, 
the probabilities provided by the model will be incorrect. However, when one of the 
variables is missing for a patient, the nomogram cannot be used for that patient. As 
mentioned by Hernandez and colleagues (10), nomograms are usually developed with 
very large series, and it has to be determined if they are applicable to lower volume 
centers. 
More advanced prognostic models are neuro-fuzzy models and ANN. The latter is 
a mathematical model based on a biological neural network. It can handle complex 
relationships between input and output and can find patterns in the data. ANN are 
adaptive systems which can change their structure during the learning phase. A neuro-
fuzzy model is a combination of an ANN and fuzzy logistics, which is a form of logistics 
that can handle reasoning. Because there is little experience in NMIBC with these 
models, they are not discussed further. 
In the next paragraphs, the advantages and disadvantages of the most well-known 
prognostic model, the EORTC risk tables, are discussed. Then, several other NMIBC 
prognostic models are described; the authors discuss the lack of use of prognostic 
models in the daily urological practice. Finally, the authors provide a future perspective 
on prognostic models: how should we develop and use prognostic models for patients 
with NMIBC? 
EORTC RISK TABLES
Development of the EORTC risk tables
In 2006, Sylvester and colleagues (9) published the EORTC scoring system for NMIBC. 
They combined individual patient data of 2596 patients from 7 EORTC trials (inclusion 
period: January 1979 – September 1989). The aim was to provide simple tables that 
would allow urologists to easily calculate the probability of recurrence and progression 
after transurethral resection of the bladder tumor (TURBT) for patients with NMIBC. 
The most appropriate adjuvant treatment after TURBT and frequency of follow-up 
can then be determined in an individual patient based on their prognosis. Data on 
patient and tumor characteristics and the endpoints of time to first recurrence and 
time to progression to MIBC were merged. The most important variables were then 
determined by regression models. Patients were divided into 4 risk groups for both 
recurrence and progression according to their total score. Probabilities of recurrence 
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and progression at 1 year and 5 years were calculated. Also, software was provided 
to calculate these probabilities at 1, 2, 3, 4 and 5 years. The model accuracy using 
Harrell’s bias corrected concordance index (c index) was calculated. The c index is 
the probability that for 2 patients chosen at random, the patient who had the actual 
event first had a higher probability of having the event according to the model; an 
uninformative model will have a c index of 0,5 or 50% (flipping a coin), and a perfect 
model will have a c index of 1 or 100%. Area under the curve (AUC) can also provide 
this information but only for binary outcomes (recurrence yes/no). To adjust for bias 
(overfitting; overoptimism), models were refit 200 times using the bootstrap technique 
(internal validation). Bootstrapping is a resampling method in which analyses are 
repeated many times but with different random samples of subjects each: in each 
analysis some subjects might not be included, others are included once, twice, and so 
forth. The 2596 eligible patients had mainly favorable characteristics. A total of 22% 
received no adjuvant intravesical treatment before recurrence; 78% of the patients 
received intravesical therapy, mostly chemotherapy. The median follow-up was 3.9 
years. In total, 47.8% of patients experienced a recurrence with a median time to 
recurrence of 2.7 years. The most important factors that influenced the time to first 
recurrence were prior recurrence rate, number of tumors, and tumor size. Only 10.7% 
of patients experienced progression to muscle-invasive disease. The median time to 
progression was not observed, with progression rates at 5 years varying from 0.8% 
to 45%. The most important factors influencing time to progression were T category, 
CIS, and grade. Scores were calculated for each patient, varying from 0 and 17 for 
recurrence and 0 to 23 for progression. Table 1 gives an overview of the probabilities 
of recurrence and progression. Furthermore, Sylvester and colleagues (9) found that 
concomitant CIS is the most important prognostic factor in patients with pT1G3-
tumors, and that recurrence at first follow-up cystoscopy at three months is associated 
with a higher chance of progression. 
As mentioned in an editorial comment by Karakiewicz, the internal validation yielded a c 
index of 0.66 for recurrence at both 1 and 5 years, which means that 66% of recurrences 
were accurately predicted at one and five years. The c index for progression was 0.74 
at 1 year, and 0.75 at 5 years (9). 
In 2013, the EORTC will start updating these risk tables for patients treated with 
maintenance Bacillus Calmette-Guerin (BCG).
The NMIBC guidelines panel of the European Association of Urology (EAU) classified 
patients into subgroups of low, intermediate and high risk based on these tables (Table 
1, last column) and provided treatment and follow-up recommendations depending 
on a patient’s risk group (11). The American Urological Association (AUA) also specified 
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therapy based on clinical risk. However, the panel of the AUA defined only 2 risk 
groups: low-risk patients (pTa, low grade) and high-risk patients (pT1, high grade, and/
or CIS) (12). 
Table 1  Probability of recurrence and progression according to total score (9) and classification 
system by the NMIBC Guidelines Panel of the European Association of Urology (11)
Probability of 
recurrence at 1 y
Probability of 
recurrence at 5 y
Recurrence score (%) (95% CI) (%) (95% CI) Recurrence risk group
0 15 (10-19) 31 (24-37) Low risk
1-4 24 (21-26) 46 (42-49) Intermediate risk 
5-9 38 (35-41) 62 (58-65) Intermediate risk
10-17 61 (55-67) 78 (73-84) High risk
Probability of 
progression at 1 y
Probability of 
progression at 5 y
Progression score (%) (95% CI) (%) (95% CI) Progression risk g roup
0 0.2 (0-0.7) 0.8 (0-1.7) Low risk
2-6 1 (0.4-1.6) 6 (5-8) Intermediate risk
7-13 5 (4-7) 17 (14-20) High risk
14-23 17 (10-24) 45 (35-55) High risk
CI = confidence interval; NMIBC = non-muscle-invasive bladder cancer. 
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Disadvantages 
As mentioned earlier, patient and tumor characteristics influence the probability of 
recurrence and progression. However, it should be taken into account that 22% of 
patients received no intravesical treatment at all, and the treatment that was given 
consisted mostly of intravesical chemotherapy. Only 171 of the patients (7%) received 
BCG and none received BCG maintenance. Also, less than 10% of patients received 
a single immediate postoperative instillation with chemotherapy, and a re-TURBT was 
not performed in high-risk patients. As mentioned in the discussion by Sylvester and 
colleagues (9), data for other factors that might be of prognostic importance were 
not available: depth of lamina propria invasion, location of the tumor on the bladder 
wall, lymphovascular invasion, and micropapillary tumors. Also, recent developments, 
such as molecular markers, fluorescence cystoscopy and re-TURBT, that are likely to 
further reduce the risks of recurrence and progression were not taken into account 
(13). Unfortunately, long-term follow-up is not available in most large series of patients 
where these new treatment developments and more recently identified prognostic 
factors have been assessed.
Many of the patients included in the EORTC series, particularly those in the high-
risk category, would be undertreated according to today’s standards. As such, the 
recurrence rates and especially the progression rates are likely to be somewhat higher 
than those found in contemporary practice. Thus, the progression rates and to a lesser 
extent the recurrence rates published in the EORTC series should be similar to the 
untreated natural history of the disease, enabling one to determine the most important 
prognostic factors without having to take into account treatment as a confounding 
factor. One can, however, ask what the real value of these risk tables is in the treatment 
decision process since the positive predictive value (PPV) of the EORTC risk table for 
progression in the high-risk patients is low, only 21%. This subject is discussed in more 
detail later in this article.
External validation
Several groups have independently validated the EORTC risk tables (10, 14-18). 
Fernandez-Gomez and colleagues (18) performed an external validation in 1062 
patients with NMIBC treated with maintenance BCG. For recurrence, Fernandez and 
colleagues found a lower risk in each group of patients than Sylvester and colleagues 
(9), but the c index was comparable. For progression, lower risks were found in the 
cohort from Fernandez and colleagues (18), especially in the highest risk group at 5 
years. The limitations as discussed by the investigators are the lack of re-TURBT, and 
a short maintenance regimen. The investigators also mention the difference in the 
distribution of patients: there are more patients with aggressive tumor characteristics 
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in this cohort than in the EORTC cohort. As mentioned in an editorial comment by 
Sylvester (13), application of the EORTC scoring system in the BCG-series to predict 
progression yields a sensitivity of 88% and a negative predictive value (NPV) of 95%, 
but the PPV is only 17%. PPV is the proportion of positive test results that are true 
positive; thus, it reflects the probability that a positive test reflects the underlying 
condition being tested for. NPV is the proportion of subjects with a negative test result 
who are correctly diagnosed and, thus, without the investigated disease. Overall, this 
is a well performed external validation, which shows that although the EORTC risk 
tables provided an adequate discrimination between patients with different prognosis, 
their calibration was poor in patients treated with BCG. 
Van Rhijn and colleagues (16) validated the EORTC risk scores in 230 Dutch patients 
with primary NMIBC. Additionally, they proposed an alternative to pathologic grade 
with molecular grade (mG) based on fibroblast growth factor receptor 3 (FGFR3) gene 
mutation and MIB-1 expression. The median follow-up was 8.6 years. In general, 5-year 
recurrence-free survival (RFS) and progression-free survival (PFS) rates were lower in 
the cohort of Van Rhijn and colleagues than in the EORTC cohort. According to the 
authors, the differences in PFS may be explained by the lower number of patients, by 
the selection of only primary patients, by the longer median follow-up, or because 
32% of patients died of other causes. Furthermore, they found that mG was related 
to progression and disease-specific survival, and adding mG increased the predictive 
accuracy for progression from 74.9% to 81.7%. These data suggest a potential 
advantage to incorporating molecular markers into the EORTC risk score. 
Sakano and colleagues (14) validated the EORTC risk group stratification in 529 
Japanese patients with NMIBC. The investigators concluded that the risk stratification 
as mentioned in the EAU’s guidelines is probably not applicable for Japanese patients 
but the subgroup classification on intermediate risk could be. Seo and colleagues 
(15) compared recurrence and progression rates between the EORTC risk tables and 
their own cohort of 251 Korean patients. All recurrence rates of the Korean patients 
were lower than in the EORTC cohort, except for the 1-year recurrence rate in the 
intermediate-risk group which was comparable to that of the EORTC cohort. In 
general, rates for progression in the Korean cohort were quite comparable to the rates 
in the EORTC risk tables despite the more aggressive patient and tumor characteristics 
of the Korean cohort. Hernandez and colleagues (10) performed an external validation 
in 417 patients with primary NMIBC. In general, probabilities for both recurrence and 
progression in this cohort were higher than in the EORTC cohort. Their results validate 
the EORTC risk tables in terms of recurrence but not in terms of progression due to 
the low number of patients that progressed. Pillai and colleagues (17) validated the 
EORTC risk model in 109 patients with primary and recurrent NMIBC. They found 
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significantly higher 1- and 5-year probabilities of recurrence for all 4 groups compared 
to the EORTC model. However, it was not possible to draw firm conclusions about the 
validity due to the low number of patients in the individual groups. 
In all, it is likely that the recurrence and especially progression rates reported by the 
EORTC risk tables are higher than those found in current clinical practice. As mentioned 
earlier, the progression probabilities and to a lesser extent the recurrence probabilities 
mentioned in the EORTC study are likely to be similar to the untreated natural history 
of the disease.
OTHER BLADDER CANCER PROGNOSTIC MODELS 
There are many prognostic models for NMIBC (19-26), as well as for muscle-invasive 
disease (27-33). In this section, the authors discuss some of the other prognostic 
models for NMIBC. The prognostic models on MIBC are not discussed. 
CUETO scoring model
The scoring model from the Spanish Urological Club for Oncological Treatment (Club 
Urologico Español de Tratamiento Oncologico [CUETO]) is the most commonly known 
prognostic model for NMIBC besides the EORTC risk tables. Fernandez-Gomez 
and colleagues (26) used the data of 1062 patients treated with BCG in four studies 
between 1990 and 1999. All patients received BCG maintenance treatment regimens 
(12 instillations within 5-6 months after TURBT) and had identical follow-up schedules, 
but the BCG dose did differ (13.5mg-81mg). Only 4.2% received less than 6 BCG-
instillations and less than 30% of patients discontinued therapy. The median follow-
up was 69 months. In total, 346 patients (32.6%) had recurrences, and 142 patients 
(13.4%) had progression to muscle-invasive disease. Prognostic factors for time to 
recurrence were gender, age, tumor status, number of tumors, associated CIS, and 
grade. For time to progression, age, tumor status, T category, and grade were of 
significant influence. A scoring system from 0 to 16 was developed for recurrence, 
and from 0 to 14 for progression. Then recurrence and progression probabilities at 
1, 2 and 5 years were calculated. Finally, these probabilities were compared with the 
EORTC recurrence probabilities. All recurrence probabilities were lower in the CUETO 
model than in the EORTC model. The progression probabilities were lower for high-
risk patients; but in most intermediate-risk patients, the 2 scoring systems gave similar 
progression probabilities. As mentioned in the discussion by Fernandez-Gomez and 
colleagues (26) limitations of this study are the retrospective analyses, and the use 
of the old TNM classification. Furthermore, no re-TURBT or immediate postoperative 
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instillations were done, and the parameters of possible influence that were missing in 
the EORTC risk tables, such as tumor location, are also missing in the CUETO scoring 
model. Also, an internal validation to test accuracy is lacking and, as mentioned in the 
editorial comment, the lower significance of CIS is likely to be caused by the small 
number of patients with CIS. The sensitivity of this scoring model is 60%, NPV is 92% 
but PPV is only 24%. 
Rosevaer and colleagues (34) conducted an external validation of CUETO model in 
718 patients treated with BCG plus interferon-alpha. The 3-year RFS was much lower 
in this study than in the CUETO study. However, comparing RFS between the 4 groups 
categorized according to the CUETO score showed a significant difference between 
the groups (p<0.001). Therefore, the discrimination when using this scoring model is 
good. Nevertheless, currently accepted practices such as immediate postoperative 
instillations, re-TURBT and long-term maintenance BCG instillations, were not taken 
into account for both this group and the CUETO model, which is of influence on the 
clinical outcome of these patients. 
OTHER PROGNOSTIC MODELS FOR NMIBC
Besides the most well-known EORTC-risk tables and the CUETO scoring model, 
several other models have been developed (19-24); but because these models are not 
commonly used in daily practice, they are beyond the scope of this review. However, 
in general, the most frequently cited prognostic factors for time to first recurrence are 
the number of tumors, whether the tumor is primary or recurrent, and, if recurrent, 
the prior recurrence rate, and the tumor size. For time to progression to MIBC, the 
most important prognostic factors are grade, stage, and the presence of CIS. Most 
frequently cited prognostic factors for the course of the disease in patients with CIS 
are age, response to BCG, type of CIS (primary, secondary, concurrent), extent of CIS 
(unifocal, multifocal or diffuse), the presence of irritative bladder symptoms, hematuria, 
and extravesical extension (35). 
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USE OF PROGNOSTIC MODELS IN UROLOGICAL PRACTICES
In general, a good prognostic model discriminates between disease and illness, gives 
an accurate prognosis, has a good calibration, is generalizable, and is easy to use. Good 
sensitivity and specificity are required for proper discrimination. But, depending on how 
the model will be used, the NPV and PPV might be more important than sensitivity and 
specificity. The accuracy of a model can be assessed by internal validation (apparent 
validation, split-sample validation, cross-validation, or bootstrapping), or, even better, 
by external validation with a new cohort. The latter also tests the generalizability of the 
model. A model with a good calibration has a good agreement between the observed/
true outcome and the predicted outcome (36). Unfortunately, none of the existing 
prognostic models for NMIBC have all of these requirements. Common problems are 
overfitting of the model because validation is done on the data used to derive it from, 
leading to a poor generalizability, a low c index, or a poor calibration when applied 
to external datasets, resulting in either overtreatment or under-treatment of patients, 
which is not in concordance with the current treatment guidelines. And if the c index 
or calibration is high, the next question is whether it is high enough to justify the use 
of the model in clinical practice. 
For use in daily practice, other variables, such as patient comorbidity and risk of major 
surgery are also important in making a final decision on which treatment best suits a 
given patient. Another current problem is the lack of validation. Prognostic models that 
have not had an external validation are less reliable and clinicians may be less eager 
to incorporate them into their clinic workflow. Practice patterns are also very difficult to 
change. The very practical nature of a busy clinic may undermine the provider’s use of 
any prognostic models, unless it is readily incorporated into an electronic health record 
that will automate the calculation of risk category or disease outcome. It is likely that 
urologic trainees exposed to these models during their residency and fellowship will 
use them, or subsequent versions, later in practice. All these factors are responsible 
for the fact that few urologists currently use prognostic models in their daily practice. 
Some risk models, such as the EORTC risk tables, are incorporated into guidelines. 
But guidelines are not commonly followed, as shown by Chamie and colleagues (37). 
They investigated practice patterns concerning treatment in 4545 American patients 
with high-grade NMIBC. The American guideline, the European guideline and the 
National Comprehensive Cancer Network (NCCN) guideline were all investigated 
for their use in daily practice. An extremely low number of patients received all the 
diagnostic and therapeutic steps in concordance with the guidelines, namely only one 
patient. However, 25.8% of patients did receive 6 or more instillations with BCG. Upper 
tract imaging and a single post-operative instillation with intravesical chemotherapy 
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were especially lacking. Despite the disadvantages of the prognostic models, clinical 
reasoning is not flawless; omission bias (bias against action), and outcome bias (it is 
easier to evaluate outcome than it is to evaluate a decision process) can influence 
treatment decisions (38), and medical doctors tend to recommend the treatment they 
deliver themselves (39). Several studies have shown that predicting clinical outcome by 
medical doctors is less accurate than when using prognostic models (40, 41).
The International Bladder Cancer Group (IBCG) recognized these flaws, and provided 
uniform terminology and recommendations for the risk classification and management 
of patients with NMIBC (42). Based on the 4 existing guideline recommendations 
(EAU, AUA, NCCN and First International Consultation on Bladder Tumors guidelines), 
they developed a simple algorithm for treatment and management of patients with 
primary NMIBC based on 3 easily definable risk groups: low risk was defined as a 
solitary, primary low-grade pTa tumor, while high risk was any pT1 and/or high-grade 
tumor and/or CIS. This is a fine example of a useful model for day-to-day urological 
practice. However, the algorithm is only for primary patients, and recommendations 
for the management of treatment failure and recurrence are less clearly defined due to 
the major differences between the 4 guidelines. 
Should we then decide to stop developing and using prognostic models? The authors 
of this article do not advise to stop, but statistical concepts, such as discrimination (c 
index, AUC), calibration, P values, hazard ratios, odds ratios, and even sensitivity and 
specificity do not really help clinicians when it comes to making clinical decisions in 
a given patient. It remains very important to give an adequate treatment as soon as 
possible because delay and inadequate therapy are associated with a worse outcome 
(43-45). The authors discuss their view on improving the use of prognostic models in 
the next paragraph. 
FUTURE PERSPECTIVES ON BLADDER CANCER PROGNOSTIC 
MODELS
Before developing new models, one should carefully think about the clinical purpose 
of the model: what is the goal of the prognostic model and how will it be used in clinical 
practice? For BC, one could consider to try to identify high-risk patients for immediate 
cystectomy or to identify low-risk patients who do not need further treatment or would 
be candidates for low intensity surveillance. When developing a model, clinically 
meaningful statistics should be used, such as PPV and NPV. For example, the PPV 
of the EORTC risk tables for progression in the high risk patients is only 21%, which 
means that if a patient is classified as high-risk and would go for cystectomy, this would 
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be overtreatment in 79% of the cases. Thus, the EORTC risk tables are not useful for 
determining what the best treatment is for high-risk patients. 
One option is to update the existing models with data that were not previously available. 
Data on recent advances that are nowadays recommended by the guidelines should 
be included in the current models, such as data on re-TURBT, fluorescence cystoscopy 
and postoperative instillations. External validation should always be performed when 
a prognostic model is updated, in order to assess its generalizability. 
As mentioned by Shariat and colleagues (46), larger data sets, better data collection 
methods, and more sophisticated modeling procedures are needed to improve 
predictive accuracy. In addition, better accuracy might be accomplished by modeling 
physician- or hospital-specific data for patients being treated by that physician or 
at that hospital. Finally, prognostic models that predict the likelihood of metastatic 
progression, cancer-specific mortality and the long-term quality of life are likely to have 
great utility for the patient and the physician when exploring treatment alternatives. 
Should we update models by combining patient and tumor characteristics with 
biomarkers? Ideally, biomarkers should help to identify patients at high risk of recurrence 
and could, therefore increase the accuracy of prognostic models. Several groups have 
already attempted to combine biomarkers in order to improve the outcome of NMIBC 
(16, 21, 47-49). Shariat and colleagues (21) combined their nomogram with nuclear 
matrix protein 22 (NMP22). This combination had a good accuracy (AUC>80%), but the 
investigators did not compare models with and without NMP22, so the additional value 
of adding NMP22 was not investigated. Another example of combining a biomarker 
with clinical data is the previously mentioned article of Van Rhijn and colleagues (16) 
in which they combined molecular grading (FGFR3 gene mutation status and MIB-
1 expression) with the EORTC risk scores. They found an additional value of this 
combination: the predictive accuracy of the EORTC risk scores increased from 74.9% 
to 81.7%. Members of this group also combined 4 molecular markers (FGFR3 gene 
mutation status, Ki67, P53 and P27 expression) with T1 substaging (2 types: T1e vs 
T1m, and T1a vs T1b vs T1c) and EORTC risk scores (49). P53 was not of any value, and 
the additional value of the other 3 markers was only 1.3% (p>0.05). However, the T1e/
T1m substaging was one of the most important variables for progression. 
Before adding biomarkers to prognostic models, we should take into account which 
(statistical) steps are necessary to make a model of additional value. According to 
Sylvester, 4 steps are needed: first the identification of interesting biomarkers, then the 
defining of a function used to combine the biomarkers together into a classification 
rule, next a validation to show its reproducibility, and finally investigating whether 
the biomarkers improves the predictive accuracy of the model (50). Also, we should 
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investigate whether we need one biomarker, or a panel of markers. We have to improve 
the scientific rigor related to biomarker evaluation and testing and the feasibility of their 
use in day-to-day clinical practice as compared to the currently available biomarkers.
Another, and perhaps the best, possibility would be to simplify the current prognostic 
models in order to make them more useable in daily practice. We should improve their 
PPV and/or NPV and pay more attention to calibration, as suggested by Sylvester (50). 
Classification tables including NPV and PPV express the results of prognostic models 
in clinical terms and can be used to compare them. Once there is a model which 
is clinically useful (i.e. with high NPV and PPV) the model should be evaluated. As 
mentioned above, P values, hazard ratios, c index and so forth have little or no direct 
consequences for day-to-day practice. A more relevant method has been suggested 
by Vickers and Cronin (51) to calculate the net benefit of a new model compared to 
the standard model as part of a decision curve analysis. This analysis is based on 2 
principles: models may influence medical decisions and decisions have consequences 
that can be directly incorporated into analyses by using weights. Decision analytic 
techniques may be used to determine whether a model is worth using at all, which 
of the 2 (or more) models is preferable, and whether an additional predictor is worth 
measuring. 
If we know what the important prognostic factors in a certain group of patients are, we 
can personalize their treatment based on their level of risk. As mentioned earlier, the 
IBCG has already published a simple algorithm for the treatment and management 
of patients with primary NMIBC (42). The EAU NMIBC Guidelines Panel is working to 
simplify the risk group definitions for their day-to-day use in the clinic. The EORTC 
will be updating their risk tables in patients treated with maintenance BCG, and 
several authors of this article are working on outcome probabilities after intravesical 
chemotherapy. All of these are practical examples of work that is being done to make 
it easier for clinicians to classify patients according to their level of risk and, thus, to 
provide the most appropriate treatment in individual patients. 
SUMMARY 
Currently, there are many prognostic models available for NMIBC but they are not 
commonly used in daily practice due to their complexity and limited usefulness in 
treatment decision making. In order to make prognostic models more useful, the focus 
should be on the clinical implications of the model for the patient, such as by focusing 
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on NPV and PPV rather than P values, sensitivity, and specificity. The net benefit of 
the a model should be compared to the standard model by means of classification 
tables and decision analytic techniques to test its additional clinical value. Currently, 
biomarkers do not have sufficient additional value, and markers under investigation 
should first stand the test of time. Ultimately, even good models will not be translated 
into clinical practice unless they can be integrated into the standard clinical work 
flow and prove their importance in improved therapeutic results. Despite the efforts 
of many, these predictive models have not replaced a practicing clinician’s treatment 
experience. 
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ABSTRACT
Objective 
To predict recurrence for patients with intermediate risk (IR) non-muscle-invasive 
bladder cancer (NMIBC) treated with intravesical chemotherapy which can be 
challenging because of the heterogeneous characteristics of these patients. 
Patients and Methods
Data from three Dutch trials were combined. Patients with characteristics conform the 
IR-definition of the EAU guideline 2013 treated with intravesical chemotherapy were 
included. Uni- and multivariable Cox-regression with selection methods were used to 
identify independent risk factors predicting recurrence at 1, 2 and 5 years. An easy 
readable table for recurrence probabilities was developed. An external validation was 
done using independent Spanish data. 
Results 
A total of 724 Dutch patients were available for analyses, of which 305 were primary 
patients. Median follow-up was 30 months. Recurrences occurred in 413 patients 
(57%). History of recurrences, history of intravesical treatment, grade 2, multiple tumors 
and adjuvant treatment with epirubicin were independent predictors for recurrence-
free survival with hazard ratios of 1.48, 1.38, 1.22, 1.56 and 1.27, respectively. An 
easy readable table for recurrence probabilities was developed using these five 
independent predictors. Internal validation showed a concordance index of 0.60, 
0.62 and 0.63 at year 1, 2 and 5, respectively. Three risk groups were identified: minor, 
moderate and major risk. For minor risk patients negative predictive value was 65% 
and positive predictive value was 68%. Finally, the external validation, including 137 
Spanish patients, showed comparable hazard ratios. Limitations include missing data 
and variability in adjuvant treatment. 
Conclusion 
History of recurrences, history of intravesical treatment, grade 2, multiple tumors 
and adjuvant treatment with epirubicin were independent predictors for recurrence-
free survival in IR-NMIBC-patients treated with intravesical chemotherapy. Analyses 
showed sufficient discrimination and good predictive accuracy of the model. 
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INTRODUCTION
Bladder cancer remains a common problem in the Western world (1). Approximately 
75-85% of bladder cancer presents as non-muscle-invasive bladder cancer (NMIBC); 
the remaining patients have muscle-invasive disease (MIBC) (2). 
Treatment of NMIBC consists of complete transurethral resection of the bladder 
tumor (TURBT), followed by a single immediate post-operative instillation (POI) with 
chemotherapy. Further treatment with chemotherapy or immunotherapy (Bacillus 
Calmette Guerin; BCG) depends on patient- and tumor characteristics. In the guideline 
of the European Association of Urology (EAU) patients are divided into three risk 
groups: low, intermediate and high risk (2) (Table 1). This stratification is similar to that 
provided by the International Bladder Cancer Group (IBCG) (3), and is partially based 
on the well-known risk tables developed by the European Organization for Research 
and Treatment of Cancer (EORTC) (4).
Table 1  Risk group stratification according to EAU guideline 2013 (2)
Risk group Definition
Low risk tumors Primary, solitary, Ta, LG/G1, <3 cm, no CIS
Intermediate risk tumors All tumors not defined in the two adjacent categories 
(between the category of low and high risk)
High risk tumors Any of the following: 
T1 tumor 
HG/G3 tumor 
CIS  
Multiple and recurrent and large (>3 cm) Ta, G1/G2 tumors 
(all conditions must be presented in this point)
CIS = carcinoma in situ; HG = high grade; LG = low grade.
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In general, much is known about low risk and high risk groups, but treatment advises 
for intermediate risk (IR) patients are less clear. This is an important lack of information 
as the IR-group covers a large number of patients with heterogeneous characteristics, 
making selection of appropriate therapy challenging. A proper prediction model 
for recurrence probabilities in IR-patients treated with intravesical chemotherapy is 
currently lacking, but is very much needed as recently mentioned by the IBCG (5). 
Therefore, our goal was to develop a prediction model after intravesical chemotherapy 
in order to identify factors predicting recurrences in IR-patients. 
PATIENTS AND METHODS
Data of three prospective Dutch studies (6-8) were available for analyses, providing us 
with individual data of 2006 patients. Treatment and follow-up have been described in 
detail before (6-8), and can be found in Table 2.
For the development of the prediction model in this study, we included only patients 
with Ta G1/2 urothelial carcinoma without carcinoma in situ (CIS) and without the 
combination ‘multiple & recurrent & diameter >3cm’. This is consistent with the 
definition of IR-group according to the EAU-guideline (2). All included patients 
received intravesical chemotherapy (either mitomycin C [MMC] or epirubicin). 
Primary outcome measurement was time to first recurrence (recurrence-free survival; 
RFS): time from randomization to the date of the first bladder recurrence. Patients who 
were still alive and without recurrence were censored at the date of the last follow-up 
appointment. Since deaths were not related to bladder cancer, deaths were analyzed 
as a competing risk.
As progression to stage ≥T2 is uncommon in IR-patients, this was not taken into 
account in the analyses. 
Statistical methods
First, baseline demographics of the selected Dutch patients are presented (n=724). 
Univariable Cox-regression was used to study the influence of the clinicopathological 
factors on RFS. The estimated hazard ratios (HR) with the 95% confidence interval (CI) 
are presented. Multivariable Cox-regression with selection procedures and likelihood 
analyses was used for selecting independent variables for RFS. All variables in the 
model were eligible for entering into the model. Smoking and diameter were removed 
from analyses based on the limited clinical relevance, number of missing data and the 
HR. 
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Table 2  Treatment details
Dutch cohort Spanish cohort
MMC versus 
BCG-Tice versus 
BCG-RIVM (6)
Epirubicin trial 
(7)
KLH versus 
MMC (8)
Study 
design
Multicenter RCT Multicenter RCT Multicenter RCT Fundacio 
Puigvert, 
Barcelona, 
Spain
Inclusion 
period
April 1987 – 
December 1990
April 1998 – 
April 2004
July 2003 – 
November 2007
March 2000 – 
December 2009
Patients Primary and 
recurrent 
pTa-T1, 
including CIS
Intermediate- 
and high risk, 
no CIS
Intermediate- 
and high risk, 
no CIS
All new NMIBC 
patients 
Treatment 
schedule
All: complete 
TURBT
MMC: 4 weekly 
instillations, 
6 monthly 
instillations, 
and in case 
of persistent 
or recurrent 
disease 3 
additionally 
monthly 
instillations.
BCG: 6 weekly 
instillations, 
in case of 
persistent 
or recurrent 
disease 6 
additional 
weekly 
instillations
All: complete 
TURBT.
Group 1: 4 
weekly
and 5 monthly 
instillations 
(standard 
schedule),
Group 2: 
standard 
schedule + 1 
instillation <48h 
after TURBT. 
Group 3: 
standard 
schedule + 2 
instillations at 9 
and 12 months
All: complete 
TURBT
MMC: 4 weekly 
instillations, 
5 monthly 
instillations, 
2 additional 
instillations at 9 
at 12 months.
KLH: pre-
immunization 
with 
intracutaneous 
KLH, 6 weekly 
instillations 
and 10 monthly 
instillations
All: complete 
TURBT 
including 
random 
biopsies, direct 
postoperative 
instillation with 
MMC, 4 weekly 
instillations 
and 3 monthly 
instillations with 
MMC.
Dose 30mg MMC in 
50mL saline
50mg epirubicin 
in 50mL saline
40mg MMC in 
50mL saline
40mg MMC in 
50mL saline
BCG = bacillus Calmette Guerin; CIS = carcinoma in situ; KLH = keyhole limpet 
hemocyanin; MMC = mitomycin C; RCT = randomized clinical trial; TURBT = transurethral 
resection of bladder tumor. 
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For the final model, the adjusted HR are presented, including 1, 2 and 5 years 
probabilities for recurrence. To assess the model’s accuracy (discrimination) Harrell’s 
bias corrected concordance index (c-index) was calculated at 1, 2 and 5 years and 
models were refitted 200 times with bootstrap resampling techniques. 
Three risk groups were constructed based on the risk profiles of the final model. In 
addition, sensitivity, specificity, negative and positive predictive value (NPV, PPV) were 
calculated for the minor risk group at 2 years, as most recurrences occurred within two 
years.
External validation
Prospectively collected, independent, individual patient data provided by Fundacio 
Puigvert, Barcelona, Spain, were used to study the final prediction model (n=137). 
However, this cohort included only data of primary patients. For the comparison we 
used a subcohort of primary patients from the Dutch cohort (n=305). The prediction 
model was applied to the data of these cohorts. 
Statistical analyses were done with SPSS 20.0.0 for Windows (SPSS Inc., Chicago, 
Il, USA), in SAS 9.2 for Windows (SAS Institute Inc., Cary, NC, USA) and in R 2.2 for 
Windows. 
RESULTS
Demographics of Dutch cohort
Data of 724 Dutch patients met our inclusion criteria. The baseline demographics are 
presented in Table 3. The median follow-up was 29.6 months (range 2-239 months). A 
total of 413 patients (57%) experienced a recurrence, and median time to recurrence 
was 29.9 months (95%CI 24.2-35.6). Most recurrences were NMIBC G1 or G2 without 
CIS. As expected, only few patients progressed to MIBC (16 patients; 2.2%). 
Recurrence
In Table 4 we show the crude HR with 95%CI of the clinicopathological characteristics 
using univariable Cox-regression. Recurrent tumor, previous intravesical treatment, 
number of tumors and current adjuvant treatment were statistical significant predictors 
for time to recurrence. The adjusted HR with 95%CI of the clinicopathological 
characteristics, using the final multivariable Cox-regression model after the selection 
procedure are shown in Table 5. The following five variables were included in the 
final model: history of previous recurrences, history of intravesical treatment, tumor 
grade, number of tumors, and adjuvant treatment with epirubicin, with hazard ratios of 
Table 3  Demographics of the three cohorts
                    Dutch cohort                  Dutch subcohort of primary patients Spanish cohort
Total (n=724) Recurrence 
(n=413)
Total (n=305) Recurrence 
(n=148)
Total (n=137) Recurrence 
(n=79)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
Age in years 67.5 (33-89) 66.9 (35-86) 65.0 (33-86) 64.9 (35-85) 69 (37-89) 69 (37-84)
Age 
classification
≤66yr
>66yr
335
389
(46)
(54)
195
218
(47)
(53)
161
144
(53)
(47)
78
70
(53)
(47)
61
76
(45)
(55)
37
42
(47)
(53)
Gender
Male
Female
Unknown
592
130
2
(82)
(18)
337
74
2
(82)
(18)
246
59
0
(81)
(19)
117
31
0
(79)
(21)
109
28
0
(80)
(20)
61
18
0
(77)
(23)
Primary or 
recurrent
Primary
Recurrent
305
419
(42)
(58)
148
265
(36)
(64)
305
NA
(100) 148
NA
(100) 137
NA
(100) 79
NA
(100)
History of 
intravesical 
treatment
No
Yes
Unknown
580
115
29
(84)
(16)
309
83
21
(79)
(21)
305
NA
(100) 148
NA
(100) 317
NA
(100) 79
NA
(100)
Tumor grade 
G1
G2
351
373
(48)
(52)
205
208
(50)
(50)
102
203
(33)
(67)
51
97
(35)
(65)
14
123
(10)
(90)
10
69
(13)
(87)
No. of tumors
Single 
Multiple
Unknown
176
542
6
(25)
(75)
83
324
6
(20)
(80)
57
248
0
(19)
(81)
23
125
0
(16)
(84)
85
50
2
(63)
(37)
42
36
1
(54)
(46)
Adjuvant 
treatment
Mitomycin C
Epirubicin
218
506
(30)
(70)
113
300
(27)
(73)
105
200
(34)
(66)
46
102
(31)
(69)
137
0
(100) 79
0
(100)
Median follow up 
in mo (range) 29.6 (2-239) 19.2 (2-239) 37.2 (2-128) 21.0 (2-128) 30.6 (3-112) 18.4 (3-97)
CI = confidence interval; CIS = carcinoma in situ; HR = hazard ratio; NA = not applicable for primary patients.
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1.48, 1.38, 1.22, 1.56 and 1.27, respectively. Tumor grade and adjuvant treatment have 
p-values very near the cutoff of 0.05. However, the five-variable-model outperformed 
the model without tumor grade and adjuvant treatment (LR test). 
Table 3  Demographics of the three cohorts
                    Dutch cohort                  Dutch subcohort of primary patients Spanish cohort
Total (n=724) Recurrence 
(n=413)
Total (n=305) Recurrence 
(n=148)
Total (n=137) Recurrence 
(n=79)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
N (%) / 
Median (range)
Age in years 67.5 (33-89) 66.9 (35-86) 65.0 (33-86) 64.9 (35-85) 69 (37-89) 69 (37-84)
Age 
classification
≤66yr
>66yr
335
389
(46)
(54)
195
218
(47)
(53)
161
144
(53)
(47)
78
70
(53)
(47)
61
76
(45)
(55)
37
42
(47)
(53)
Gender
Male
Female
Unknown
592
130
2
(82)
(18)
337
74
2
(82)
(18)
246
59
0
(81)
(19)
117
31
0
(79)
(21)
109
28
0
(80)
(20)
61
18
0
(77)
(23)
Primary or 
recurrent
Primary
Recurrent
305
419
(42)
(58)
148
265
(36)
(64)
305
NA
(100) 148
NA
(100) 137
NA
(100) 79
NA
(100)
History of 
intravesical 
treatment
No
Yes
Unknown
580
115
29
(84)
(16)
309
83
21
(79)
(21)
305
NA
(100) 148
NA
(100) 317
NA
(100) 79
NA
(100)
Tumor grade 
G1
G2
351
373
(48)
(52)
205
208
(50)
(50)
102
203
(33)
(67)
51
97
(35)
(65)
14
123
(10)
(90)
10
69
(13)
(87)
No. of tumors
Single 
Multiple
Unknown
176
542
6
(25)
(75)
83
324
6
(20)
(80)
57
248
0
(19)
(81)
23
125
0
(16)
(84)
85
50
2
(63)
(37)
42
36
1
(54)
(46)
Adjuvant 
treatment
Mitomycin C
Epirubicin
218
506
(30)
(70)
113
300
(27)
(73)
105
200
(34)
(66)
46
102
(31)
(69)
137
0
(100) 79
0
(100)
Median follow up 
in mo (range) 29.6 (2-239) 19.2 (2-239) 37.2 (2-128) 21.0 (2-128) 30.6 (3-112) 18.4 (3-97)
CI = confidence interval; CIS = carcinoma in situ; HR = hazard ratio; NA = not applicable for primary patients.
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Table 4  Crude hazard ratios (HR) and the 95% confidence intervals (CI), using univariable Cox-regression for time to recurrence for 
the three cohorts
Dutch cohort (n=724) Dutch subcohort of primary 
patients (n=305)
Spanish cohort (n=137)
N HR 95%CI P-
value
N HR 95%CI P-
value
N HR 95%CI P-
value
Age
≤66yr
>66yr
722 1.00
1.00
(ref)
(0.83-1.22) 0.978
305 1.00
1.05
(ref)
(0.76-1.45) 0.774
137 1.00
0.92
(ref)
(0.59-1.43) 0.703
Gender
Male 
Female
720 1.00
0.98
(ref)
(0.76-1.26) 0.854
305 1.00
1.07
(ref)
0.72-1.58) 0.742
137 1.00
1.25
(ref)
0.74-2.21) 0.407
Primary or recurrent
Primary
Recurrent
722 1.00
1.54
(ref)
(1.25-1.88) <0.001
NA NA NA NA NA NA NA NA
History of intravesical 
treatment
No
Yes
694 1.00
1.71
(ref)
(1.34-2.18) <0.001
NA NA NA NA NA NA NA NA
Tumor grade
G1
G2
722 1.00
1.01
(ref)
(0.84-1.23) 0.885
305 1.00
1.01
(ref)
(0.72-1.42) 0.936
137 1.00
0.80
(ref)
(0.41-1.56) 0.511
Number of tumors
Single
Multiple
716 1.00
1.48
(ref)
(1.16-1.88) 0.002
305 1.00
1.41
(ref)
(0.90-2.21) 0.129
135 1.00
1.82
(ref)
(1.16-2.84) 0.009
Treatment
Mitomycin C
Epirubicin
722 1.00
1.36
(ref)
(1.09-1.69) 0.006
305 1.00
1.33
(ref)
(0.94-1.89) 0.110
- - - -
NA = not applicable to primary patients; - = no data available due to 100% treatment with mitomycin C.
Table 5  Adjusted hazard ratios (HR) and 95% confidence intervals (CI), using multivariable Cox-regression with selection 
procedures for time to recurrence for the three cohorts
Dutch cohort (n=724) Dutch subcohort of primary 
patients (n=305)
Spanish cohort (n=137)
HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
Primary versus recurrent
Primary
Recurrent
1.00
1.48
(ref)
(1.17-1.88) 0.001
NA
NA
(NA)
(NA) NA
NA
NA
(NA)
(NA) NA
History of intravesical treatment
None
Yes
1.00
1.38
(ref)
(1.05-1.80) 0.021
NA
NA
(NA)
(NA) NA
NA
NA
(NA)
(NA) NA
Tumor grade
G1
G2
1.00
1.22
(ref)
(0.99-1.51) 0.061
1.00
1.11
(ref)
(0.78-1.58) 0.485
1.00
0.94
(ref)
(0.48-1.85)
0.861
No. of tumors
Single
Multiple
1.00
1.56
(ref)
(1.20-2.01) 0.001
1.00
1.47
(ref)
(0.92-12.34) 0.286
1.00
1.80
(ref)
(1.15-2.84) 0.011
Treatment
Mitomycin C
Epirubicin
1.00
1.27
(ref)
(1.00-1.62) 0.048
1.00
1.24
(ref)
(0.84-1.84) 0.278
-
-
-
- -
NA = not applicable to primary patient; - = no data available due to 100% treatment with mitomycin C.
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Table 4  Crude hazard ratios (HR) and the 95% confidence intervals (CI), using univariable Cox-regression for time to recurrence for 
the three cohorts
Dutch cohort (n=724) Dutch subcohort of primary 
patients (n=305)
Spanish cohort (n=137)
N HR 95%CI P-
value
N HR 95%CI P-
value
N HR 95%CI P-
value
Age
≤66yr
>66yr
722 1.00
1.00
(ref)
(0.83-1.22) 0.978
305 1.00
1.05
(ref)
(0.76-1.45) 0.774
137 1.00
0.92
(ref)
(0.59-1.43) 0.703
Gender
Male 
Female
720 1.00
0.98
(ref)
(0.76-1.26) 0.854
305 1.00
1.07
(ref)
0.72-1.58) 0.742
137 1.00
1.25
(ref)
0.74-2.21) 0.407
Primary or recurrent
Primary
Recurrent
722 1.00
1.54
(ref)
(1.25-1.88) <0.001
NA NA NA NA NA NA NA NA
History of intravesical 
treatment
No
Yes
694 1.00
1.71
(ref)
(1.34-2.18) <0.001
NA NA NA NA NA NA NA NA
Tumor grade
G1
G2
722 1.00
1.01
(ref)
(0.84-1.23) 0.885
305 1.00
1.01
(ref)
(0.72-1.42) 0.936
137 1.00
0.80
(ref)
(0.41-1.56) 0.511
Number of tumors
Single
Multiple
716 1.00
1.48
(ref)
(1.16-1.88) 0.002
305 1.00
1.41
(ref)
(0.90-2.21) 0.129
135 1.00
1.82
(ref)
(1.16-2.84) 0.009
Treatment
Mitomycin C
Epirubicin
722 1.00
1.36
(ref)
(1.09-1.69) 0.006
305 1.00
1.33
(ref)
(0.94-1.89) 0.110
- - - -
NA = not applicable to primary patients; - = no data available due to 100% treatment with mitomycin C.
Table 5  Adjusted hazard ratios (HR) and 95% confidence intervals (CI), using multivariable Cox-regression with selection 
procedures for time to recurrence for the three cohorts
Dutch cohort (n=724) Dutch subcohort of primary 
patients (n=305)
Spanish cohort (n=137)
HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
Primary versus recurrent
Primary
Recurrent
1.00
1.48
(ref)
(1.17-1.88) 0.001
NA
NA
(NA)
(NA) NA
NA
NA
(NA)
(NA) NA
History of intravesical treatment
None
Yes
1.00
1.38
(ref)
(1.05-1.80) 0.021
NA
NA
(NA)
(NA) NA
NA
NA
(NA)
(NA) NA
Tumor grade
G1
G2
1.00
1.22
(ref)
(0.99-1.51) 0.061
1.00
1.11
(ref)
(0.78-1.58) 0.485
1.00
0.94
(ref)
(0.48-1.85)
0.861
No. of tumors
Single
Multiple
1.00
1.56
(ref)
(1.20-2.01) 0.001
1.00
1.47
(ref)
(0.92-12.34) 0.286
1.00
1.80
(ref)
(1.15-2.84) 0.011
Treatment
Mitomycin C
Epirubicin
1.00
1.27
(ref)
(1.00-1.62) 0.048
1.00
1.24
(ref)
(0.84-1.84) 0.278
-
-
-
- -
NA = not applicable to primary patient; - = no data available due to 100% treatment with mitomycin C.
Prediction model
The recurrence probabilities of the final Cox-regression model at 1, 2 and 5 years are 
presented in an easy readable table (Table 6). In general, estimated recurrence-free 
probabilities varied between 89% (95%CI 86-93) for a single primary G1-tumor treated 
with MMC at one year, and 15% (95%CI 9-25) for multiple recurrent G2-tumors treated 
with epirubicin at five years. The c-index for this RFS-model was 0.60, 0.62 and 0.63 
at year 1, 2 and 5, respectively. Three risk groups were constructed based on the risk 
profiles of the final model. The Kaplan-Meier curves of minor, moderate, and major risk 
based on the risk profiles of the final model are presented in Figure 1. 
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The model can distinguish clearly between recurrence outcomes, e.g. a patient with 
multiple G2 recurrences without previous treatment who received adjuvant treatment 
with epirubicin has according to Table 6 67% change of being recurrence-free at 12 
months, which is associated with major risk in Figure 1. We calculated sensitivity, 
specificity, PPV and NPV for minor risk patients at 2 years (Table 7). PPV is 68.4% and 
NPV is 65.2%. 
Demographics of Spanish cohort and external validation
For the external validation, a cohort of 137 Spanish patients was used (treatment and 
demographics can be found in Table 2 and 3). 
Table 6  Probabilities of being recurrence-free at 1, 2 and 5 years in patients with non-muscle-invasive bladder cancer after treatment 
with intravesical chemotherapy
Primary Recurrent
Previous treatment
One year No Yes
Grade 1 Single Mitomycin C
Epirubicin
89 (86-93)
87 (82-91)
85 (80-89)
81 (76-86)
79 (73-87)
75 (76-83)
Multiple Mitomycin C
Epirubicin
84 (79-89)
80 (75-85)
77 (71-83)
72 (67-77)
70 (62-79)
63 (56-71)
Grade 2 Single Mitomycin C
Epirubicin
87 (83-91)
84 (79-89)
81 (76-87)
77 (71-83)
75 (68-84)
70 (62-79)
Multiple Mitomycin C
Epirubicin
81 (76-86)
76 (71-81)
73 (66-80)
67 (60-74)
64 (56-75)
57 (49-67)
Two years
Grade 1 Single Mitomycin C
Epirubicin
80 (73-86)
74 (67-82)
71 (63-79)
64 (57-73)
62 (52-74)
54 (44-67)
Multiple Mitomycin C
Epirubicin
69 (62-77)
63 (56-70)
58 (50-68)
50 (44-57)
47 (37-60)
39 (31-49)
Grade 2 Single Mitomycin C
Epirubicin
75 (69-82)
69 (62-78)
65 (57-75)
58 (50-68)
56 (45-69)
48 (37-61)
Multiple Mitomycin C
Epirubicin
64 (57-72)
57 (50-64)
52 (43-63)
43 (36-52)
40 (30-54)
31 (23-42)
Five years
Grade 1 Single Mitomycin C
Epirubicin
68 (60-78)
61 (52-72)
57 (47-68)
49 (40-59)
46 (34-61)
37 (27-52)
Multiple Mitomycin C
Epirubicin
55 (47-65)
47 (39-55)
41 (32-53)
33 (26-41)
30 (20-44)
21 (14-32)
Grade 2 Single Mitomycin C
Epirubicin
63 (54-72)
55 (46-66)
50 (40-62)
41 (32-53)
39 (28-54)
30 (20-44)
Multiple Mitomycin C
Epirubicin
48 (40-58)
40 (33-48)
34 (25-47)
25 (18-35)
23 (14-37)
15 (9-25)
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Table 6  Probabilities of being recurrence-free at 1, 2 and 5 years in patients with non-muscle-invasive bladder cancer after treatment 
with intravesical chemotherapy
Primary Recurrent
Previous treatment
One year No Yes
Grade 1 Single Mitomycin C
Epirubicin
89 (86-93)
87 (82-91)
85 (80-89)
81 (76-86)
79 (73-87)
75 (76-83)
Multiple Mitomycin C
Epirubicin
84 (79-89)
80 (75-85)
77 (71-83)
72 (67-77)
70 (62-79)
63 (56-71)
Grade 2 Single Mitomycin C
Epirubicin
87 (83-91)
84 (79-89)
81 (76-87)
77 (71-83)
75 (68-84)
70 (62-79)
Multiple Mitomycin C
Epirubicin
81 (76-86)
76 (71-81)
73 (66-80)
67 (60-74)
64 (56-75)
57 (49-67)
Two years
Grade 1 Single Mitomycin C
Epirubicin
80 (73-86)
74 (67-82)
71 (63-79)
64 (57-73)
62 (52-74)
54 (44-67)
Multiple Mitomycin C
Epirubicin
69 (62-77)
63 (56-70)
58 (50-68)
50 (44-57)
47 (37-60)
39 (31-49)
Grade 2 Single Mitomycin C
Epirubicin
75 (69-82)
69 (62-78)
65 (57-75)
58 (50-68)
56 (45-69)
48 (37-61)
Multiple Mitomycin C
Epirubicin
64 (57-72)
57 (50-64)
52 (43-63)
43 (36-52)
40 (30-54)
31 (23-42)
Five years
Grade 1 Single Mitomycin C
Epirubicin
68 (60-78)
61 (52-72)
57 (47-68)
49 (40-59)
46 (34-61)
37 (27-52)
Multiple Mitomycin C
Epirubicin
55 (47-65)
47 (39-55)
41 (32-53)
33 (26-41)
30 (20-44)
21 (14-32)
Grade 2 Single Mitomycin C
Epirubicin
63 (54-72)
55 (46-66)
50 (40-62)
41 (32-53)
39 (28-54)
30 (20-44)
Multiple Mitomycin C
Epirubicin
48 (40-58)
40 (33-48)
34 (25-47)
25 (18-35)
23 (14-37)
15 (9-25)
Table 7  Sensitivity, specificity, positive and negative predictive value for minor risk 
patients at 2 years
n/N %
Patients who had a recurrence and are moderate or major risk 
(sensitivity)
210/298 70.5%
Patients who had no recurrence and are minor risk (specificity) 165/362 45.6%
Patients with moderate or major risk who recurred (positive 
predictive value)
210/307 68.4%
Patients with minor risk who remained recurrence-free 
(negative predictive value)
135/253 65.2%
In Table 5 we present the HR of the prediction model combining the Spanish data 
and the data of the Dutch subcohort (n=305). It needs to be stressed that in the 
Spanish cohort only 10 patients had grade 1. Therefore, only the HR of the number 
of tumors was updated using the data of Dutch subcohort and the Spanish cohort. 
The associated Kaplan-Meier curves are presented in Figure 2. The HR of the number 
of tumors of 1.65 (95%CI 1.28-2.00) in the combined cohorts was comparable to the 
development (Dutch) cohort: 1.56 (95%CI 1.20-2.01). 
Figure 1  Proportion of recurrence-free patients per risk group
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DISCUSSION
In this article, we present a study comparing recurrence outcome and treatment options 
for the heterogeneous spectrum of IR-patients and we propose a prediction model on 
recurrence probabilities with external validation. This is very important as the number 
of IR-patients is high and due to heterogeneity the choice of best treatment can be 
challenging. We found five independent predictors for RFS: a history of recurrences, 
history of previous treatment, tumor grade, number of tumors and adjuvant treatment 
type, with hazard ratios of 1.48, 1.38, 1.22, 1.56 and 1.27, respectively. There is a huge 
difference between 1 year and 5 years outcome, and between having none or all of the 
independent predictors (Table 6). This is why we split the IR-group into three subgroups 
(minor, moderate, and major risk). Now, the recurrence probabilities as predicted in 
Table 6 can be related to a risk group in Figure 1. As mentioned in the recent systematic 
review of Kamat et al. (5) the IR-patients are a group of very divers patients, and in the 
international guidelines there is no clear consensus about the best treatment for these 
patients. As can be seen in Figure 1, the three risk groups have their own recurrence 
profile and thus should be treated different (more or less aggressive). Therefore, to the 
best of our knowledge, this study is the first to investigate outcome specifically in IR-
patients and relate the outcome to intravesical chemotherapy. 
The EORTC have developed risk tables based on a group of 2596 patients treated 
in seven EORTC studies with different treatments and with different risk profiles (4). 
Figure 2  The 2-year probability of recurrence-free by number of tumors and by cohort,  
using Kaplan-Meier analyses.
A  Dutch subcohort of primary patients (n=305) B  Spanish cohort (n=137)
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However, the EORTC risk tables have several limitations: 22% of patients received no 
intravesical treatment at all, only 171 patients (7%) received treatment with bacillus 
Calmette-Guerin (BCG) and none received BCG-maintenance. Therefore, the EORTC 
risk tables could be interpreted as probabilities of the untreated natural history of 
the disease, especially for progression. Another well-known prediction model is the 
scoring model of Club Urologico Español de Tratamiento Oncologico (CUETO) (9). 
Data of 1062 patients, all treated with BCG, were used to identify risk factors for 
recurrence and progression after BCG-treatment. Several other prediction models 
have been developed for NMIBC (10-16), but none of them included solely patients 
that, according to the guidelines, should have been and in fact were treated with 
intravesical chemotherapy. 
Recently, Kamat et al. developed an algorithm specifically for IR-patients based on the 
consensus of the IBCG (5). They consider tumor size, tumor multiplicity, timing and 
frequency of recurrences, and previous treatment to be key factors. Based on these 
key factors, they divide IR-patients in three groups: patients having none of the factors 
can be considered to be, and should be treated as low risk patients; patients with one 
or two factors are the ‘true’ IR-patients and should receive adjuvant treatment, choice 
of treatment depends on (results of) previous intravesical treatment; patients with three 
or more factors should be considered to be, and must be treated as high risk patients 
(BCG-maintenance). Our analyses and model support these recommendations; only 
tumor size is of no influence in our model, and tumor grade is not considered to be a 
key factor by the IBCG. 
Concerning tumor diameter, Kamat et al. do mention that the well-known cutoff of 
3cm might be no longer relevant as the number of patients with large tumors is very 
low (5), which we could confirm (in the Dutch cohort only 6%). Within the IBCG it was 
suggested to further study a new cutoff of 1cm, which was also the median tumor 
diameter in our cohort. However, when analyzing tumor diameter with a cutoff of 
1cm in our cohort, no statistical significant influence on recurrence outcome was seen 
(p=0.480), but this might be due to the high number of missing data. 
The term ‘low grade’ is based on the WHO-2004 grading system, which was not 
yet available during the inclusion period of the three Dutch studies. Therefore, we 
considered G1- and G2-tumors to be low grade, but G2-tumors are a mixture of low 
grade and high grade tumors. According to Chen et al. approximately 80% of the G2-
tumors are low grade (17). Thus, in this study we could have misclassified 75 patients, 
and consequently these patients could be treated insufficiently with subsequently 
more recurrences. However, the EAU-guideline recommends to use both the 1973 and 
the 2004 classification until the 2004 classification is validated. 
74
II.3  |  Prediction model recurrence probabilities for intermediate risk patients
In this study we showed that epirubicin is inferior to MMC: it was an independent 
predictor for shorter RFS with HR of 1.27. There is sparse literature comparing MMC to 
epirubicin: three studies found no differences (18-20), and one study comparing MMC 
to epirubicin in marker lesion setting found less complete response after treatment 
with epirubicin compared to MMC: 56% versus 67% (21). Indirect comparison is 
possible with more up-to-date data, e.g. EORTC 30911 study (22) versus Ojea et al. 
(23): both studies are multicenter randomized clinical trials for IR-patients, in which the 
patients were treated with complete TURBT, induction and maintenance treatment. 
The EORTC 30911 study randomly assigned patients for either epirubicin or BCG; in 
the study by Ojet et al. patients were randomly assigned for either MMC or BCG. 
The indirect comparison between epirubicin and MMC shows more recurrences, 
progression and death due to bladder cancer after epirubicin compared to MMC: 
59% versus 39%, 14% versus 9%, and 7% versus 5%, respectively. This is in line with the 
expert opinions and with our results. However, a proper comparison is lacking.
The c-index of our model was 0.60, 0.62 and 0.63 at year 1, 2 and 5, respectively. This 
is comparable to the c-index for recurrence probabilities of the EORTC risk tables 
(0.66 both at 1yr and 5yrs) and that of the CUETO scoring model (0.64 both at 1yr and 
5yrs) (4, 9). However, the clinical relevance of the c-index is doubtful and there is no 
consensus how high the c-index should be to make a model clinically relevant. For 
a more practical approach we split the patients based on their risk factors in three 
subgroups: minor, moderate and major risk. As can be seen in Figure 1, this subdivision 
is clearly related to recurrence outcome and thus one could considered to treat the 
major risk group more aggressively, and the minor risk group less aggressively. The 
relevance of this subdivision is also reflected in the predictive accuracy of our model 
(Table 7). For treatment options NPV and PPV are more important than sensitivity 
and specificity, as this is associated with under- and overtreatment. Compared to the 
EORTC and CUETO our model is clearly better in preventing overtreatment in minor 
risk patients as PPV is much higher (68% versus 21% and 24%) but NPV is somewhat 
lower (65% versus 94% and 92%) which, however, is less of a problem in minor risk 
patients (24). Additionally, the external validation shows very good overlap in HR. 
However, as the Spanish cohort only included primary patients, it is in fact a partial 
external validation. Nevertheless, as agreement between the Dutch subcohort and the 
Spanish cohort is high, one could hypothesize that these result could be extrapolated 
to the total model. An external validation including primary and recurrent patients 
would give us an answer to this hypothesis.
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Limitations of this study are the long inclusion period, the missing data, and the 
differences with the current standard of treatment including the quality of TURBT 
due to e.g. the introduction of fluorescence cystoscopy, and the lack of POI in most 
patients (only 23% of patients received POI). Oppositely, fluorescence cystoscopy is 
most useful in CIS, and we excluded CIS-patients. In the Dutch cohort no re-TURBT 
was done, but this is not always necessary in IR-patients. Thus, there is a chance that 
the probabilities overestimate those found in current clinical practice. Also, using 
combined data from different studies where the intent of the individual studies was 
not the same might subject the analyses to biases and confounding factors. Another 
limitation is the variability in adjuvant treatment, including the dose, the concentration 
of chemotherapy used, and the treatment schedule which might have influenced the 
outcome. However, median number of instillations received was 10, and only 2.1% 
of patients received less than six instillations. Since differences in efficacy between 
intravesical chemotherapy regimens are not evident, both European and American 
guidelines do not recommend specific chemotherapy schedules (2, 25). 
CONCLUSION
Treatment of IR-NMIBC-patients is difficult due to heterogeneity. We developed 
an easy readable risk table for IR-patients treated with intravesical chemotherapy 
including five independent variables predicting shorter RFS: history of recurrences, 
history of intravesical treatment, grade 2, multiple tumors and adjuvant treatment 
with epirubicin, with hazard ratios of 1.48, 1.38, 1.22, 1.56 and 1.27, respectively. 
These variables were used to subdivide these patients into three risk groups, which 
is related to recurrence outcome and could be a decision guide for further treatment. 
Internal validation showed sufficient discrimination and good accuracy. Partial external 
validation with Spanish data showed good overlap.
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ABSTRACT
Objective
To compare the risks according to the American Urological Association (AUA), European 
Association of Urology (EAU), European Organization for Research and Treatment of 
Cancer (EORTC) and Club Urológico Español de Tratamiento Oncologico (CUETO) 
classifications with real outcomes in a cohort of patients in the Netherlands, and to 
confirm that patients who were undertreated according to these risk models have 
worse outcomes than adequately treated patients.
Patients and methods
Patients treated with complete transurethral resection of bladder tumour and 
intravesical chemotherapy were included. Not all patients would have received 
intravesical chemotherapy had they been treated to current standards, and thus 
comparison of the observed outcomes in our Dutch cohort vs expected outcomes 
based on the EORTC risk tables and CUETO scoring model was possible. The cohort 
was reclassified according to the definitions of five Index patients (IPs), as defined by 
the AUA guidelines, and three risk groups, defined according to the EAU guidelines, 
to compare the outcomes of undertreated patients with those of adequately treated 
patients. 
Results
A total of 1001 patients were available for comparison with the AUA definitions and 
728 patients were available for comparison with the EORTC and CUETO models. 
There was a large overlap between the observed outcomes and expected recurrence 
and progression probabilities when comparison was made using the EORTC risk 
tables. The observed recurrence outcomes were in general higher than the expected 
probabilities according to the CUETO risk classification, especially in the long term. 
No differences in progression were found when comparing these two models to the 
Dutch cohort. Patients who were undertreated according to the guidelines showed, in 
general, a higher risk of developing recurrence and progression. Limitations are i.a. its 
retrospective nature and the differences in grading system. 
Conclusion
Comparison between the observed outcomes in our Dutch cohort and the expected 
outcomes based on EORTC and CUETO risk models and the EAU and AUA guidelines 
showed that the lack of adherence to existing guidelines translates into worse 
outcomes.
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INTRODUCTION
In the Western world, bladder cancer is the sixth most common cancer in men and 
the seventeenth most common cancer in women (1). Approximately 75% of bladder 
cancer is non-muscle-invasive bladder cancer (NMIBC). NMIBC has a spectrum of 
aggressiveness for both recurrence and progression: from low grade Ta urothelial 
carcinomas to high grade T1 urothelial carcinomas and/or carcinoma in situ (CIS). 
Several risk models and guidelines are commonly used to predict outcomes for NMIBC 
after treatment. In 2006, Sylvester et al. (2) developed risk tables based on seven 
studies of the European Organization for Research and Treatment of Cancer (EORTC). 
Four groups of patients with different probabilities on recurrence and progression 
were identified. The European Association of Urology (EAU) guidelines used these risk 
tables to construct three groups of patients: low, intermediate and high risk (3). The 
guidelines provide recommendations for adjuvant treatment, depending on the risk 
group: all patients should receive complete transurethral resection of bladder tumour 
(TURBT), followed by a single postoperative instillation of chemotherapy. Further 
treatment depends on the risk group (Table 1). In 2007, the American Urological 
Association (AUA) also developed guidelines for the treatment of NMIBC (4). Based 
on tumour characteristics, five index patients (IP) were identified, for each of which the 
AUA guideline recommended on treatment options (Table 1).
Finally, Fernandez et al. developed a scoring model to predict outcomes after 
treatment with Bacillus Calmette-Guérin (BCG) (5). The Club Urológico Español de 
Tratamiento Oncologico (CUETO) combined data of 1062 patients, almost all treated 
with at least six BCG instillations after complete TURBT. They categorized patients 
into four groups accordint to score, and calculated 1-, 2- and 5-year recurrence and 
progression probabilities for each group. 
The aim of the present study was to compare the risks according to the AUA, EAU, 
EORTC and CUETO classifications with the real outcomes of a cohort of patients in 
the Netherlands. Furthermore, we wanted to confirm that patients who had been 
undertreated according to current guidelines had worse outcomes than adequately 
treated patients. 
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Table 1  Classification of patients according to the AUA and EAU guideline and recommended 
treatments
IP/ Risk group Definition and recommended treatment No. of patients in 
Dutch cohort (%)
AUA IP
IP 1 Patients who present with suspicion of bladder cancer. 
Recommended treatment: complete transurethral 
resection of all visible bladder tumours (TURBT) and 
pathological analyses.
0 (0)
IP 2 Patients with a small volume, low-grade Ta bladder 
tumour. 
Recommended treatment: postoperative instillation. 
19 (2)
IP 3 Patients with a multifocal and/or large volume low-
grade Ta tumour, or a patient with a recurrent low-
grade Ta tumour. 
Recommended treatment: an induction course with 
either intravesical MMC or BCG. Maintenance treatment 
is an option. 
696 (69)
IP 4 Patients with a high-grade Ta/T1 bladder tumour, and/
or CIS.
Recommended treatment: (re-)TURBT, then an 
induction course with BCG, followed by maintenance 
BCG. 
264 (26)
IP 5 Patients with a recurrent high-grade Ta/T1 bladder 
tumour, and/or recurrent CIS. Recommended 
treatment: cystectomy or intravesical treatment 
(optional). 
22 (2)
EAU risk groups
Low risk of 
recurrence
Score 0. Recommended treatment: one immediate 
instillation of chemotherapy
1 (0.1)
Intermediate 
risk of 
recurrence
Score 1-9. Recommended treatment: one immediate 
instillation of chemotherapy, followed by further 
instillations, either chemotherapy or a minimum of 
1yr BCG (the final choice is determined by the risk of 
tumour progression)
686 (92)
High risk of 
recurrence
Score 10-17. Recommended treatment: one immediate 
instillation of chemotherapy, followed by further 
instillations, either chemotherapy or a minimum of 
1yr BCG (the final choice is determined by the risk of 
tumour progression)
59 (8)
Low risk of 
progression
Score 0. Recommended treatment: one immediate 
instillation of chemotherapy (followed by further 
chemotherapy instillations if the patient has an 
intermediate risk of recurrence at the same time)
19 (3)
Intermediate 
risk of 
progression
Score 2-6. Recommended treatment: One immediate 
instillation of chemotherapy, followed by a minimum of 
1 yr of BCG or further chemotherapy instillations
524 (72)
High risk of 
progression
Score 7-23. Recommended treatment: Intravesical BCG 
for at least 1 yr or immediate cystectomy
185 (25)
AUA = American Urological Association; EAU = European Association of Urology; CIS = 
carcinoma in situ; BCG = bacillus Calmette Guerin; IP = index patient; MMC = mitomycin C; 
TURBT = transurethral resection of bladder tumour.
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PATIENTS AND METHODS
Data of three Dutch studies (6-8) were available for analyses. All the studies included 
patients with NMIBC treated with complete TURBT and adjuvant intravesical treatment 
(BCG, epirubicin, mitomycin C [MMC], keyhole limpet hemocyanin). Only patients 
treated with intravesical chemotherapy, epirubicin or MMC, were included in the 
present analyses. These patients were treated between May 1987 and October 2010 in 
41 hospitals in the Netherlands. Details of treatment schedule and follow-up regimes 
have been described previously (6-8).
Briefly, Vegt et al. (6) compared BCG RIVM strain to BCG Tice strain and MMC. Patients 
in the MMC group received 10 or 13 instillations with 30mg MMC in 50mL saline. The 
schedule consisted of four weekly instillations and six monthly instillations. If the 
disease recurred or persisted after 6 months, three additional monthly instillations 
were given. In the epirubicin study of Hendricksen et al. (7), patients were treated 
with 50mg epirubicin in 50mL NaCl in three different schedules: group 1 received four 
weekly and five monthly instillations (standard schedule); group 2 received the standard 
schedule with an additional instillation <48h after TURBT; and group 3 received the 
standard schedule with two additional instillations at 9 and 12 months. In the KLH-
study by Lammers et al. (8) patients were randomized for either KLH or MMC. Patients 
in the MMC group received four weekly instillations, five monthly instillations and two 
additional instillations at 9 and 12 months, with 40mg MMC in 50mL saline. Follow-
up in all three studies included urinary cytology and cystoscopy at 3-month intervals 
during the first 1 or 2 years, and thereafter at 4- and 6-month intervals.
For the analyses in the present retrospective study, we took advantage of the fact 
that not all of the patients would have received intravesical chemotherapy had they 
been treated according to current guidelines. Thus, part of these Dutch patients 
received substantially more or less treatment as recommended by the current 
treatment standards; some of the patients in our cohort received substantially more or 
less treatment then recommended by these guidelines. This enabled us to compare 
expected outcomes according to the EORTC risk tables and CUETO scoring model 
with the observed outcomes. The patient cohort of the present study was reclassified 
according to the definitions of the four risk groups of the EORTC and observed 
outcomes were compared with both recurrence and progression probabilities at years 
1, 2 and 5. 
Treatment recommendations from the AUA and EAU guidelines were also applied to 
the patient cohort: we reclassified the patients according to the five IP definitions in the 
AUA guidelines and the three risk groups in the EAU guidelines. As all the patients were 
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treated with intravesical chemotherapy, it was possible to compare the outcomes of 
undertreated patients (patients who should have received more aggressive treatments, 
e.g. BCG, cystectomy, according to the guidelines) with adequately treated patients 
(patients who received intravesical chemotherapy according to the guidelines).
The outcomes measures are recurrence- (RFS) and progression-free survival (PFS). 
Both recurrences and progression were diagnosed by cystoscopy and/or cytology and 
were confirmed by histological examination. 
We investigated the number of patients who experienced recurrence and progression, 
and RFS and PFS rates. Two-sided Fisher’s exact tests were used to compare numbers 
of patients, and log-rank tests and Kaplan-Meier analyses were used to compare for 
RFS and PFS rates. A P-value <0.05 was considered to indicate statistical significance. 
RESULTS
Data were available on 1045 patients after combining the three studies. Figure 1 is a 
flow chart showing the analyses performed. 
Data on 728 patients were available for comparison with the EORCT and CUETO 
scoring models (last column of Table 2). Data from 327 patients were incomplete and 
these patients were therefore excluded from this comparison analysis. The patients 
were reclassified according to the EORTC risk groups in concordance with the EAU 
guidelines.
Table 3 shows the expected outcome probabilities at years 1, 2 and 5 according to the 
EORTC risk tables and CUETO scoring model, compared to the observed outcomes of 
the 728 patients who were all treated with intravesical chemotherapy. 
Unfortunately, 2-year probabilities as expected according to the EORTC risk tables 
were not available. In general, comparison using the EORTC risk tables showed that 
the observed recurrence probabilities in the present Dutch cohort were somewhat 
lower than the expected recurrence probabilities. Expected and actual progression 
rates were similar; there was a large overlap between the observed rates and expected 
probabilities. Comparison with the CUETO scoring model showed, not surprisingly, 
that the observed recurrence rates in the Dutch cohort were higher than the expected 
recurrence probabilities, especially in the long term (5-year probabilities). There was 
much overlap between observed and expected progression probabilities according to 
the CUETO scoring model.
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Figure 1  Flow chart showing performed analyses
AUA = American Urology Association. EAU = European Association of Urology. 
EORTC = European Organisation for Research and Treatment of Cancer. CUETO = 
Club Urologico Espanol de Tratamiento Oncologico. IP = index patients.
Three combined studies: 
1045 patients
A total of 1001 patients available 
for comparison with the AUA 
guidelines; 44 patients with 
missing data. Table 1 and 2. 
A total of 728 patients available 
for comparison with the EAU 
guidelines; 317 patients with 
missing data. Table 1 and 2.
AUA guidelines compared with 
Dutch cohort: undertreated (IP 4 
and IP5) vs adequately treated (IP3). 
Table 4.
Dutch cohort vs EORTC risk 
tables and CUETO scoring model. 
Patients in Dutch cohort were 
reclassified according to the four 
EORTC risk groups. 
Table 3.
EAU guidelines compared with 
the Dutch cohort: undertreated vs 
adequately-treated. Table 5.
Figure 1  Flow chart showing performed analyses
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Table 2  Baseline demographics of patients in the Dutch cohort, all treated with 
intravesical chemotherapy
Characteristics No. of patients 
reclassified into 
AUA IP groups
No. of patients 
reclassified into EAU 
risk groups
Available for analysis, n (%) 1001 (100) 728 (100)
Sex, n (%)
Male
Female
Unknown
816 
183 
2
(82)
(18)
600 
127 
1
(83)
(18)
Median (range) age 66.8 (33-89) 68.3 (33-86)
Primary or recurrent, n (%)
Primary
Recurrent
518 
483 
(52)
(48)
381 
347 
(52)
(48)
History of CIS, n (%)
No
Yes
Unknown
831 
12 
158
(99)
(1)
650 
7 
71
(99)
(1)
Previous treatment, n (%)
No
Yes
831 
140 
(86)
(14)
619 
103 
(86)
(14)
Tumour stage, n (%)
Ta
T1
761 
240 
(76)
(24)
568 
160 
(78)
(22)
Tumour grade*1 , n (%)
G1
G2
G3
385 
493 
123 
(39)
(49)
(12)
294 
346 
88 
(40)
(48)
(12)
CIS, n (%)
No
Yes
Unknown
987 
7 
7
(99)
(1)
728 
0
0
(100)
Number of tumours, n (%)
Single
Multiple
Unknown
250 
743 
8
(25)
(75)
184 
544 
0
(25)
(75)
Tumour size, n (%)
<3cm
≥3cm
Missing
579 
156 
266
(79)
(21)
574 
154 
0
(79)
(21)
Adjuvant treatment, n (%)
Epirubicin
Mitomycin C
680 
321 
(68)
(32)
518 
210 
(71)
(29)
Median (range) number of instillations
Treated according to study 
protocol*2, n (%)
Missing, n
10 
837 
78
(1-11)
(91)
10 
672 
0
(1-11)
(92)
AUA IP, n (%)
IP 2
IP 3
IP 4
IP 5
19 
696 
264 
22 
(2)
(69)
(26)
(2)
NA
NA 
NA
NA
EAU risk group for recurrence, n (%) 
Low risk
Intermediate risk
High risk
NA
NA
NA
1 
668 
59 
(0.1)
(92)
(8)
EAU risk group for progression, n (%)
Low risk
Intermediate risk
High risk
NA
NA
NA
19 
524 
185 
(3)
(72)
(25)
Median (range) follow-up in months
Missing
29.6 
21
(2-239) 28.2 
0
(2-76)
*1 Tumour grade was classified according to the 1973 WHO grading system. *2 One of 
five treatment schedules as described in the study protocol of the three studies. AUA = 
American Urology Association. EAU = European Association of Urology. CIS = carcinoma 
in situ. IP = index patient. NA = not applicable.
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Table 2  (continued)
Characteristics No. of patients 
reclassified into 
AUA IP groups
No. of patients 
reclassified into EAU 
risk groups
AUA IP, n (%)
IP 2
IP 3
IP 4
IP 5
19 
696 
264 
22 
(2)
(69)
(26)
(2)
NA
NA 
NA
NA
EAU risk group for recurrence, n (%) 
Low risk
Intermediate risk
High risk
NA
NA
NA
1 
668 
59 
(0.1)
(92)
(8)
EAU risk group for progression, n (%)
Low risk
Intermediate risk
High risk
NA
NA
NA
19 
524 
185 
(3)
(72)
(25)
Median (range) follow-up in months
Missing
29.6 
21
(2-239) 28.2 
0
(2-76)
*1 Tumour grade was classified according to the 1973 WHO grading system. *2 One of 
five treatment schedules as described in the study protocol of the three studies. AUA = 
American Urology Association. EAU = European Association of Urology. CIS = carcinoma 
in situ. IP = index patient. NA = not applicable.
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We had sufficient data of 1001 of the 1045 patients to categorize them according to the 
five AUA guideline IPs (Table 2). All of our patients received intravesical chemotherapy. 
As expected, those patients who were actually in the high risk category (AUA IP 5) 
had a significant higher rate of progression than expected with only intravesical 
chemotherapy (Table 4). Similarly, of the 728 patients whose data were available for 
Table 3  Comparison of expected outcomes according to the EORTC risk tables and 
CUETO scoring model vs observed outcomes in the Dutch cohort
   
95%CI 
recurrence 
probabilities 
at 1 year 
95%CI 
recurrence 
probabilities 
at 2 years
95%CI 
recurrence 
probabilities 
at 5 years
Lowest score 
for recurrence
EORTC 0
CUETO 0-4
Dutch cohort 0
10-19
6-11
NE
 NA
10-15
NE
24-37
17-25
NE
  EORTC 1-4
CUETO 5-6
Dutch cohort 1-4
21-26
8-16
16-21
 NA
17-28
26-32
42-49
29-42
44-55*
 
EORTC 5-9
CUETO 7-9
Dutch cohort 5-9
35-41
20-31
27-31
 NA
33-46
48-53*
58-65
41-55
66-71*
Highest score 
for recurrence
EORTC 10-17
CUETO 10-16
Dutch cohort 10-17
55-67
28-56
41-54
 NA
38-67
59-72
73-84
54-82
NE
   
95%CI 
progression 
probabilities
at 1 year
95%CI 
progression 
probabilities 
at 2 years
95%CI 
progression 
probabilities 
at 5 years
Lowest score 
for progression
EORTC 0
CUETO 0-4
Dutch cohort 0
0-0.7
0.2-2
NE
NA 
0.8-4
NE
0-1.7
2-6
NE
 
EORTC 2-6
CUETO 5-6
Dutch cohort 2-6
0.4-1.6
0.8-5
0.8-2
 NA
2-8
2-3
5-8
8-16 
NE
 
EORTC 7-13
CUETO 7-9
Dutch cohort 7-13
4-7
3-8
3-7
 NA
8-16
4-9
14-20
16-27
NE
Highest score 
for progression
EORTC 14-23
CUETO 10-16
Dutch cohort 14-23
10-24
7-21
NE
NA 
16-34
NE
35-55
23-44
NE
The Dutch cohort was reclassified according to the EORTC risk groups. * No overlap in 
95% CI, and thus significantly different. EORTC = European Organization for Research and 
Treatment of Cancer; CUETO = Club Urologico Espanol de Tratamiento Oncologico; CI = 
confidence interval; NE = no events; NA = not available. 
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Table 4  Outcome comparison of the Dutch cohort after reclassification according to the AUA IP 
definitions
IPs3 (adequately treated) IPs4 (undertreated) IPs5 (undertreated)
N (%) N (%) P *1 N (%) P *1
Number of patients 696 (100) 264 (100) 22 (100)
Number of recurrences 403 (58) 154 (58) 0.942 17 (77) 0.008
Median RFS, months 29 30 0.955 16 0.014
Number of progression 15 (2) 30 (11) <0.001 3 (14) 0.015
Mean PFS, months*2 113 139 <0.001 48 <0.001
*1 Comparison with IPs3. *2 Median PFS was not possible to calculate due to low numbers of progression 
events. AUA = American Urological Association; IP = index patient; RFS = recurrence-free survival in 
months; PFS = progression-free survival in months. 
Table 5  Outcome comparison of the Dutch cohort after reclassification according to 
definition of risk groups according to the EAU guidelines
Adequately treated group Undertreated group P
N (%) N (%)
Number of patients 542 (100) 185 (100)
Number of recurrences 287 (53) 117 (63) 0.016
Median RFS, months 37 21 0.002
Number of progression 11 (2) 18 (10) <0.001
Mean PFS, months* 74 64 <0.001
* Median PFS was not possible to calculate due to low numbers of progression events. 
EAU = European Association of Urology; RFS = recurrence-free survival in months; PFS 
= progression-free survival in months.
comparison with the EAU risk groups, 185 patients who did not receive adequate 
treatment according to the EAU guidelines had significantly worse outcomes for both 
recurrence and progression (Table 5). 
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DISCUSSION
In the present study we tried to confirm the relevance of classifying patients for 
treatment recommendations using a combined dataset of patients treated with 
intravesical chemotherapy in the Netherlands. We also investigated the implications 
of the fact that not all of these patients would have received intravesical chemotherapy 
if they were treated according to the current standards. 
We compared the observed recurrence and progression outcomes in the Dutch cohort 
with expected outcomes according to the EORTC risk tables and CUETO scoring 
model. Not surprisingly, there was much overlap between the observed rates and the 
predictions according to the EORTC risk tables. 
In the EORTC cohort by Sylvester et al. (2), 21% of the patients did not receive intravesical 
treatment and ~10% of the patients received only a single immediate postoperative 
instillation. Likewise, ~6-7% of these patients received induction BCG. This reflects the 
fact that patients in the EORTC study by Sylvester et al. (2) were treated in a different 
time frame from that the present Dutch cohort and therefore the comparison between 
the Dutch cohort and the EORTC is biased. Nevertheless, the EORTC risk tables are 
currently the most used prediction model in bladder cancer. 
The more recently CUETO cohort was a different cohort of patients in that patients 
had more aggressive tumour characteristics, and received BCG instillations, which is 
considered to be a more aggressive treatment; therefore, we expected the recurrence 
and progression probabilities in the CUETO cohort to be lower than the observed 
outcomes in the Dutch cohort, especially for progression, as a Cochrane meta-
analysis has shown that BCG is superior to chemotherapy in preventing progression 
(9). Indeed, the observed number of recurrences in the present Dutch cohort with 
low- and intermediate risk categories were higher than the expected recurrence 
probabilities at 2 years for the intermediate risk group, and at 5 years for both the 
low- and intermediate risk (Table 3); however, we found no difference in progression 
as there was much overlap between the observed progression rates and the expected 
progression probabilities (Table 4). 
Additionally, we found that, in general, patients in the high-risk group who should 
have been treated with more than intravesical chemotherapy only, outcomes were, 
not surprisingly, worse; undertreated patients were more prone to develop recurrence 
and progression. This also confirms that categorizing patients is relevant for outcomes. 
Furthermore, we were able to confirm the relevance of distinction in risk groups 
according to the EORTC risk model and EAU guidelines, as the actual outcomes were 
very much similar to the predicted outcomes mentioned in the EAU guidelines. 
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The overlap between the risk groups and outcomes may be attributable to the accuracy 
of the risk models: the accuracy of a model can be described by the concordance-
index (10), or, perhaps more appropriately, in terms of sensitivity, specificity, negative- 
(NPV) and positive predictive value (PPV). For the EORCT risk tables the concordance-
indices at 1 and 5 years were both 0.66, with a sensitivity of 64%, a specificity of 70%, a 
NPV of 94% and a PPV of 21%. For the CUETO scoring model the concordance-indices 
at 1 and 5 years is both 0.64, with a sensitivity of 60%, a specificity of 72%, a NPV of 92% 
and a PPV of 24% (11). The accuracy of the guidelines in general cannot be expressed 
in numbers.
Comparison of EAU/EORTC and CUETO risk groups with patient cohorts has been 
assessed before (12-20), but, to our knowledge, this is the first time that the classification 
of the IP as stated in the AUA guidelines has been compared with the actual outcomes 
in a cohort of patients with NMIBC treated with intravesical chemotherapy. This might 
be attributable to a frequent lack of compliance to the AUA guidelines, which has 
been shown in several studies (21-23). The most recent study was by Chamie et al. (23) 
who investigated if bladder cancer care was given in accordance with the guidelines in 
4545 patients with high grade NMIBC. They found that only one out of 4545 patients 
received all the recommended measures (eight cystoscopies, eight cytologies, two 
upper tract imaging studies, one postoperative instillation MMC and six instillations 
of BCG or another intravesical agent after TURBT); however, 1173 of the 4545 patients 
(25.8%) did receive six or more BCG-instillations after TURBT.
In contrast to patients categorized as being in low- and high-risk groups, there has 
been much discussion about the best treatment for intermediate-risk group patients. 
There is level 1 evidence that intravesical chemotherapy is better than TURBT alone 
in preventing recurrences (24, 25) and that BCG is better than chemotherapy in 
preventing recurrence (9, 26, 27), but treatment side effects have to be taken into 
account. The superiority of BCG compared to chemotherapy in the prevention of 
progression in intermediate-risk groups is less clear. Horvath et al. (28) have written 
a review about therapeutic options specifically for patients in the intermediate-risk 
group. They conclude that these patients are a heterogeneous group with varying risks 
of recurrence and progression. They recommend that patients receive one immediate 
instillation chemotherapy after TURBT, followed by further intravesical therapy to 
minimize the risk of recurrence and progression; however, they were unable to identify 
the optimum type of chemotherapy, the schedule and duration of treatment. These 
variables are also stated in the AUA and EAU guidelines (3, 4). 
When comparing the observed outcomes in the present Dutch cohort with the 
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expected outcomes according to the AUA guidelines, two issues had to be resolved. 
Firstly, there is no bladder tumour volume threshold in the AUA guidelines so we used 
the EORTC threshold of 3cm. Secondly, as the timeframe of the Dutch cohort was 
between 1987 and 2007, only the WHO 1973 grading system was available, but the 
AUA guidelines use the 2004 WHO grading system. We decided to consider G1 and 
G2 tumours as low grade tumours, and G3 tumours as high grade tumours, but, 1973 
WHO G2-tumours are a mixture of low grade and high grade tumours (Figure 2). 
Figure 2  Comparison of different grading systems
According to Chen et al. (29) ~80% of the G2 tumours are low grade, 20% of G2 
tumours are high grade and all G3 tumours are high grade. When extending these 
results to the present study, this would mean that we have misclassified 99 patients, 
and thus these patients were definitely undertreated as they should have received re-
TURBT and additional treatment. Chen et al. confirmed this: they found that G2 high 
grade tumours have significantly longer PFS than G3 high grade tumours. 
WHO = World Health Organization. ISUP = International Society of Urological Pathologists; 
PUNLMP = papillary urothelial neoplasm of low malignant potential; G = grade; LG = urothelial 
carcinoma of low grade malignancy; HG = urothelial carcinoma of high grade malignancy. 
Reproduced with permission from http://www.oncoline.nl 
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Recently, several studies have shown that there are certain advantages of WHO 1973 
grading over the WHO 2004 grading system. Otto et al. (30) concluded that the 
1973 WHO grading system is more suitable for predicting outcomes in pT1 tumours. 
Pellucchi et al. (31) found that both grading systems are effective in predicting tumour 
progression, but that WHO 1973 grading system is more suitable for predicting 
recurrences. Chen et al. (29) concluded the same; thus, the additional value of the 
WHO 2004 grading system over the WHO 1973 system is not yet clear. This is also 
recognized in the EAU guidelines, which state that both classification systems can 
be used until more prospective trials validate the prognostic role of the WHO 2004 
grading system (3). 
Other limitations of the present study are the number of missing data, the long 
inclusion period and the lack of a single postoperative instillation: only one of five 
combined studies in the present cohort included a single postoperative instillation. In 
our comparison this accounts for 161 patients (22%) in the comparison with the EAU 
guidelines and 215 patients (21%) in the comparison with the AUA guidelines.
Further limitations include the heterogeneity of the different adjuvant intravesical 
treatments and the fact that the treatments were not necessarily in accordance 
with the current EAU guidelines because of the dates of diagnosis (between 1987-
2010). In addition, the number of patients at high risk of recurrence included 
was low. Finally, in the original three studies from which our Dutch cohort 
was taken the patients were randomized, but in the present (retrospective) 
analyses, patients who were treated with chemotherapy were pooled. 
Despite its limitations one could consider the present study to be an external validation 
of the AUA and EAU guidelines as we confirmed that categorizing patients according 
to these guidelines is relevant, and that patients who are undertreated according 
to these guidelines are more prone to recurrence and progression compared with 
adequately treated patients.
To conclude, after comparing outcomes in a Dutch cohort with the expected outcomes 
according to the EORTC risk tables, CUETO scoring model and international 
guidelines, we confirmed the relevance of these patient classification systems. As 
expected we confirmed that undertreated patients according to these guidelines and 
scoring models, do have worse outcomes compared with adequately treated patients. 
Moreover, the study underlines that fact that suboptimum compliance with these 
guidelines is associated with potentially worse outcomes. 
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Chapter III.2 
Intracutaneous and intravesical 
immunotherapy with keyhole 
limpet hemocyanin is inferior 
to intravesical mitomycin-c in 
preventing recurrences in 
patients with non-muscle-
invasive bladder cancer: results 
from a prospective randomized 
phase III trial
Rianne J.M. Lammers, Wim P.J. Witjes, Maria H.C. Janzing-Pastors, 
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ABSTRACT
Purpose
Despite current treatment after transurethral resection of a bladder tumor, recurrences 
and progression remain a problem. Keyhole limpet hemocyanin (KLH) was beneficial 
in earlier studies. In this study, safety and efficacy of KLH were compared with that of 
mitomycin (MM). 
Patients and methods
Patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) 
without carcinoma in situ were enrolled in a randomized phase III trial. In all, 283 
patients were randomly assigned for 16 adjuvant intravesical instillations with KLH 
after preimmunization, and 270 patients were randomly assigned for 11 adjuvant 
intravesical instillations with MM. Primary outcome measurement was recurrence-
free survival (RFS). Secondary outcome measurements were progression-free survival, 
adverse events (AEs), and the effect of delayed-type hypersensitivity (DTH) response 
on clinical outcome.
Results
There were significantly more pT1 tumors in the MM group (P=0.01). In a log-rank 
test, univariate and multivariate Cox-regression analysis, KLH was less effective than 
MM regarding RFS (all P<0.001). Progression was uncommon (n=20). In univariate Cox-
regression analyses, KLH tended to prevent progression more effectively than MM, but 
in multivariate Cox-regression analyses, this could not be shown. AEs were common 
but mild. Fever, flu-like symptoms and fatigue occurred significantly more after KLH 
treatment. Allergic reactions and other skin disorders occurred significantly more after 
MM treatment. Significantly more DTH-positive patients developed a recurrence than 
DTH-negative patients.
Conclusion
KLH had a different safety profile and was inferior to MM in preventing NMIBC 
recurrences. KLH tended to be more effective than MM in preventing progression. 
More research is needed to clarify the immunologic effects of KLH and the effects of 
KLH on progression. 
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INTRODUCTION
Worldwide, about 386,300 new cases and 150,200 deaths from bladder urothelial cell 
carcinoma occurred in 2008 (1). Approximately 70% of bladder cancer is non-muscle-
invasive (NMIBC) (2). The risk of recurrence and progression after treatment varies. 
Low-grade Ta NMIBC has a high chance of recurrence and a low chance of progression, 
whereas high-grade tumors have a high potential for malignancy. Treatment consists 
of transurethral resection of the bladder tumor (TURBT), followed by intravesical 
treatment. The choice of adjuvant treatment with either chemotherapy (eg, mitomycin 
[MM]) or immunotherapy (eg, bacillus Calmette-Guérin [BCG]) depends on the risk 
group to which the patient belongs (3-6). Unfortunately, recurrences and adverse 
events (AEs) are common. 
Keyhole limpet hemocyanin (KLH), a glycoprotein from the gastropod mollusc 
Megathura crenulata, is an immunocyanin that contributes in the uptake, transport and 
release of oxygen during respiration. It also activates both the humoral and cellular 
immune systems, but the precise mechanism of action of KLH remains unknown (7). A 
commercially available intravesical immunocyanin is Immucothel® (Biosyn, Fellbach, 
Germany).
Olsson et al. (8) were the first to report on KLH in 1974, with promising results on tumor 
recurrence. Results of other small phase II studies suggested a potential benefit of KLH 
over known treatments and a favorable safety profile (9-12). Our goal was to compare 
the efficacy and safety of KLH with MM in a prospective, randomized phase III trial. 
PATIENT AND METHODS
Eighteen Dutch institutions participated in this multicenter, prospective randomized 
phase III trial. The study was conducted compliant with Good Clinical Practice, 
the Declaration of Helsinki (version 1996), and with permission of all local ethical 
committees. 
Patient selection
Patients with a histologically proven pTa/1 grade 2 to 3 tumor, or with multiple or 
recurrent pTa grade 1 tumors, in whom complete TURBT was possible, were included 
after obtaining informed consent. Patients who received intravesical therapy within 
6 months before entry or more than one instillation of MM within 2 years before 
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inclusion were excluded. Patients with primary solitary pTa grade 1 tumors, carcinoma 
in situ (CIS), or tumors ≥pT2 tumors were also excluded. Other exclusion criteria 
were concurrent malignancy (except basal cell or squamous cell carcinoma of the 
skin), history of another malignancy with a disease-free interval ≤5 years, expected 
poor compliance, WHO performance status more than 2, uncontrollable urinary 
tract infection, any previous systemic cancer therapy or radiotherapy within 5 years, 
localization of tumor in prostatic urethra or upper urinary tract, pregnancy or lactation 
for women of reproductive age who refuse to take adequate contraceptive measures, 
congenital or acquired immune deficiency syndromes, known hypersensitivity to MM, 
and previous (≤1 month) or current treatment with an investigational drug.
Treatment schedule
After TURBT was complete and informed consent was signed, patients were randomly 
assigned for treatment with either KLH (Immucothel) or MM. The restricted block wise 
procedure was used for random assignment.
In the KLH arm, patients started with preimmunization: intracutaneous (IC) injection 
of 1mg KLH at intervals of 2 to 7 days until a delayed-type hypersensitivity (DTH) 
response was obtained. A real DTH response was defined as a palpable infiltrate in 
the skin. In case no DTH response developed, up to four IC injections were given. 
Intravesical treatment was started within 2 weeks after the TURBT, independent of the 
preimmunization result. If there was no DTH response after four injections, this was not 
a reason for discontinueing the treatment. Patients received a total of 16 intravesical 
instillations (20mg KLH in 20ml solvent), given once per week for 6 weeks and then 
once per month for 10 months (month 3,4,5,6,7,8,9,10,11 and 12). 
In the MM arm, patients received a total of 11 instillations (40mg MM in 50mg saline) 
given once per week for 4 weeks (week 1,2,3 and 4) and once per month for 5 months 
(months 2,3,4,5 and 6), and then at 9 and 12 months. 
Follow-up and evaluation of therapy 
Patients received urinary cytology and cystoscopy every 3 months for the first year, 
every 4 months during the second and third year, and every 6 months thereafter. All 
visible lesions were completely resected and confirmed by histological examination. 
If a recurrence without progression was observed during the treatment period, the 
therapy was continued after complete TURBT. Patients went off-study in case of 
withdrawal of informed consent, second recurrence during treatment, first recurrence 
after completion of therapy, 5-year disease-free survival, occurrence of CIS, tumor of 
upper tract or prostatic urethra, or distant metastasis. 
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Patients in whom a lesion was coagulated, not biopsied, or not treated at all continued 
in follow-up and were censored at the time of last follow-up.
Objectives and statistical analysis
The primary endpoint was the duration of recurrence-free survival (RFS). Secondary 
objectives were recurrence rate, number of recurrent tumors, duration of progression-
free survival (PFS), AEs, and the effect of DTH response on clinical outcome. RFS was 
defined as the time interval between TURBT and time to first recurrence. Recurrence 
was defined as a positive cystoscopy and histological confirmed positive biopsies. 
Recurrence rate was defined as the number of cystoscopies at which recurrences were 
observed divided by the duration of follow-up in months multiplied by 100. PFS was 
defined as the time interval between TURBT and time to progression. Progression was 
defined as recurrence with histologic pathology stage ≥pT2, distant metastases, or 
death related to bladder cancer.
KLH is registered for prevention of bladder cancer after TURBT and after failure of 
established therapies. Therefore, a subgroup analysis was done in which RFS after KLH 
treatment was compared with MM treatment in patients with recurrence disease and a 
history of intravesical treatments. 
Power analysis showed that 251 evaluable patients were needed in each treatment 
group to reject the hypothesis of noninferiority, at error rates of α/2=0.025 and β=0.20. 
With an expected dropout rate of 10%, a total of 552 patients were needed in this 
study. The study was designed as a non-inferiority study regarding RFS. Inferiority 
was defined as a ratio of median RFS (tKLH/tMM) more than 0.75 (eg, 1.31/1.75 years), 
assuming proportional hazards. 
The Kaplan-Meier method and one-sided log-rank test were used to compare for 
differences in RFS and PFS between the two treatments. Crude hazard ratios (HRs) 
with univariate Cox-regression were used to analyze the influence of patient and 
tumor characteristics separately on RFS and PFS. Adjusted HRs with multivariate 
Cox-regression were used to correct for confounding factors. Patient and tumor 
characteristics were compared using a two-sided Chi-square test. Number of patients 
with a recurrence was compared by using a one-sided Fisher’s exact test. Number of 
recurrent tumors was compared by using the one-sided Mann-Whitney U test, and 
toxicity was compared by using the two-sided Chi-square test. Effect of DTH response 
on outcome was analyzed with two-sided Chi-square tests and log-rank tests. All two-
sided analyses were performed at a 5% level of significance; all one-sided analyses 
were performed at a 2.5% level of significance. Statistical analyses were done with 
SPSS version 16.0 software (SPSS, Chicago, IL). 
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RESULTS
Between July 2003 and November 2007, 553 patients were randomly assigned: 283 
patients to treatment with KLH and 270 to treatment with MM. For safety analysis, 537 
patients were available: 273 patients in the KLH group and 264 patients in the MM 
group. A total of 272 patients received at least one KLH instillation and 263 patients 
received at least one MM instillation. One patient was randomly assigned for KLH but 
received MM and was included in the MM group. One patient did not receive KLH 
treatment but experienced an AE before instillation, so he was included in the KLH 
group (Fig 1).
For the efficacy analyses, 267 patients in the KLH arm and 256 patients in the MM 
arm were included. In the KLH arm, 16 patients were excluded: 10 did not receive 
any instillation, one patient was treated with MM and five patients were ineligible 
(concurrent malignancy n=3; incomplete TURBT n=2). In the MM arm, 14 patients were 
excluded: seven did not receive any instillation, and seven were ineligible (concurrent 
malignancy n=6; tumor in prostatic urethra n=1; Fig 1).
Patient and tumor characteristics
Patient and tumor characteristics were comparable in both efficacy groups (Table 1), 
with the exception of tumor stage. Patients in the MM group had significantly more 
pT1 tumors (two-sided Chi-square test P=0.015) but not significantly more grade 3 
tumors (two-sided Chi-square test P=0.235). DTH response was positive in 61.8% of 
patients treated with KLH (165 of 267), negative in 97 patients (36.3%), and unknown in 
five patients (1.9%).
Safety
AEs were common (72% of all patients) but generally mild (56%), with no differences 
between the KLH and MM arms (557 AEs v 514 AEs). No differences in frequency of 
AEs grouped in system classes were found, except for two AE system classes. General 
disorders such as fever, flu-like symptoms, and fatigue occurred significantly more 
frequently in the KLH group (51 AEs v 28 AEs; two-sided Chi-square test P=0.02). Allergic 
reactions and skin disorders such as eczema, rash, and itch occurred significantly more 
frequently in the MM group (53 AEs v 9 AEs; two-sided Chi-square test P<0.001).
Significantly more mild AEs occurred in patients with a positive DTH response (two-
sided Chi-square test P=0.004; Table 2). 
Figure 1. CONSORT diagram
Assessed
(N = 553)
Enrollment
Random allocation
Allocation
Follow-Up
Analysis
Excluded (n=0)
Allocated to KLH (n=283) 
Received allocated (n=272)
intervention 
Did not receive allocated (n=11)
intervention
Allocated to KLH but (n=1)
received MM
Consent withdrawn (n=2) 
Ineligible (n=8)
Allocated to MM (n=270) 
Received allocated (n=263)
intervention
Did not receive allocated (n=7)
intervention; ineligible
Allocated to KLH (n=283) 
Lost to follow-up (n=1)
Reason: unknown 
Discontinued intervention (n=103) 
Second recurrence during (n=45)
treatment
Administrative error (n=13)
Adverse events (n=11)
CIS recurrence (n=11) 
First recurrence during (n=11) 
treatment
Safety analysis (n=273): received 
at least one instillation (n=272) + 
patient with AE prior to treatment 
(n=1)
Effi cacy analysis (n=267): 283 – no
treatment received (n=10) – treated
with MM (n=1) – ineligible (n=5)
Lost to follow-up (n=0)
Reason: unknown
Discontinued intervention (n=61) 
Adverse events (n=30) 
Administrative error (n=7)
Consent withdrawn (n=6)
Progression (n=6)
Safety analysis (n=264): received at
least one instillation (n=263) +
patient was randomized for KLH but
received MM (n=1)
Effi cacy analysis (n=256): 270 – no
treatment received (n = 7) – ineligible
(n=7)
KLH = keyhole limpet hemocyanin; MM = mitomycin C. 
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Table 1  Patient demographics and clinical characteristics at study entry for all patients in 
the efficacy analyses
KLH MM Total P-value
No. of patients 267 256 523
Sex
Male
Female
218
49
210
46
428
95
0.910
Mean age, years (SD) 66,9 (10,3) 67,7 (9,3) 67,3 (9,8) 0.428 
History of CIS 3 4 7 0.502
Tumor status (%)
Primary
Recurrent
144 (54)
123 (46)
146 (57)
110 (43)
290 (55)
233 (45)
0.476
Previous treatment in patients with 
recurrent tumors at baseline (n=233) (%)
Current single-post TURBT 
intravesical chemotherapy 
Previous single-post TURBT 
intravesical chemotherapy in past
Local adjuvant intravesical therapy
Other therapy
No therapy other than TURBT
5 (4)
10 (8)
31 (25)
3 (2)
74 (60)
2 (2)
3 (3)
27 (25)
0 (0)
78 (71)
7 (3)
13 (6)
58 (25)
3 (1)
152 (65)
0.086
Tumor stage (%)
pTa
pT1
216 (81)
51 (19)
184 (72)
72 (28)
400 (76)
123 (24)
0.015
Tumor grade (%)
1
2
3
88 (33)
148 (55)
31 (12)
79 (31)
134 (52)
43 (17)
167 (32)
282 (54)
74 (14)
0.235
Number of tumors (%)
Single
Multiple
Unknown
89 (33)
178 (66)
0
83 (32)
172 (67)
1 (0)
172 (33)
350 (67)
1 (0)
0.849
Largest diameter, mm (SD) 20 (29) 19 (16) 39 (24) 0.496
Patients in the MM-group had significantly more pT1-tumors than patients in the KLH-
group (two-sided Chi-square test P=0.015). CIS = carcinoma in situ; KLH = keyhole 
limpet hemocyanin; MM = mitomycin-C; SD = standard deviation; TURBT = transurethral 
resection of bladder tumor.
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Table 2  Severity and number of adverse events per delayed type hypersensitivity 
response
DTH response
Positive Negative Unknown
Severity No. (%) No. (%) No. (%) Total
Mild 207 64 111 50 1 12.5 319
Moderate 96 30 89 39 6 75 189
Severe 22 7 25 11 1 12.5 48
Unknown 0 0 1 0 0 0 1
Total 325 224 8 557
Patients with a positive DTH response had significantly more adverse events (two-sided 
Chi-square test P=0.004). DTH = delayed type hypersensitivity.
Efficacy
In total, 163 patients (61%) developed a recurrence after KLH instillations, compared 
with 87 (34%) after MM instillations (one-sided Fisher’s exact test P<0.001). Median RFS 
in the KLH group was significantly shorter than in the MM group (106 weeks [95%CI 
86-126] v 297 weeks [95%CI 202-392]; log-rank test P<0.001; Fig. 2). 
Some recurrences occurred outside of the bladder: three recurrences in the MM group 
(once in prostatic urethra; twice in upper urinary tract) and four in the KLH group (all in 
prostatic urethra).
Univariate Cox regression for RFS showed a crude HR of 2.26 for KLH (95%CI 1.74-
2.94; P<0.001; Table 3). Multivariate Cox-regression showed an adjusted HR of 2.32 
for KLH (95%CI 1.79-3.02; P<0.001). Ratio of median RFS was 106 of 297 or 0.36 (95%CI 
0.321-0.426). Because 0.426 is far below the threshold of 0.75, KLH is inferior to MM 
regarding RFS at a 0.001 level of significance.
Significantly more patients developed progression after MM (n=15) than after KLH 
(n=5) (one-sided Fisher Exact test; P=0.015). Univariate analyses showed a possible 
relationship between treatment and progression chances in favor of KLH (log-rank test 
P=0.049; univariate Cox-regression HR 0.38 [95%CI 0.14-1.04] P=0.059; Table 3). In the 
multivariate Cox regression analysis, this relationship was less obvious (adjusted HR 
0.43 [95%CI 0.15-1.17] P=0.099; Table 4).
The mean number of recurrent tumors after KLH was 3.1 (standard deviation 3.1) 
and 2.4 after MM (standard deviation 2.2; one-sided Mann-Whitney U test P=0.154). 
Recurrence rate was 2.32 after KLH, and 1.05 after MM. 
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Figure 2  Kaplan meier curve for recurrence-free survival
0 52 104 156 208 260 Weeks
      No. at risk 
267 189 120 69 48 22 KLH group
256 220 155 96 66 28 MM group
KLH = keyhole limpet hemocyanin; MM = mitomycine; RFS = recurrence-free survival.
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Table 3  Individual crude hazard ratios calculated with univariate cox-regression for 
recurrence-free survival and progression-free survival
RFS PFS
Variable HR (95% CI) P-value HR (95% CI) P-value
Treatment 
(Reference group: MM)
2.26 (1.74-2.94) <0.001 0.38 (0.14-1.04) 0.059
Gender 
(Reference group: male)
0.94 (0.68-1.31) 0.720 1.22 (0.41-3.66) 0.719
Prior recurrence rate *1
(Reference group: primary)
1.43 (1.12-1.84) 0.005 0.60 (0.23-1.57) 0.297
Tumor stage
(Reference group: Ta)
0.99 (0.73-1.35) 0.967 3.85 (1.59-9.33) 0.003
Grade 2 tumor
(Reference group: grade 1) 
1.26 (0.96-1.66) 0.097 7.16 (0.92-55.45) 0.060
Grade 3 tumor
(Reference group: grade 1)
0.88 (0.57-1.36) 0.562 19.89 (2.49-
159.03)
0.005
Tumor size
(Reference group: ≤15mm)
0.82 (0.62-1.08) 0.152 0.65 (0.24-1.75) 0.392
Number of tumors *2
(Reference group: single) 
1.94 (1.45-2.58) <0.001 1.39 (0.53-3.61) 0.505
*1 Prior recurrence rate: primary versus recurrent. *2 Number of tumors: single versus 
multiple tumors. CI = confidence interval; HR = hazard ratio; MM = mitomycin; PFS = 
progression-free survival; RFS = recurrence-free survival.
Table 4  Adjusted hazard ratios calculated with multivariate cox-regression for recurrence-
free survival and progression-free survival
RFS PFS
Variable HR (95% CI) P-value HR (95% CI) P-value
Treatment 
(Reference group: MM)
2.32 (1.79-3.02) <0.001 0.43 (0.15-1.17) 0.099
Prior recurrence rate *1
(Reference group: primary)
1.36 (1.06-1.75) 0.015 N/A N/A
Tumor stage
(Reference group: Ta)
N/A N/A 2.13 (0.82-5.56) 0.121
Grade 2 tumor
(Reference group: grade 1) 
N/A N/A 5.66 (0.71-
44.90)
0.101
Grade 3 tumor
(Reference group: grade 1)
N/A N/A 11.76 (1.34-
103.53)
0.026
Number of tumors *2
(Reference group: single) 
1.88 (1.41-2.51) <0.001 N/A N/A
*1 Prior recurrence rate: primary versus recurrent. *2 Number of tumors: single versus 
multiple tumors. CI = confidence interval; HR = hazard ratio; MM = Mitomycin; NA = not 
applicable; PFS = progression-free survival; RFS = recurrence-free survival.
0 52 104 156 208 260 Weeks
      No. at risk 
267 189 120 69 48 22 KLH group
256 220 155 96 66 28 MM group
KLH = keyhole limpet hemocyanin; MM = mitomycine; RFS = recurrence-free survival.
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Significantly more DTH-positive patients than DTH-negative patients developed 
a recurrence (two-sided Chi-square test P=0.031; Table 5), but RFS and number of 
recurrences were not significantly different (log-rank test P=0.163 and two-sided t test 
P=0.108, respectively).
Significantly more patients with a negative DTH response (n=4) than DTH-positive 
patients (n=1) showed progression (two-sided Chi-square test P=0.044), and time to 
progression tended to be shorter for DTH-negative patients (log-rank test P=0.051).
For the subgroup analysis in patients with recurrent disease and a history of intravesical 
treatments, a total of 81 patients were identified (49 in the KLH group, and 32 in the 
MM group). The number of patients with recurrences and time to recurrence was not 
statistically significantly different for the two treatment groups (one-sided Fisher exact 
test P=0.194 and log-rank test P=0.558, respectively). 
Table 5  Relationship between delayed type hypersensitivity response and clinical 
outcome
DTH response
Positive Negative Unknown Total
Response No % No % No %
Recurrence Yes 109 66 51 53
3
60 163
No 56 34 46 47
2
40 104
Total 165 100 97 100 5 100 267
Progression Yes 1 1 4 4 0 0 5
No
164 99 93 96
5
100 262
Total 165 100 97 100
5
100 267
A positive DTH is associated with higher recurrence chances (two-sided Pearson χ2 test 
P=0.031). A negative DTH is associated with higher progression chances (two-sided 
Pearson χ2 test P=0.044). DTH =delayed type hypersensitivity.
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DISCUSSION
In this prospective, randomized phase III trial, significantly more recurrences occurred 
after treatment with KLH compared with MM (P<0.001). Literature reporting on 
KLH and recurrence chances is diverse and number of patients is low. Jurincic et al. 
(10) treated 44 patients with either KLH (single IC preimmunization followed by an 
unknown number of monthly instillations with 10mg KLH) or MM (unknown number 
of monthly instillations with 20mg MM in 30mL saline) and found significantly fewer 
recurrences after KLH treatment than after MM treatment (P<0.05). Kälble et al. (11) 
compared KLH (IC preimmunization followed by instillations [10mg KLH in 20mL saline] 
given once per week for 6 weeks, once per month for the next 4 months, followed by 
two more instillations given at months 7 and 10) to BCG (instillations [120mg BCG in 
50mL saline] given once per week for 6 weeks, once per month for the next 4 months, 
followed by two more instillations at months 7 and 10) in 38 patients and reported more 
recurrences after treatment with KLH (41.2% v 14.3% after BCG-instillations). Jurincic 
et al. (13) found that in 11 (52%) of 21 patients with CIS achieved a complete response 
after preimmunization and instillations with 20mg KLH in 20mg saline once per week 
for 2 weeks, of which five patients (24%) remained CIS free during follow-up (mean 
follow-up 31.7 months). The long-term outcome showed long-term tumor remission 
in only two patients (14). Echarti et al. (15) found a significant longer RFS in 37 patients 
after KLH treatment compared to several other intravesical treatments (P=0.0012). 
However, treatment schedule and KLH dosage varied among these patients. Lamm et 
al. (9) treated 64 patients with CIS and/or residual tumor with KLH (IC preimmunization 
followed by instillations once per week for 6 weeks with KLH in increasing dosage: 0.4, 
2.0, 10, and 50mg). Complete response was seen in 50% of patients with CIS and in 20% 
of patients with residual tumor. Linn et al. (16) reviewed KLH efficacy and concluded 
that it appeared to be similar or better than intravesical chemotherapy. However, best 
dosage, treatment interval and manner of application (intravesical, intralesional or 
systemic) remains uncertain. In all, studies on KLH are small with a wide variation of 
inclusion criteria and treatment schedules and therefore diverse results.
In our study, progression was uncommon (3.8%; n=20) since patients were followed 
until they developed a first recurrence, not until progression. Nevertheless, progression 
occurred significantly more often after MM treatment than after KLH treatment. 
Univariate Cox regression analysis for PFS showed no statistically significant difference 
between KLH and MM (HR 0.38; 95%CI 0.14-1.04; P=0.059). When correcting for 
confounding factors by including more pT1 tumors in the MM group, the statistical 
significance was even less obvious (adjusted HR 0.43; 95%CI 0.15-1.17; P=0.099). 
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This suggests that the larger number of patients with pT1 tumors in the MM group 
might have introduced a bias. Because our results on progression are conflicting and 
paradoxical compared with the results of other studies, further research should focus 
on clarifying this. 
There is only little literature on progression after KLH. Jurincic et al. (10) found 
progression in three patients treated with MM versus in one patient treated with KLH. 
However, progression was defined as upgrading. No progression was found after KLH 
treatment in patients with CIS, but mean follow-up was only 23.5 months. Kälble et al. 
(11) found an increase in grade or stage in two patients (11.8%) after KLH treatment 
versus no progression after BCG. As in other studies (9-11, 13, 15, 16), we found 
generally mild AEs after KLH instillations.
In this study, the MM schedule was instillations once per week for 4 weeks and then 
once per month for 7 months, which was the schedule commonly in use when this trial 
was conducted. Currently, many different schedules are being used for MM, and also 
guidelines do not recommend any particular schedule (5, 17, 18). 
Patients in this study had mainly intermediate or high risk of recurrences. The current 
guidelines advise BCG treatment for these patients (5, 18), because randomized 
controlled trials and meta-analyses have shown BCG maintenance to be superior to 
MM in preventing recurrences (19, 20). However, literature on superiority of BCG over 
MM for progression is less clear, as shown by Mälmstrom et al. (20) This suggests that 
KLH is also inferior to BCG. Only Kälble et al. (11) compared BCG with KLH, and they 
indeed found that KLH is inferior to BCG. 
Our results are contradictory on the need for preimmunization: a positive skin test 
appeared to be a prognostic factor for recurrences, but a negative DTH response was 
associated with progression. However, preimmunization was adequate in only 62% of 
the patients.
The exact mechanism behind KLH is not known. Most important hypothesis is that 
KLH enhances the cellular immune system (21-25), which is the rationale behind 
preimmunization. Several studies reported on the need of preimmunization: Swerdlow 
et al. (26) found fewer tumors in mice preimmunized with KLH than in mice without 
preimmunization. However, the effect depended also on the intravesical KLH dose. 
Lamm et al. (27) found significant reduced tumor incidence and tumor volume (P<0.001), 
and significant increased survival (P=0.001) of mice after immunization before tumor 
transplantation compared with immunization after tumor transplantation. Jurincic et al. 
(25) found a relationship between positive skin test and fewer recurrences in only nine 
patients with primary NMIBC treated with intravesical KLH. As suggested by Oyelaran et 
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al. (28) differences in clinical responses with KLH may be due to differences in antibody 
profiles, which vary considerably from person to person. In all, the immunology behind 
KLH has not been clarified and needs further testing.
KLH is registered for prevention of bladder cancer after TURBT and after failure of 
established therapies. In a subgroup analysis with these patients (n=81), RFS was not 
significantly different between the KLH and MM arms. However, these results should 
be interpreted with care because subgroup analyses are prone to selection bias 
and, because of the small sample size, are often underpowered. Therefore, no firm 
conclusions can be drawn from these subgroup analyses.
In daily urological practice, NMIBC is sometimes coagulated instead of resected, but 
this means a lack of histologic confirmation. Therefore, additional analyses were done 
in which coagulated lesions, lack of biopsies, or lack of any resection were considered 
to be a protocol violation. Then, 210 patients developed a recurrence, with significantly 
more recurrences and significantly shorter RFS for KLH patients (both P<0.001). 
Sometimes in daily urological practice a recurrence is seen at cystoscopy but not 
immediately resected. When considering the date at which the recurrence was first 
seen to be the date of recurrence, RFS was significantly shorter after KLH treatment than 
after MM treatment (P<0.001). When considering all lesions, whether pathologically 
confirmed, coagulated or not resected at all, to be a recurrence, RFS was once more 
significantly shorter for patients treated with KLH (P<0.001). 
CONCLUSIONS
This prospective, randomized phase III trial shows that KLH had a safety profile different 
from that of MM. Patients with a positive skin test as a result of preimmunization with 
intracutaneous KLH had significantly more recurrences. KLH was inferior to MM in 
preventing NMIBC recurrences. KLH tended to prevent progression more effectively 
than MM, but when correcting for the higher number of patients with pT1 tumors, this 
could not be shown. More research is needed to clarify the immunologic effects of KLH 
and the effects of KLH on progression.
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ABSTRACT 
Context
Due to the suboptimal clinical outcomes of current therapies for non-muscle-invasive 
bladder cancer (NMIBC), the search for better therapeutic options continues. One 
option is chemohyperthermia (C-HT): microwave-induced hyperthermia (HT) with 
intravesical chemotherapy, typically mitomycin C (MMC). During the last 15 yr, the 
combined regimen has been tested in different clinical settings.
Objective
To perform a systematic review to evaluate the efficacy of C-HT as a treatment for NMIBC. 
Evidence acquisition
The review process followed the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines. An electronic search of the Medline, Embase, 
Cochrane Library, CancerLit, and ClinicalTrials.gov databases was undertaken. Relevant 
conference abstracts and urology journals were also searched manually. Two reviewers 
independently reviewed candidate studies for eligibility and abstracted data from studies 
that met inclusion criteria. The primary end point was time to recurrence. Secondary end 
points included time to progression, bladder preservation rate, and adverse event (AE) 
rate.
Evidence synthesis
A total of 22 studies met inclusion criteria and underwent data extraction. When possible, 
data were combined using random effects meta-analytic techniques. Recurrence was 
seen 59% less after C-HT than after MMC alone. Due to short follow-up, no conclusions 
can be drawn about time to recurrence and progression. The overall bladder preservation 
rate after C-HT was 87.6%. This rate appeared higher than after MMC alone, but valid 
comparison studies were lacking. AEs were higher with C-HT than with MMC alone, but 
this difference was not statistically significant. 
Conclusions
Published data suggest a 59% relative reduction in NMIBC recurrence when C-HT is 
compared with MMC alone. C-HT also appears to improve bladder preservation rate. 
However, due to a limited number of randomized trials and to heterogeneity in study 
design, definitive conclusions cannot be drawn. In the future C-HT may become standard 
therapy for high-risk patients with recurrent tumors, for patients unsuitable for radical 
cystectomy, and in case for which bacillus Calmette-Guérin treatment is contraindicated. 
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INTRODUCTION
Management of non-muscle-invasive bladder cancer (NMIBC) after transurethral 
resection of bladder tumor generally consists of surveillance and intravesical therapy. 
Unfortunately, current intravesical therapies are associated with undesirable toxicities 
and suboptimal efficacy. Particularly challenging is the treatment of patients who 
have not responded to first-line intravesical bacillus Calmette-Guérin (BCG) or that 
have high-risk features (1). For such patients, radical cystectomy remains a commonly 
recommended treatment alternative (1, 2). 
One of the developing treatments for high-risk NMIBC is the combination of 
intravesical chemotherapy and hyperthermia (HT), called chemohyperthermia (C-
HT). The most common form of C-HT uses the Synergo HT system, in which local 
HT is administered via direct microwave irradiation of the urothelium by means of a 
915-MHz intravesical microwave applicator. The target intravesical temperature is set 
between 41°C and 44°C and is measured by five thermocouples integrated in a 20-F 
treatment catheter. To avoid injury, the urethra is continuously cooled (Fig. 1). Due to 
extensive global experience with its use and a significant amount of preclinical data 
demonstrating improved antineoplastic efficacy when heated, mitomycin C (MMC) is 
the most common intravesical chemotherapy agent used in conjunction with HT. 
There are several potential reasons for improved MMC efficacy when combined 
with heat. One explanation is that heat increases the penetration of MMC into the 
urothelium due to increased cellular membrane permeability and/or modified blood 
perfusion. HT is also directly cytotoxic and is known to alter intracellular metabolism, 
to damage DNA, to impair cellular proliferation, and to increase tumor cell apoptosis 
(4, 5). Lastly, HT has been shown to increase the cytotoxicity of MMC, making the drug 
itself more effective (4, 5). 
This collaborative review provides a critical overview of current literature concerning 
the role of HT for the treatment of NMIBC. 
126
III.3  |  Chemohyperthermia: a systematic review
EVIDENCE ACQUISITION
Although the term thermochemotherapy has been used to describe the combination 
of HT and intravesical chemotherapy, in this review we preferentially use the terms 
HT and C-HT to describe supraphysiologic HT given in the 40–45°C range. Unless 
otherwise stated, C-HT in this manuscript refers to the combination of HT and MMC. 
A search of the Medline, Embase, Cochrane Library, CancerLit, and ClinicalTrials.gov 
databases was undertaken in January 2011. Candidate manuscripts were limited to 
the English language with a publication range between 1990 and 2011. The Journal of 
Urology and European Urology were searched manually for manuscripts. Additionally, 
abstracts from the annual meetings of the European Association of Urology and the 
American Urological Association were searched manually. A detailed description of 
the search strategy is given in Appendix A. Authors and experts in the field were asked 
for additional studies. 
Figure 1  Synergo SB-TS 101 system during treatment
Applicator heats bladder wall. Thermocouples measure temperature of different areas of 
bladder surface and bladder neck. Intravesical cytostatic agent solution (most commonly 
mitomycin C) circulates in this closed circuit. Solution is cooled through the catheter to 
prevent overheating of the urethra and disintegration of the solution. Reproduced with 
permission of Elsevier (3).
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Candidate manuscripts were reviewed according to the Cochrane Collaboration 
criteria and reported following the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines (6, 7). Two reviewers (RL and BI) independently 
performed database searches, assessed candidate manuscripts for inclusion criteria, 
and extracted primary data. The primary end point was time to recurrence, with 
recurrence defined as the presence of positive cytology, positive bladder biopsy, 
or tumor at cystoscopy. Secondary end points were time to progression, bladder 
preservation rate, and adverse events (AEs), with progression defined as worsening 
pathologic stage, including muscle invasion or metastases. 
A random effects meta-analysis was performed on the recurrence rate by comparing 
C-HT with MMC alone, using the method of DerSimonian and Laird implemented in 
MetaAnalyst Beta v.3.13 (8, 9).
EVIDENCE SYNTHESIS
Search results
The search strategy generated 68 hits, of which 38 were excluded because the abstract 
or the manuscript did not meet inclusion criteria (3, 5, 10-36). Of the remaining 30 
eligible publications, full review determined that 11 were reviews. Another four articles 
were excluded because they were about preclinical work, Consequently, 15 original 
articles were eligible for analysis (10, 12, 15, 17, 20, 23-25, 27-30, 32, 33, 36). Manual 
searches did not result in additional clinical studies on C-HT. Two studies were added 
by authors of this review (37, 38). An interim analysis from the Lombardia project was 
added (unpubl. data, R. Colombo, Milan, Italy), and the AE results from one clinic 
were contributed (unpubl. data, J.A. Witjes, Nijmegen, the Netherlands). Additionally, 
CancerLit and ClinicalTrials.gov searches identified three ongoing clinical trials, 
bringing the total number of studies discussed in this review to 22. Appendix B shows 
the flow diagram of evidence acquisition. Some studies were executed by the same 
groups (10, 15, 20, 27, 28, 37), but the authors of these articles have confirmed that 
there was either no overlap (10, 27, 28) or minimal overlap (15, 20) of patients.
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Chemohyperthermia versus mitomycin C alone and recurrences
Table 1 provides an overview of all clinical trials concerning clinical outcome after 
treatment with C-HT for NMIBC.
To investigate whether outcomes are really better when combining C-HT with MMC, a 
meta-analysis was performed on four primary studies (10, 27, 30, 37). A marker lesion 
study demonstrated significantly more complete response (CR) rates after C-HT 
compared to MMC alone (Table 1) (30). Additionally, the recurrence rate appeared 
lower with C-HT (27% vs 39%), although time to recurrence was similar (30). However, the 
reporting of this study was inadequate, and details about randomization procedures 
and inclusion/exclusion criteria were lacking. In 2001, Colombo et al. compared the 
efficacy of C-HT to electromotive drug administration (EMDA) with MMC and to 
MMC (27). CR was observed in 27.7% (10 patients) after MMC alone versus 40.0% (6 
patients) after EMDA and 66.0% (19 patients) after C-HT (27). Several problems with 
this study merit mention. First, patients were free to choose their treatment. Second, 
the duration of therapy and MMC concentration were different among the three arms 
(Table 1). Finally, these patients were not followed for long-term risk of recurrence or 
progression. 
Several of these methodological problems were addressed in a prospective, 
multicenter, randomized clinical trial that compared C-HT and MMC alone (10). With 
an overall follow-up of 24 mo, the recurrence rate after MMC alone was several-fold 
higher than that of C-HT (17.1% vs 57.5%; hazard ratio [HR]: 4.821; 95% confidence 
interval [CI], 1.953–11.899). After a long follow-up (median: 90 mo), recurrences were 
noted in 40% of C-HT patients and 80% of patients treated with MMC alone (37). The 
10-yr disease-free survival rate was estimated at 52.8% for the C-HT arm versus 14.6% 
for the MMC arm (p < 0.001) (37). It is noteworthy that follow-up procedures after 2 
yr were not standardized and could have introduced bias. It is also important to note 
that all studies mentioned in this section were executed by the same group (although 
patient groups did not overlap) and were performed with the Synergo® system.
The studies are summarized in Table 2, and C-HT and MMC alone are compared 
graphically in Figure 2. The overall risk ratio was 0.410 (95% CI, 0.290–0.579), which 
indicates 59.0% less recurrence after C-HT compared to MMC alone. 
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Table 2  Recurrence risk in patients with non-muscle-invasive bladder cancer after chemo-hyperthermia 
with mitomycin-C (MMC), versus MMC alone
Study Patient 
population 
C-HT with MMC MMC alone Weight, 
%
Odds 
ratio
(95% CI)No. of 
patients 
treated
No. of 
patients 
with 
recurrences
No. of 
patients 
treated
No. of 
patients 
with 
recurrences
Colombo 
et al, 
1996 (30)
Ta/1 G1-3 29 10 23 18 40.0% 0.441
(0.400–
0.761)
Colombo 
et al, 
2001 (27)
Single, small 
(<2 cm) Ta/1 
G1-2, which 
were not 
earlier treated 
with MMC
29 10 36 26 40.8% 0.477
(0.278–
0.820)
Colombo 
et al, 
2003 (10)
Intermediate- 
or high-
risk, with 
confirmed 
complete 
TURBT
35 6 40 23 19.2% 0.255
(0.116–
0.560)
Recurrence risk was in all three studies lower after C-HT with MMC, compared with MMC alone. 
Heterogeneity is given as random effects variance (τ2=0) and degree of agreement (I2=0%). 
Heterogeneity is very low, which means that all single studies show same odds ratios. Studies are sorted 
by year of publication. CI = confidence interval; C-HT = chemo-hyperthermia; MMC = mitomycin-C; 
TURBT = transurethral resection of bladder tumor.
Figure 2  Forest plot for risk of recurrence in patients with non-muscle-invasive bladder cancer after 
treatment with chemo-hyperthermia and mitomycin-C versus MMC alone
Overall risk ratio is 41.0%, which means recurrence risk is 59.0% lower after C-HT with MMC 
compared with MMC alone. Studies are sorted by year of publication. CTH = chemohyperthermia; 
MMC = mitomycin C
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Chemohyperthermia after intravesical treatment failure
The outcome for patients who fail intravesical therapy and progress to muscle-invasive 
disease is poor. Schrier et al. found a 3-yr bladder cancer–specific survival of 37% 
for patients with NMIBC that progressed to muscle-invasive bladder cancer (MIBC) 
compared with 67% for patients presenting with MIBC (39). These results have been 
confirmed by Guzzo et al. (40).
Several studies have investigated the role of C-HT in salvaging NMIBC that has not 
responded to other intravesical regimens. Van der Heijden et al. examined 90 patients 
treated with C-HT (Table 1) of which 76 had failed prior intravesical therapy (23). Patients 
that had failed BCG fared significantly worse than other patients (2-yr Kaplan-Meier 
recurrence: 41.2% vs 24.6%) (23). Witjes et al. treated 49 carcinoma in situ (CIS) patients 
with C-HT but did not observe a difference in response rate between patients that had 
failed BCG and those that had not (p = 0.63) (17). Similarly, Halachmi et al. reported 
on 56 high-grade T1 patients treated with C-HT and noted no difference in the 4-yr 
recurrence rate between those that had failed BCG and those that had not (46% vs 
44%, respectively; p = 0.54) (15). Ayres et al. prospectively evaluated 38 high-risk 
patients that had failed BCG and were treated with C-HT and found a 2-yr recurrence 
rate of 50% (38). Finally, an interim analysis of an ongoing multicenter Italian study (ie, 
the Lombardia project) showed that patients treated with C-HT after failing a previous 
intravesical therapy regimen did substantially worse than patients treated with C-HT 
de novo, with 2-yr recurrence-free survival rates of 62% and 91%, respectively (p = 
0.006) (unpubl. data, R. Colombo, Milan, Italy). 
The results of C-HT in patients that have previously failed other intravesical regimens 
are heterogeneous. Despite this, a significant number of these patients are salvaged 
with C-HT, and this appears to be a major advantage of this treatment regimen. 
Progression after chemohyperthermia
Most studies assessing C-HT consider progression to MIBC as a secondary end point 
(Table 1). Reported progression varies between 0% and 8% (10, 12, 15, 20, 23, 24, 28, 
32, 37, 38) (unpubl. data, R. Colombo, Milan, Italy). In general, although most studies of 
C-HT have a follow-up duration that is too short to detect progression reliably, studies 
with adequate follow-up show lower progression rates with C-HT than with MMC alone 
(37).
Chemohyperthermia as bladder-sparing therapy
Bladder preservation is another important end point to consider when managing 
NMIBC because both recurrence and progression can lead to radical cystectomy. 
Table 3 summarizes available data concerning C-HT as bladder-sparing therapy. 
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Of the 357 patients treated in all studies, 38 patients (10.6%) underwent radical 
cystectomy: 11 (3.1%) for progression to MIBC, 25 (7.0%) for highly recurrent disease, 1 
(0.003%) for disease-worsening lower urinary tract symptoms (LUTS), and 1 (0.003%) for 
contracted bladder. At meta-analysis, a pooled bladder preservation rate of 87.6% was 
found after C-HT. This rate appears higher than after MMC alone, but comparison is 
difficult due to differences in patient characteristics and in median follow-up duration 
(Table 1). 
Adverse events associated with chemohyperthermia
Comparison of AEs is difficult because older studies used nonvalidated questionnaires, 
whereas more recent studies used the Common Toxicity Criteria for Adverse Effects 
(CTCAE). Moreover, some studies used intention-to-treat analysis, whereas other 
studies used per-protocol analysis. The prophylactic use of anticholinergic drugs 
and pain medication was not mentioned in most reports, and this could have led to 
underestimation of the true AE rate. 
The most common AEs during treatment were bladder spasms and bladder pain (Table 
4). Bladder spasms occurred in 21.6% of patients, and bladder pain occurred in 17.5%. 
Bladder spasms tended to occur more frequently with the prophylactic schedule 
(17.8% vs 10.7%; p = 0.398), whereas pain was present equally in the prophylactic and 
ablative schedules but more commonly after the ablative schedule (17.0% vs 15.6%; p 
= 0.366). 
Table 3  Rate of bladder preservation in various studies using chemohyperthermia for 
treatment of non-muscle-invasive bladder cancer
Study Follow-
up, mo, 
median
No. patients 
with bladder 
in situ (%)
Colombo et al. (28) 0 9/19 (47.4)
Gofrit et al. (24), prophylactic treatment 15.2 23/24 (95.8)
Gofrit et al. (24), ablative treatment 20 22/28 (78.6)
Witjes et al. (17) 22 40/45 (88.9)
Halachmi et al. (15) 18 45/51 (88.2)
Ayres et al. (38) 9 31/38 (81.6)
Colombo et al. (37) 90 NA (86.1)
Lombardia project (unpubl. data R. Colombo, Milan, Italy) 23 149/152 (98.0)
Overall NA 87.6
NA = not available.
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Table 4  Overview of the adverse effects patients experience during chemohyperthermia with 
mitomycin C
Study No. patients with 
bladder spasms (%)
No. patients with 
pain (%)
Rigatti et al. (36) 5/12 (40.0) 3/12 (25.0)
Gofrit et al. (24) 8/52 (15.4) 12/52 (23.1)
Moskovitz et al. (20) 8/398 (2.0) 31/398 (7.8)
Witjes et al. (17) 66/503 (13.1) 64/503 (12.7)
Nativ et al. (12) 34/111 (30.6) 30/111 (27.0)
Halachmi et al. (15) 13/56 (23.8) 6/56 (10.7)
Lombardia project (unpubl. data, R. Colombo, Milan, 
Italy)
483/1354 (35.7) 278/1354 (20.5)
Witjes et al (unpubl. data, J.A. Witjes, Nijmegen, 
The Netherlands)
202/968 (20.9) 65/968 (6.7)
Overall 21.6% 17.5%
Table 5  Overview of adverse events that patients experience after chemohyperthermia with 
mitomycin C
Study No. patients with 
storage LUTS (%)
No. patients with 
hematuria (%)
Gofrit et al. (24) 30/52 (57.7) NA
Van der Heijden et al. (23) 22/90 (24.4) 8/90 (8.9)
Moskovitz et al. (20) 2/47 (4.3) 8/398 (2.0)
Witjes et al. (17) 50/503 (9.9) 15/503 (3.0)
Halachmi et al. (15) 7/56 (12.1) 1/56 (2.0)
Nativ et al. (12) 18/111 (16.2) 21/111 (18.9)
Ayres et al. (38) 28/38 (73.7) 10/38 (26.3)
Witjes et al (unpubl. data, J.A. Witjes, Nijmegen, 
The Netherlands)
407/968 (42.0) NA
Overall 25.6% 6.0%
Storage LUTS include frequency, dysuria, urgency and nocturia. LUTS = lower urinary tract symptoms. 
NA = not available.
In the first days following C-HT, storage LUTS (frequency, dysuria, urgency, nocturia) 
and hematuria are the most common AEs (Table 5). Storage LUTS occurred in 25.6% of 
patients, and hematuria occurred in 6.0%. Most studies mention that these symptoms 
were mild (CTCAE grade 1) and transient, resolving spontaneously within a few days of 
treatment. One study described severe cystitis complaints in three patients (16%), but 
other studies have not confirmed this AE (28). 
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Less common AEs include nonspecific rash, which was noted in 7.5% of patients (15, 
20, 23, 24, 32, 36, 38) (unpubl. data, J.A. Witjes, Nijmegen, the Netherlands; unpubl. 
data, R. Colombo, Milan, Italy). The incidence of rash is comparable with that observed 
after MMC alone (12%) (41). The overall rate of urethral strictures was 3.5% (12, 15, 
20, 23, 24) (unpubl. data, J.A. Witjes, Nijmegen, the Netherlands; unpubl. data, R. 
Colombo, Milan, Italy).
Serious burn injuries to the bladder were not reported, but posterior wall thermal 
reaction (PWTR) was commonly seen. At cystoscopy, PWTR appears as a small, 
superficial, darkly discolored patch surrounded by hyperemia in the location where 
the heating device contacted the bladder wall during treatment. PWTR is normally not 
associated with symptoms and disappears spontaneously after several months. The 
overall rate of PWTR was 40.2% (20, 23, 24) (unpubl. data, J.A. Witjes, Nijmegen, the 
Netherlands; unpubl. data, R. Colombo, Milan, Italy), and most cases were mild, with 
only two cases of severe and prolonged (asymptomatic) PTWR reported (10, 23).
Two studies report the development of a contracted bladder and severe urinary 
incontinence after ablative C-HT (10, 28). However, the possibility cannot be excluded 
that previous transurethral resection and intravesical chemotherapy might have 
contributed to this event (28).
The overall AE-related dropout rate during C-HT was 3.8% (10, 12, 15, 17, 24, 27, 28, 
30, 32, 36, 38) (unpubl. data, J.A. Witjes, Nijmegen, the Netherlands; unpubl. data, R. 
Colombo, Milan, Italy). 
Four studies compared the AE rates of C-HT and MMC alone and collected subjective 
symptom scores using a nonvalidated questionnaire. The questionnaire graded 
symptoms on a 4-point scale (1, better; 4, worse) for frequency, nocturia, and dysuria. 
Urgency, hematuria, and pain were ranked on a 3-point scale (1, better; , worse). 
Colombo et al. found a score of 10.5 in C-HT patients and 9.8 in patients treated 
with MMC alone. During active treatment, C-HT patients were more symptomatic 
(symptom score: 18.3) than MMC patients (symptom score: 13.1). Following treatment, 
the symptom scores improved to pretreatment levels (C-HT: 12.6; MMC: 10.7). The 
differences in AE scoring between the groups were not statistically significant (30). The 
same group found several years later that local toxicity was slightly (but not significantly) 
higher after C-HT than after EMDA or MMC alone: the symptom score was 17.4 after 
C-HT, 13.2 after MMC alone, and 14.6 after EMDA (27). However, the differences in 
symptom score could be due to the lower dose of MMC and the shorter treatment 
time used in the EMDA arm (Table 1). One study found only significant differences 
between C-HT and MMC alone in pelvic pain and PWTR, both of which were more 
prevalent after C-HT (10). Long-term follow-up of this last study found no delayed 
treatment-related toxicity (37). 
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In summary, although studies inadequately report AEs, C-HT appears to cause more 
symptoms than MMC alone and may be associated with slightly more but mild and 
reversible AEs. We believe structured questionnaires for AEs should be developed 
according to the CTCAE and should be used in future research. 
Ongoing research
Currently there are two studies in which C-HT is compared with other treatment. In 
2002, a multicenter phase 3 study was started to compare 1 yr of BCG with 1 yr of C-HT 
(using MMC). A total of 300 high-risk patients will be randomized. Primary outcome 
measures will be recurrence-free survival, time to CR (for CIS), and progression rate. 
Secondary outcomes include local and systemic AEs (42).
Another phase 3 study started in 2009 compares C-HT with MMC to BCG or standard 
therapy after failure of intravesical therapy. A total of 242 patients will be randomized 
to C-HT and either a second induction course of BCG with subsequent maintenance 
for patients that previously failed induction BCG or standard therapy for patients 
that previously failed maintenance BCG. Standard therapy is defined by the treating 
centers. Primary outcome measures are disease-free survival and CR rates (for patients 
with CIS). Secondary outcomes include recurrence-free survival, progression-free 
survival, overall survival, disease-specific survival, safety and tolerability, quality of life, 
cost effectiveness, and biomarkers of response (43).
A phase 1 trial investigating the role of deep regional (external) C-HT using MMC for 
treating NMIBC patients failing BCG has completed accrual and is in follow-up. In this 
trial HT was administrated with the BSD 2000® HT system, which is fundamentally 
different from the Synergo system. The BSD 2000 device uses external, phased-array 
radiofrequency antennae to focus HT into deep locations in the body (44). Primary 
outcome measures are safety and tolerability. Secondary outcomes include time to 
second recurrence (45).
Comments and future perspectives 
The optimal treatment schedule for C-HT is unknown, and current schedules have 
been based largely on existing MMC trials. Additionally, just like MMC, it is not known 
whether or not maintenance treatments are valuable (3, 46). One article specifically 
mentioned the need for maintenance and found a higher risk of recurrence if <10 
treatments were given (61% vs 39%; p = 0.01) (12). Colombo et al. also found significantly 
fewer recurrences after 12 sessions compared with fewer sessions (p < 0.001) (10). The 
data suggest that maintenance C-HT may be beneficial. The commonly used duration 
for HT is 40–60 min, but this has not been studied prospectively in humans. Nakajima 
et al. showed that 120 min of HT was more toxic to bladder cancer cell lines than 30 
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min of HT, suggesting that longer durations of treatment may be beneficial (47). It is 
also unclear whether the target temperature of 42°C is the optimal temperature for HT. 
Moreover, it is uncertain if HT-related AEs increase as temperature rises.
All clinical trials evaluated in this study were performed with MMC. However, alternative 
intravesical agents that remain to be tested in combination with HT include gemcitabine 
and epirubicin as well as several other novel drugs, such as apaziquone (EOquin). Van 
der Heijden et al. investigated the in vitro effect of HT on four chemotherapeutic 
agents and found that apaziquone was the most potent drug (4). Uchibayashi et al. 
investigated the combination of HT and peplomycin for NMIBC and found only a 9% 
CR rate. All initial responders had recurred with tumor 9 mo later (33). HT can also 
be combined with radiation therapy and photodynamic therapy for treating bladder 
cancer (48). 
The cost effectiveness of C-HT needs to be investigated because C-HT is more 
expensive than MMC alone. The increased initial cost of treatment needs to be 
balanced by the decreased costs of treating recurrences. 
Finally, as mentioned earlier, follow-up time of at least 5 years is needed to draw 
conclusions about recurrences, progression and survival.
CONCLUSIONS 
Our systematic review indicates that C-HT reduces the risk of NMIBC recurrence by 
59% when compared to MMC alone. Overall bladder preservation after C-HT is 87.6%. 
However, due to a limited number of randomized trials and different study designs, 
definitive conclusions cannot be drawn with respect to time to recurrence and time 
to progression. AEs are more common after C-HT than with MMC alone, but this 
difference is not statistically significant. In the future, C-HT may become standard 
therapy for high-risk patients with recurrent tumors (despite earlier treatment), for 
patients that are not candidates for radical cystectomy (because of medical reasons or 
refusal), and for high-risk patients with de novo bladder tumor with contraindications 
for BCG treatment. 
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Appendix A  Literature analysis search terms and strategy
#1 Transitional cell carcinoma urinary bladder
#2 Urothelial cell carcinoma urinary bladder
#3 Urinary bladder cancer
#4 Urinary bladder neoplasm
#5 Urinary bladder tumor
#6 Urinary bladder tumour
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 Papill*
#9 Superficial
#10 Non-muscle invasive
#11 Non-invasive
#12 Meta*
#13 Advanced
#14 #8 OR #9 OR #10 OR #11 NOT #12 NOT #13
#15 #7 AND #14
#16 Thermo-chemotherapy
#17 Thermo chemotherapy
#18 Microwave induced local hyperthermia
#19 Hyperthermia
#20 Synergo
#21 #16 OR #17 OR #18 OR #19 OR #20
#22 #15 AND #21
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Appendix B  Flow diagram of evidence acquisition
Database search
68 hits
Unrelated topics
38
Manual selection
30 publications 
Reviews; referring to original articles
11
19 publications
Review of 22 studies
Publications about pre-clinical work
4
Ongoing studies
3
(Un)published work, added by 
authors of this review
4
Final selection
15 publications
Appendix B  Flow diagram of evidence acquisition
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DISCUSSION
This thesis focuses on risk management and intravesical treatment of non-muscle-
invasive bladder cancer (NMIBC). In the first part we described factors that influence 
the risk of getting (a recurrence of) NMIBC, e.g. smoking (Chapter II.1). There are 
already several risk models for predicting outcome of bladder cancer, but they are not 
very commonly used in daily practice. In Chapter II.2 we discussed why this is the case, 
and what should be done to improve the use of prediction models. Furthermore, we 
have developed a new risk model for estimating the chance of getting a recurrence 
after earlier intravesical chemotherapy including an external validation of this model 
(Chapter II.3).
In the second part we focused on the treatment of NMIBC. First, we showed that 
treating patients according to the international guidelines leads to better clinical 
outcome; undertreated patients have worse outcome (Chapter III.1). Then, we 
presented a prospective, randomized phase 3 study which showed that keyhole limpet 
hemocyanin (KLH) is inferior to mitomycin C (MMC) in preventing recurrences (Chapter 
III.2). In Chapter III.3 the results of a meta-analysis on chemohyperthermia (CHT) are 
presented, which showed that CHT reduces recurrence chances with 59% and has an 
87.6% rate of bladder preservation. 
In this final part of the thesis I will discuss the previous chapters in a broader perspective 
and I will present my view on (the future for) risk management and (intravesical) 
treatment of NMIBC. 
RISK MANAGEMENT OF NMIBC
Smoking
As mentioned in Chapter I, smoking is the most important risk factor for the development 
of bladder cancer. Therefore, one could hypothesize that there might be a relationship 
between smoking status and recurrence- and progression-free survival (RFS; PFS). We 
investigated the role of smoking status on the prognosis of NMIBC in a group of patients 
treated with complete transurethral resection of the bladder tumor (TURBT) followed 
by intravesical instillations with epirubicin. Data were obtained during a multicenter 
prospective randomized phase 3 trial on the efficacy of epirubicin. The physicians of 
patients who were randomized were asked to answer a set of questions in which the 
smoking status of their patients was qualified and quantified. In total, 718 patients 
were suitable for analyses. Patients were divided into three groups: those who never 
smoked (nonsmokers; n=121; 16.9%), versus those who used to smoke but stopped 
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smoking prior to entering the study (ex-smokers; n=359; 50%) and patients who still 
smoked when entering the study (current smokers; n=238; 33.1%). After a mean follow-
up of 2.5 years (range: 0-6.3 yr), 284 recurrences were found (39.6%). In multivariate 
analyses only a history of recurrence, multiplicity and smoking status were significant 
predictors of RFS. Results are more extensively presented in Chapter II.1. The influence 
of smoking status on recurrence outcome is confirmed by several other groups (1-4). 
Unfortunately, in our study results on PFS were inconclusive mainly due to low numbers 
of progression events (n=25; 4%). As mentioned in the discussion of Chapter II.1, this 
is a result of excluding CIS patients, too short follow-up, and progression not being 
a primary outcome measure. Many other articles had the same issues, and could not 
conclude that smoking is an independent predictor for progression. However, Rink 
et al. included progression as primary outcome measurement and found in both 
primary and recurrent patients that smoking is indeed an independent predictor for 
progression outcome (1, 2). 
Not only smoking status is relevant; it appears that increasing pack years or cumulative 
exposure is also of influence on bladder cancer outcome (1, 2). We also investigated 
the influence of number of cigarettes per day, age when started smoking, number of 
years smoked and number of pack-years. In our study only the number of pack-years 
≥35 almost significantly influenced RFS (p=0.057); the other variables did not. 
One clear limitation seen in our study and in other studies is the manner of investigating 
smoking status. We used a questionnaire which was filled out by the physician at the 
beginning of the study. This can cause bias. The quality of the research on smoking 
would improve by using anonymous questionnaires on smoking behavior, including 
passive smoking, which should be filled out by the patients themselves at several 
moments during follow-up. This prevents bias and should give us more information on 
the variability of smoking status in time and the (clinical) consequences. 
Several studies have shown that there is a positive effect of cessation of smoking on 
bladder cancer outcome (1, 2, 5), and it appears that the effect is noticeable after 10 
years (6). Although the latency time (time between exposure and manifestation of the 
disease) is long for bladder cancer, more efforts should be taken to stimulate cessation 
of smoking. This is not only helpful for the prevention of bladder cancer, but also for 
lung cancer, pulmonary obstructive disease, cardiovascular disease et cetera. 
It all starts with awareness: it seems that many people are not aware of the relationship 
between smoking and bladder cancer (7-10). But patients are willing to stop, especially 
at the moment of diagnosis, as shown by Bassett et al. (11). Secondly, it should be 
less attractive to smoke. Comparison with other European countries shows that in the 
Netherlands prices are relative low, labels with health warnings are insufficient, and 
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spending on tobacco control including public information campaigns is also low (12). 
On the other hand, the Dutch government has improved some issues in the last few 
years. As of January 2014 the age limit for buying tobacco has risen from 16 to 18 years. 
Moreover, since 2013 cessation programs (both behavioral and medical support) are 
part of the basic health insurance. Since time for discussions on smoking cessation is 
limited for medical specialists, this might best be addressed by GP´s or trained nurse-
practitioners. 
Prediction models
Since the publication of the European Organization for Research and Treatment 
of Cancer (EORTC) risk tables in 2006 many manuscripts have been published on 
predicting prognosis for NMIBC. As mentioned in Chapter II.2, a good prognostic 
model discriminates between disease and illness, gives an accurate prognosis, has a 
good calibration, is generalizable, and is easy to use. Unfortunately, none of the existing 
prognostic models for NMIBC have all of these requirements. Common problems are 
overfitting of the model because validation is done on the data used to derive it from, 
leading to a poor generalizability and poor internal validation. Subsequently, this 
results in either overtreatment or undertreatment of patients, which is not conform the 
current treatment guidelines. And if internal validation (e.g. the concordance index or 
calibration) is high, the next question is whether it is high enough to justify the use of 
the model in clinical practice. 
Most clinicians do not use the prediction models. This is due to many factors, including 
lack of time, outdated models, the model not being applicable for this particular 
patient, and so forth. Therefore, it helps to incorporate good models into online 
calculators for easy access. 
As over- and undertreatment is a major issue for both the patient and the clinician, 
prediction models should focus on preventing over- and undertreatment. Therefore, 
hazard ratio, sensitivity and specificity should receive less focus and more attention 
should be given to positive- and negative predictive value (PPV, NPV). E.g. the PPV of 
the EORTC risk table for progression in high risk patients is 21%; would you recommend 
a cystectomy knowing that 75-80% of high risk patients would not progress and thus 
would be overtreated? One could conclude that the EORTC risk tables are not useful to 
determine treatment options for high risk patients concerning progression outcome. 
These are issues of great importance and are clinically very relevant. Also, outcome 
measurements such as progression, cancer-specific mortality and long-term quality of 
life are of great importance for both patients and clinicians. Thus, further studies on 
prediction models should have more attention on these outcome measurements as 
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primary or secondary end points. 
Another concern is the relevance of the models: which patient benefits from it? We 
should focus on developing prognostic models for patients in which treatment is 
challenging. Treatment for low risk patients with small, primary, solitary TaG1/ low grade 
tumors is rather clear and uniform. Overtreatment in this group of patients is a major 
issue, as too many intravesical treatments or too frequent follow-up cystoscopies are 
stressful for the patients and not cost-effective. High risk patients, on the other hand, 
have other problems: undertreatment with an insufficient TURBT and/or insufficient 
intravesical treatment and/or insufficient follow-up. 
The real challenges are, in my opinion, two groups of patients: patients with 
intermediate risk, and patients who cannot or do not wish to undergo cystectomy. The 
percentage of patients with intermediate risk is large as the definition of intermediate 
risk according to the European Association of Urology (EAU) is broad: “all tumors 
between the category low and high risk” (13). Therefore, it would help to subdivide 
these patients to see which patients are more at the low risk end and can be treated 
less aggressively, and which patients are more at the high risk end and thus should 
be treated more aggressively including a more intensive follow-up. This is why we 
developed a prediction model for these intermediate risk patients, which is presented 
in Chapter II.3. We found five independent predictors for shorter time to recurrence: 
history of previous recurrences, history of previous intravesical treatment, number of 
tumors, tumor grade and adjuvant treatment. We developed an easy readable table 
with recurrence-free probabilities at 1, 2 and 5 years, and these probabilities can 
be related to a subdivision of minor, moderate and major risk, in order to decide if 
this particular patient should receive less or more aggressive treatment depending 
on the subdivision. Finally, we validated this model using an external dataset with 
patients treated in Fundacio Puigvert, Barcelona, Spain, which showed good overlap 
in predictors, although it was only a partial external validation. This prediction model 
for recurrence outcome after intravesical chemotherapy in intermediate risk NMIBC 
patients is a practical model for a challenging patient category.
Another challenging group are patients who recur despite proper BCG treatment 
(induction and maintenance). Cystectomy is the treatment option of choice, but it is 
major surgery with significant morbidity and mortality. Intravesical therapy after BCG 
failure is another option but almost only as part of clinical trials. CHT amongst others is 
a good alternative but this will be discussed in detail below. Prediction models are not 
very useful in this group of patients as the selection of treatment is mainly depending 
on the patients well-being, comorbidity and/or treatment wishes. 
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TREATMENT OF NMIBC
Management of all NMIBC starts with a complete TURBT. Further treatment depends 
on the risk group of the individual patient. In the Netherlands, we follow the Dutch 
guideline which is based on one of the previous EAU guidelines (14, 15). The latest 
EAU guideline mentions that patients with low risk should receive a single instillation 
of chemotherapy directly after TURBT (13). Patients with intermediate risk should 
receive one direct postoperative instillation followed by intravesical chemotherapy or 
BCG for one year. The advantage of a postoperative instillation in high risk patients is 
limited, and thus not necessary. However, these patients should receive re-TURBT and 
full dose BCG for 1-3 years. Cystectomy is also an option in these patients. 
Compliance to guidelines
In general, compliance to the guidelines varies considerably. Non-compliance is 
often seen in all parts of NMIBC treatment and follow-up (16-22). Research about 
the reasons for not complying to the guideline is very limited. Palou et al. conducted 
a multivariate analysis to determine significant predictors for the use of direct 
postoperative instillations, and found five variables: country, risk of progression, if 
the urologist completed a uro-oncology fellowship, risk of recurrence, and number 
of patients treated (20). It might also be due to the guidelines itself: e.g. in the 
American guideline the direct postoperative instillation is optional, whereas in the EAU 
guideline TURBT with direct postoperative instillation for low risk patients is a grade 
A recommendation. Other (speculative) reasons are pharmacy preparation difficulties 
and (lack of) experience (16-22). Side-effects are also mentioned often, but in general 
dropout due to side-effects is uncommon (16, 21). 
Even less is known about the consequences of non-compliance. In chapter III.1 the 
expected risks of recurrence and progression based on several risk models and the 
EAU and AUA guidelines were compared with the real outcomes in a cohort of NMIBC 
patients treated with intravesical chemotherapy. The cohort was reclassified according 
to the definitions of the three risk groups, as defined according to the EAU guideline, 
and five index patients, as defined by the AUA guideline, in order to compare the 
outcome of undertreated patients with those who were treated adequately. In general, 
undertreatment was associated with significantly more recurrences and progression, 
and with significantly shorter time until recurrence or progression. Therefore, this study 
showed that lack of adherence to existing guidelines (undertreatment of patients) 
translates into worse outcome. Better compliance to guidelines might also reduce 
the health costs spent on bladder cancer: Madeb et al. calculated, based on several 
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assumptions, that giving direct postoperative instillations after TURBT could lead to 
savings up to 25 million USD per year (17). 
Recurrence- and progression rates can probably drop if we put more effort in performing 
a good TURBT and following the guidelines concerning adjuvant treatment. This starts 
with education of the urologists (in training) to get familiar with the content of the 
guidelines. On the other hand, more research on the lack of adherence is needed; once 
we know why urologists do not follow the guidelines measures for improvement can be 
taken. In the end, more compliance to the guideline could not only improve outcome 
but could also save money, which is an important issue as bladder cancer is one of the 
most costly cancers. 
Chemohyperthermia
CHT is the combination of intravesical chemotherapy and hyperthermia (HT). The 
most common form of CHT uses the Synergo HT system®. Due to extensive global 
experience with its use and a significant amount of preclinical data demonstrating 
improved antineoplastic efficacy when heated, mitomycin C (MMC) is the most common 
intravesical chemotherapy agent used in conjunction with HT. 
In Chapter III.3 we described a systematic review of the current literature and meta-
analyses on recurrence outcome and bladder preservation rates, by comparing CHT 
with MMC to MMC alone. We found evidence that CHT reduces the risk of NMIBC 
recurrences by 59% when compared to MMC alone. Overall bladder preservation 
after CHT was 87.6%. Due to a limited number of randomized trials and different study 
designs, definitive conclusions could not be drawn with respect to time to recurrence 
and time to progression. Side-effects were more common after CHT than with MMC 
alone, but this difference was not statistically significant.
Colombo et al. updated our meta-analysis presented in Chapter III.3 with new studies 
(23): they found two additional studies (n=24), but the overall numbers concerning 
recurrence and bladder preservation remained the same. A randomized phase 3 trial 
comparing CHT with BCG in patients with intermediate- and high risk characteristics 
was closed recently (24), and we are awaiting the results eagerly. 
As mentioned in the systematic review (Chapter III.3), CHT has several disadvantages. 
One of which are the frequently occurring side-effects. Fortunately, the side-effects are 
almost exclusively local (lower urinary tract symptoms), mild, and self-limiting. Although 
often related to CHT, side-effects might also be the result of previous TURBT and 
previous intravesical treatment. Therefore, colleagues from Israel are currently studying 
the severity of overactive bladder symptoms after CHT and the response to standard 
treatment of overactive bladder symptoms in an observational study (NCT01955408). 
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Another disadvantage of CHT is the posterior wall thermal reaction (PWTR): the tip of 
the specially designed catheter is lying at the posterior wall of the bladder and from 
this point the heat is conducted throughout the rest of the bladder wall. The heat is 
not completely equally distributed, causing the PWTR. This can be deceiving during 
cystoscopy if one does not recognize PWTR; it is red and might look as CIS (Figure 
1). Finally, CHT with Synergo® is expensive, due to the use of the specially designed 
catheter and the heating device itself. Cost-effectiveness analyses are not (yet) done, 
but are very interesting and are very much needed. 
Although results on CHT are promising, the exact mechanism of action is still unknown. 
There are several hypotheses on this topic (25-27): one explanation is that heat increases 
the penetration of MMC into the urothelium due to increased cellular membrane 
permeability and/or increased blood supply. Secondly, hyperthermia might be directly 
cytotoxic by causing cell cycle arrest and deficiencies in repair mechanisms which leads 
to apoptosis. The third hypothesis is that hyperthermia increases cytotoxicity of MMC, 
making the drug itself more effective. And, finally, it might be that the physiological 
immune-related responses to heat (comparable to fever) also adds in the efficacy of 
CHT, but the latter has yet to be studied in bladder cancer (25-27). 
We are currently investigating the first theory of increased penetration in a study in 
which we compared MMC uptake in bladder tissue between CHT and cold MMC. 
Patients will be treated with one of both treatments before TURBT and during TURBT 
we will take biopsies of both tumor tissue and normal tissue. These tissues will then be 
analyzed and compared for their MMC concentration. Rozenberg et al. investigated 
this theory on urothelial cell in vitro and found (reversible) decreased transepithelial 
electrical resistance, a surrogate for permeability, and increased intercellular space 
after heating until 50°C (28). 
Figure 1  Posterior wall thermal reaction after treatment with Synergo® as can been seen 
during cystoscopy. Source: Radboud UMC 
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The second hypothesis (direct cytotoxic effect of CHT) was explored by our research 
group by collecting urine samples of patients treated with CHT and of patients treated 
with cold MMC (29). Urine was collected on 8-12 time points before and after each 
treatment, and was investigated on cytokine and chemokine levels. In general, the 
cytokine and chemokine levels were lower in the cold MMC group compared to the 
CHT group. Monocyte chemotactic protein-1 and interleukine 6 were significantly 
higher in the CHT group. A sub-analysis was done concerning CHT responders and 
non-responders. Responders were defined as no tumor in the pathology report after 
six CHT sessions. The analysis showed that macrophage-derived chemokine levels 
were significantly higher in the first week in the responders group compared to the 
non-responders, and thus might be useful for personalizing CHT treatment (29). 
In all, although the exact mechanism of action of CHT remains unknown, there is an 
increasing amount of evidence that there is an additional value for CHT in NMIBC, 
especially in high risk patients unwilling or unsuitable for radical cystectomy. 
Systematic reviews and meta-analyses
In Chapter III.3 we performed a systematic review and meta-analysis on CHT. The 
systematic review is a highly appreciated analysis, considered Level 1a of Evidence. 
The goal of a systematic review is to clarify and summarize the available data. If the 
collected data is sufficiently similar concerning included patients, interventions, and 
outcome measurements, one could consider to perform a meta-analysis in which 
the included studies are weighted; bigger studies have more impact on the overall 
outcome. The ideal meta-analysis is the individual patient data meta-analysis (IPDMA). 
When performing such an analysis, all available raw data is collected, validated and 
analyzed. This might cost a lot of time and money, but it is a major improvement in 
data quality and data analysis. Especially subgroup analysis is far more reliable in an 
IPDMA then in a ‘normal’ meta-analysis. 
In our meta-analysis on CHT (Chapter III.3) we did not perform a IPDMA due to lack of 
time, but it would have been a good solution to the important question which patients 
benefit most of CHT. 
Another interesting topic for an IPDMA might be the choice of the chemotherapeutic 
drug: CHT is commonly combined with MMC but some patients are or become 
allergic to MMC. In that case, in the Radboud UMC we switch to the less commonly 
used epirubicin. There are only few studies that compared epirubicin to MMC (30, 31), 
and they found comparable results concerning bladder cancer remission rates. These 
results were confirmed by Arends et al. who treated 20 patients with CHT+epirubicin 
and 140 patients with CHT+MMC and found comparable two years RFS (55% versus 
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46%, respectively, p=0.30) (32). However, the number of treated patients with epirubicin 
is small. 
New developments in device-assisted treatment for NMIBC
Another well-known device-assisted treatment for NMIBC is electromotive drug 
administration (EMDA). It is administered by a battery that delivers a controlled electric 
low voltage current, which is passed between two electrodes: the active intravesical 
electrode, which is integrated into a catheter, and the dispersive ground electrodes, 
which are placed on lower abdomen skin (33). Several clinical studies and trials have 
been done with EMDA (34-39). In summary, it is a save technique with the advantage 
of less costs for equipment and promising short-term results, but long-term results are 
not yet known and most studies were done by one research group. 
One interesting study compared sequential BCG and EMDA to BCG alone (37). The 
authors showed that the sequential treatment schedule led to better recurrence-, 
progression-, and survival outcome. One can imagine that combining two mechanisms 
of action improves outcome: BCG-induced inflammation might increase the 
permeability of the bladder wall for other drugs. This sequential schedule might, 
therefore, be interesting to investigate with other drugs, e.g. CHT and BCG. 
Results on EMDA are promising for this cohort of (high risk) patients, but studies with 
a larger amount of patients and comparison with conventional treatments (BCG or 
cystectomy) are necessary. More importantly, the current studies on EMDA do not 
address to the issue of importance: is EMDA better than BCG (maintenance)? And also 
it is not yet investigated if there might be a role for EMDA in BCG-failure patients, as 
most studies have been performed only in BCG-naïve patients. This is very different for 
CHT: numerous studies have included patients previously treated with BCG (32, 40-48), 
and the results of a phase 3 trial comparing CHT with BCG will be presented soon (24). 
New treatments for NMIBC
Recurrences occur frequent and patients experience side-effects of intravesical 
treatment. Therefore, a quest for new therapies remains and fortunately there are 
many developments ongoing to improve the treatment of NMIBC. In Chapter III.2 
we presented the results of a prospective, randomized phase 3 trial in which we 
compared MMC to KLH. KLH is a glycoprotein for a mollusk which contributes to the 
uptake, transport, and release of oxygen during respiration, but it also activates both 
the humoral and cellular immune system. In this trial, 553 patients with intermediate 
and high risk NMIBC without CIS were included. After complete TURBT and adjuvant 
treatment (either 11 instillations with MMC, or pre-immunization and 16 instillations of 
KLH) patients were followed until first recurrence. We found that KLH was inferior to 
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MMC regarding RFS (p<0.001), but KLH tended to prevent progression more effectively 
than MMC although results were not statistically significant in multivariate analyses 
(p=0.1). It seemed that the immune response of a patient treated with KLH was related 
to recurrence outcome: patients with a positive delayed-type hypersensitivity (DTH) 
response developed significantly more recurrences than patients with a negative DTH 
response. However, we do not know the exact mechanism of action of KLH. In the end, 
KLH is inferior to MMC in preventing recurrences and there is no clear advantage of 
KLH for progression outcome and, therefore, we do not recommend the use of KLH 
for patients with NMIBC. 
Most new treatments are based on schedules and/or drugs we already use, but some 
are totally different. Interesting new treatments are neoadjuvant treatment and new 
medical devices combined with existing drugs. 
Neoadjuvant chemotherapy is commonly used in many cancers, including MIBC (49). 
In NMIBC it has been used in marker lesion studies to test the toxicity and the ablative 
effect of new drugs. However, it might be interesting to further investigate neoadjuvant 
treatment, especially in the low risk patients. If the bladder is perforated during TURBT, 
the postoperative instillation should not be given as this might cause a chemical 
peritonitis, but the postoperative instillation is an essential part of the treatment for 
low risk patients. Bladder perforations and the consequences of not receiving a direct 
postoperative instillation can be avoided by giving neoadjuvant instillations, which 
therefore might be of most interest for low risk patients. 
Several studies have investigated the role of neoadjuvant treatment in NMIBC (35, 
50, 51), of which the phase 2 study by Colombo et al. is the most interesting (51): 54 
recurrent patients were divided in two groups of neoadjuvant treatment: six weekly 
instillations (group 1) versus six instillations in two weeks (intensive schedule; group 
2), both with MMC. TURBT within two weeks after completing the treatment showed 
complete pathological response in 44% in group 1 versus 70% in group 2 (p=0.04). 
After three months one patient in both groups had a recurrence. Therefore, results 
look promising, but long-term results including more patients are awaited. However, if 
the results on larger scale are comparable this could mean TURBT could be avoided in 
over half of the low risk patients.
As developing new drugs is difficult, time-consuming and very expensive, an 
alternative would be to use existing drugs and change the method of delivery, making 
it a medical device. Currently under investigation are TC-3 gel, nanotechnology and 
(adeno)viruses.
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TC-3 gel has a very interesting way of working. It is a reversible thermal degradable 
gel: it is liquid when it is cold, and it becomes a solid gel at body temperature, 
forming a drug reservoir in the bladder. Therefore, it is expected to increase treatment 
efficiency due to prolongation of treatment duration and consequently improving 
bladder exposure to MMC. Upon contact with urine the gel dissolves. TC-3 is currently 
under investigation in three studies. First, blood- and tissue levels of MMC are being 
investigated in patients who will undergo cystectomy (NCT01648010). Secondly, TC-3 
gel combined with MMC versus MMC dissolved in water in patients prior to TURBT 
to compare cystoscopic and pathological effect and to compare one year recurrence 
rates (NCT01803295). Lastly, in patients prior to TURBT three arms with different MMC 
doses in TC-3 gel are being compared to investigate differences in cystoscopic and 
pathological effect and adverse events (NCT01799499). We are eagerly awaiting the 
results, as this is a very promising new method.
Another option would be combining drugs to nanotechnology, which increases tissue 
penetration due to its small size. The combination of nanoparticles and paclitaxel 
has already proven to be of additional value in several cancers (52). The first trials 
in NMIBC have started recently: McKiernan et al. investigated nanoparticle albumin 
bound (nab-) paclitaxel in 28 patients who failed on BCG treatment (53) and results 
are quite good in this heavily pretreated group of patients: ten patients (36%) had 
complete response and all remained in complete response after one year of follow-up; 
only one of these patients underwent cystectomy during follow-up, versus seven of the 
18 non-responders. Further studies on nanoparticles and chemotherapy are awaited 
(NCT02009332). 
Also viruses can function as a vector for the delivery of drugs or targeted proteins. 
The immune system will detect the viruses as foreign invaders and will attack them 
after which its content will be released. Currently one study is ongoing for NMIBC 
(NCT02015104).
New drugs are constantly under investigation, but it is hard to get a firm position next to 
the existing drugs used in daily practice. This is a general problem in the development 
of new drugs: money is always an issue, especially considering the average time 
between creating a new drug and established use in daily practice is 10-15 years.
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BLADDER CANCER AND COSTS
Economic burden of bladder cancer
Bladder cancer remains one of the most expensive malignancies worldwide: e.g. 
the annual  costs  of  bladder cancer  in the USA in 2010 were 4 billion USD and are 
expected to rise to 5 billion USD by 2020 (54). The costs are mainly due to the 
(lifelong) surveillance with cystoscopy, TURBT, adjuvant treatment and cystectomy (55). 
Interestingly, the costs vary widely per country (56). This is due to differences in type 
of practice (peripheral or academic clinics), duration of hospitalization, methods of 
calculating costs, and billing. 
The question arises where we could reduce the costs. Interesting topics and promising 
methods are TURBT with photodynamic diagnosis (PDD), active surveillance for low 
risk tumors, and in-office fulguration. 
Three recent systematic reviews found better recurrence outcome after PDD compared 
to white light TURBT (57-59), and several articles have shown a reduction in costs 
(59, 60), which leads to the conclusion that PDD is most likely cost-effective as the 
advantage in recurrence outcome outweighs the costs. The advantage, however, is 
only seen after several years which makes the initial investments more difficult. 
Another way to lower costs in bladder cancer might be active surveillance for low risk 
bladder cancer instead of immediate resection if a (low risk) recurrence is detected. 
The goal of active surveillance is to avoid or delay the morbidity associated with 
treatment, while still allowing for curative intervention if needed. Tiu et al. conducted a 
systematic review on this topic and conclude that patients with small recurrent papillary 
tumors may not need prompt resection (61). Another advantage of active surveillance 
is prevention of recurrences by dissemination and implantation after TURBT. However, 
the best follow-up schedule and best moment of resection after active surveillance are 
not known, and some patients cannot handle the idea of having a recurrence in situ. 
Therefore, careful counseling is very important. 
TURBT could, in selected low risk patients, also be replaced by less expensive in-office 
fulguration (62-64). However, studies on this topic concern only small numbers of tumors 
with relative short follow-up. Also, fulguration is done under local anesthesiology 
which may still cause pain, and pathological evaluation is difficult due to damage to 
the tissue. Therefore, it might be optional for low risk patients only. 
As mentioned in earlier paragraphs, better quality of TURBT and following guidelines 
improves outcome and thus a good (re)TURBT and prevention of overtreatment by 
acting according to the guidelines will most likely reduce costs. Especially as several 
studies have shown that high intensity treatment in bladder cancer is associated with 
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overtreatment without an outcome advantage; it only leads to more major medical 
and surgical interventions and thus higher costs (65, 66). 
Research funding in bladder cancer
Another money issue is research funding. In the current scientific climate research is 
extremely expensive and unfortunately bladder cancer is not a hot topic; it is one of 
the most underfunded areas of cancer research (67, 68). E.g., currently only three out 
of 500 ongoing research projects of the Dutch Cancer Society (KWF kanker bestrijding) 
are bladder cancer related. 
It is unclear why research funding for bladder cancer is so difficult, but funding for other 
cancers, e.g. breast cancer, might be higher due to the organized efforts of patients 
groups and charitable organizations to raise awareness and concern about the burden 
caused by this cancer (68). There is a clear lack of awareness amongst non-urological 
scientists (69) and of coordinated advocacy between patients and urologists (70). Thus, 
we should take efforts in improving awareness of the burden of bladder cancer in both 
the public and scientists. If there is more awareness the lobbying for research funding 
will improve as well, as shown in prostate cancer research. 
CONCLUSION
There are many new and promising developments concerning risk management and 
treatment of NMIBC. However, translation into the clinical practice remains difficult 
and many promising techniques fail to get there. Lack of awareness and funding are 
part of the problem. Currently there are also too few activities to prevent NMIBC. 
The difficulty is that, due to long latency time, it takes many years to see the results 
of preventive actions. Furthermore, we should seek for practical solutions to better 
classify patients and thus prevent over- and undertreatment. This can lead to better 
outcome at patient level and to lower costs at society level. 
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SUMMARY 
Bladder cancer (BC) is the most common malignancy of the urinary tract and 
approximately 75% of BC presents as non-muscle-invasive bladder cancer (NMIBC). 
Diagnosis depends mainly on the results of cystoscopy, urinary cytology and histology. 
Treatment starts with a complete transurethral resection of the tumor (TURBT). Based 
on patient- and tumor characteristics patients can be divided in risk groups. The need 
and type of adjuvant (intravesical) treatment depends on the risk group a patient is 
allocated to. Further information on the background of BC and the outline of this 
thesis is described in Chapter I. 
The first part of this thesis is about risk management of NMIBC. The most well-
established risk factor for BC is cigarette smoking: smokers have an overall two- to 
fourfold increased risk of developing BC and approximately 60% of all BC result from 
smoking. Therefore, one could hypothesize that there might be a relationship between 
smoking status and clinical prognosis of BC. In Chapter II.1 we investigated this theory 
in 718 patients with NMIBC. All patients in this prospective trial were treated with 
complete TURBT and adjuvant intravesical treatment with epirubicin. Smoking status 
(obtained when entering the study), other prognostic variables and clinical outcome 
measures were analyzed. We found that well-known risk factors (history of recurrence 
and multiplicity) were independent predictors for predicting recurrence-free survival 
(RFS). Also smoking status was an independent predictor for RFS: ex-smokers and 
current smokers had a significantly shorter RFS compared to nonsmokers, and so we 
could confirm our hypothesis. We could not draw conclusions on progression because 
it was uncommon, the follow-up was too short and the primary outcome measurements 
were focused on recurrence instead of progression. In all, this study showed that 
smoking status is an independent predictor of recurrence in patients with NMIBC. 
NMIBC varies from low grade Ta tumors with low risk of progression and high risk 
of recurrence to high grade tumors with high malignant characteristics and thus is 
predicting clinical outcome in these patients is difficult. There are many prognostic 
models available for NMIBC, including the risk tables of the European Organization for 
Research and Treatment of Cancer (EORTC) which can be used to calculate the short-
term and long-term risks of recurrence and progression after TURBT. Another well-
known scoring model was developed by the Club Urológico Español de Tratamiento 
Oncologico (CUETO) to predict outcome after treatment specifically with Bacillus 
Calmette Guérin (BCG). In Chapter II.2 we described the development and validation 
of these models and other prognostic models for NMIBC. Despite the availability 
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of these models they are not commonly used in daily practice. This because of the 
complexity and limited usefulness in treatment decision making. In Chapter II.2 we also 
described how we could make prognostic models more useful: we should focus on the 
clinical implications of the model for the patient by focusing on relevant outcome 
measurements such as negative and positive predictive value. Furthermore, the net 
benefit of the model should be compared with the standard model(s) and the model 
should be integrated into the standard clinical workflow. 
Within NMIBC there are several difficulties to address, one of which is decision making 
for the treatment of intermediate risk (IR) patients. Treatment of these patients is more 
complex due to the heterogeneity of this group of patients, which is also reflected 
in the definition of IR patients: “All patients between the category of low and high 
risk”. In order to improve outcome in these patients we developed a prediction model 
on recurrence outcome for IR patients. Results were presented in Chapter II.3. We 
combined data from three Dutch trials and included only patients with characteristics 
conform the IR definition of the guideline of the European Association of Urology 
(EAU). All 724 patients received complete TURBT and adjuvant treatment with 
intravesical chemotherapy (either mitomycin-C [MMC] or epirubin). We identified 
five independent risk factors predicting recurrence at 1, 2, and 5 years: history of 
recurrences, history of intravesical treatment, grade 2 tumor, multiplicity and adjuvant 
treatment with epirubicin. An easy readable table for recurrence probabilities was 
developed using these five independent predictors. Three risk groups were identified: 
minor, moderate and major risk. Internal validation showed sufficient discrimination 
and good predictive accuracy of the model. The external validation, with 137 Spanish 
patients, showed good overlap. 
The second part of thesis focused on treatment of NMIBC. In Chapter III.1 we 
compared the risks according to several guidelines (EAU and American Urological 
Association [AUA]) and prediction models (EORTC, CUETO) with the real outcomes 
in a cohort of Dutch patients. We included patients treated with complete TURBT and 
adjuvant intravesical chemotherapy. Not all patients would have received intravesical 
chemotherapy had they been treated to current standards, and thus comparison of 
the observed outcomes in our Dutch cohort versus expected outcomes based on the 
guidelines and prediction models was possible. We found a large overlap between 
the observed outcomes and expected recurrence and progression probabilities 
when comparison was made using the EORTC risk tables. Concerning the CUETO 
risk classification we found that the observed recurrence outcomes were in general 
higher than the expected probabilities, especially in the long term. No differences 
in progression were found when comparing these two models to the Dutch cohort. 
Patients who were undertreated according to the guidelines showed, in general, a 
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higher risk of developing recurrence and progression. In conclusion, in this study 
we showed that the lack of adherence to existing guidelines translates into worse 
outcome. 
Despite current treatment options recurrence and progression of NMIBC remain a 
problem, and thus the need for new treatments remains. In Chapter III.2 we presented 
a prospective randomized phase 3 trial in which we compared the safety and efficacy of 
keyhole limpet hemocyanin (KLH) with MMC. KLH is a protein found in the hemolymph 
of a sea mollusk, where it acts as a non-specific immune response modifier. A total 
of 553 patients were included and treated with complete TURBT followed by either 
preimmunization and intravesical instillations with KLH or complete TURBT followed 
by intravesical instillations with MMC. Analyses showed that KLH was less effective 
than MMC concerning RFS. Progression to muscle-invasive disease tended to occur 
less after KLH than after MMC but results were not statistically significant. Side-effects 
were common but mild. To conclude, KLH had a different safety profile and was inferior 
to MMC in preventing NMIBC recurrences.
Another rather new treatment option is chemohyperthermia (CHT): microwave-
induced hyperthermia combined with intravesical MMC. In Chapter III.3 we described 
the results of a systematic review on the efficacy of CHT for NMIBC and we conducted 
several meta-analyses. In total 22 studies were available for reviewing. Combining the 
data of several of these studies in a meta-analysis showed that recurrences occurred 
59% less after CHT than after MMC alone. Overall bladder preservation rate after CHT 
was 88%. Side-effects occurred more often after CHT than after MMC alone, but the 
difference was not statistically significant. In conclusion, CHT showed promising results 
but definitive recommendations could not be defined due to the limited number of 
randomized trials and heterogeneity in study design.
Finally, in Chapter IV.1 the previous chapters in this thesis were discussed in a broader 
perspective and the future perspective on risk management and (intravesical) 
treatment of NMIBC were presented. More attention should be given to preventive 
actions, e.g. cessation of smoking, and to a better classification in order to prevent 
over- and undertreatment. This can lead to better clinical outcome for patients with 
NMIBC at lower costs. 
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SAMENVATTING
Blaaskanker (BK) is de meest voorkomende vorm van kanker van de urinewegen en 
ongeveer 75% van de BK presenteert zich als niet-spier-invasieve blaaskanker (NSIBK). 
De diagnose is vooral gebaseerd op de bevindingen van cystoscopie, urine cytologie 
en histologie. De behandeling start met een complete resectie van de blaastumor 
(CRBT). Op basis van patiënt- en tumor kenmerken worden de patiënten ingedeeld in 
bepaalde risicogroepen. De noodzaak van, en het soort nabehandeling hangt af van de 
risicogroep waar een patiënt in valt. Verdere informatie over de achtergrond van BK en 
de opbouw van deze thesis is te vinden in Hoofdstuk I. 
Het eerste deel van deze thesis gaat over risico management van NSIBK. De belangrijkste 
risicofactor voor BK is roken: rokers hebben een twee- tot viervoudige kans om BK te 
ontwikkelen en ongeveer 60% van de BK is het resultaat van roken. Er zou wellicht ook een 
relatie kunnen zijn tussen roken en de prognose van BK. In Hoofdstuk II.1 onderzochten 
we deze theorie bij 718 patiënten met NSIBK. Alle patiënten in deze prospectieve 
studie werden behandeld met een CRBT en na behandeld met blaasspoelingen met 
epirubicine. Informatie over rookgedrag (verkregen bij inclusie in de studie), andere 
prognostische factoren en klinische uitkomstmaten werden geanalyseerd. We vonden 
de bekende risicofactoren voor recidief-vrije overleving (RVO): voorgeschiedenis van 
recidieven en meerdere tumoren. Ook rookgedrag was een onafhankelijke voorspeller 
van RVO: (ex-)rokers hadden een significante kortere RVO in vergelijking met niet-
rokers en dus konden we onze hypothese bevestigen. We konden geen conclusies 
trekken over progressie naar spier-invasieve BK doordat progressie weinig voorkwam, 
de follow-up te kort was en de primaire uitkomstmaten met name gericht waren op 
recidieven en niet op progressie. Kortom, deze studie toonde aan dat rookgedrag een 
onafhankelijke voorspeller is van recidieven in patiënten met NSIBK. 
NSIBK varieert van laaggradige Ta tumoren met lage kans op progressie maar hoge 
kans op recidieven, tot hooggradige tumoren met hoge maligniteitskenmerken, en dus 
is het voorspellen van de klinische prognose bij patiënten met NSIBK moeilijk. Er zijn 
verschillende prognostische modellen beschikbaar voor NSIBK, zoals de risicotabellen 
van de European Organization for Research and Treatment of Cancer (EORTC), welke 
gebruikt kunnen worden om de korte- en lange termijn risico’s op recidief en progressie 
te berekenen. Een ander bekend model werd ontwikkeld door de Club Urológico 
Español de Tratamiento Oncologico (CUETO) en voorspelt de prognose na behandeling 
met Bacillus Calmette Guérin (BCG). In Hoofdstuk II.2 bespraken we de ontwikkeling 
en validatie van deze modellen en van andere prognostische modellen voor NSIBK. 
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Ondanks de beschikbaarheid van deze modellen worden ze maar weinig gebruikt in de 
dagelijks praktijk. Dit komt door de complexiteit en het beperkte nut bij het maken van 
beslissingen. In Hoofdstuk II.2 beschreven we ook hoe deze modellen beter bruikbaar 
te maken zijn: we moeten meer aandacht geven aan de klinische implicaties van een 
model voor de patiënt door meer nadruk te leggen op relevante uitkomstmaten zoals 
negatieve en positieve voorspellende waarde. Bovendien moet het model worden 
vergeleken met standaard modellen en moeten de modellen geïntegreerd worden in 
de standaard klinische werkpaden. 
Er zijn met betrekking tot NSIBK diverse moeilijke onderwerpen, waarvan de behandeling 
van intermediair risico (IR) patiënten er één is. De behandeling van deze patiënten is 
lastig door de heterogeniteit van deze groep. Dit is ook te zien in de definitie van de 
IR patiënten: “alle patiënten die niet tot de laag- of hoog-risicogroep behoren”. Om 
de prognose bij deze patiënten te verbeteren, ontwikkelden we een predictiemodel 
voor het voorspellen van de recidiefkans voor IR patiënten. De resultaten werden 
gepresenteerd in Hoofdstuk II.3. We combineerden data van drie Nederlandse studies 
en includeerden alleen patiënten conform de IR definitie van de Europese richtlijn. Alle 
724 patiënten kregen CRBT en nabehandeling met blaasspoelingen met mitomycine-C 
(MMC) of epirubicine. We identificeerden vijf onafhankelijke voorspellende factoren voor 
recidieven: voorgeschiedenis van recidieven, voorgeschiedenis van blaasspoelingen, 
graad 2 tumor, multipele tumoren en nabehandeling met epirubicine. Op basis van 
deze vijf factoren ontwikkelden we een gemakkelijk leesbare tabel voor recidiefkansen. 
Er werden drie risicogroepen gezien: minor, middelmatig en major. Interne validatie 
toonde voldoende discriminatie en goede voorspelbaarheid van het model. Externe 
validatie, met 137 Spaanse patiënten, toonde goede overlap. 
Het tweede deel van deze thesis gaat over de behandeling van NSIBK. In Hoofdstuk 
III.1 vergeleken we de risico’s zoals voorspeld volgens de Europese en Amerikaanse 
richtlijnen en volgens diverse modellen (EORTC, CUETO) met de echte resultaten van 
een groep Nederlandse patiënten. We includeerden patiënten die behandeld waren 
met CRBT en nabehandeling met blaasspoelingen met chemotherapie. Niet al deze 
patiënten zouden deze behandeling ontvangen hebben als de huidige standaarden 
waren opgevolgd en dus kon de geobserveerde uitkomsten van de Nederlandse 
groep vergeleken worden met de voorspelde uitkomsten op basis van de richtlijnen 
en predictie modellen. We vonden veel overlap tussen de geobserveerde uitkomsten 
en voorspelde recidief- en progressie resultaten voor wat betreft de EORTC risico 
tabellen. Voor wat betreft de CUETO risico classificatie vonden we over het algemeen 
meer recidieven in de Nederlandse groep patiënten vergeleken met de verwachte 
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uitkomsten, met name op de lange termijn. Er werden geen verschillen gezien wat 
betreft progressie. Patiënten die waren onderbehandeld ten opzichte van de richtlijnen 
hadden over het algemeen een hogere kans op het krijgen van recidieven of progressie. 
Al met al toonde deze studie aan dat afwijken van de richtlijnen wat betreft behandeling 
leidt tot slechtere klinische uitkomsten. 
Ondanks de huidige behandelingen blijven recidieven en progressie bij NSIBK 
een probleem. Daarom blijft er een noodzaak voor het ontwikkelen van nieuwe 
behandelingen. In Hoofdstuk III.2 presenteerden we een prospectieve gerandomiseerde 
fase 3 studie waarin we de veiligheid en effectiviteit van keyhole limpet hemocyanin 
(KLH) vergeleken met die van MMC. KLH is een eiwit dat gevonden kan worden in 
de lymfevaten van een zeeslak en is betrokken bij de immunologische afweer. In 
deze fase 3 studie werden 553 patiënten geïncludeerd en behandeld met een CRBT 
en nabehandeld met ofwel pre-immunisatie en blaasspoelingen met KLH, ofwel met 
blaasspoelingen met MMC. Analyses toonden dat KLH minder effectief was in het 
voorkomen van recidieven dan MMC. Progressie naar spier-invasieve BK kwam minder 
vaak voor na KLH dan na MMC maar deze resultaten waren niet statistisch significant. 
Bijwerkingen kwamen vaak voor, maar waren mild. Concluderend heeft KLH een ander 
veiligheidsprofiel dan MMC en is KLH ondergeschikt aan MMC met betrekking tot het 
voorkomen van recidieven. 
Een andere redelijk nieuwe behandeloptie is chemohyperthermie (CHT): magnetron 
geïnduceerde hyperthermie gecombineerd met blaasspoelingen met MMC. In 
Hoofdstuk III.3 beschreven we de resultaten van een systematische review over de 
effectiviteit van CHT voor NSIBK en voerden we enkele meta-analyses uit. Er waren 22 
studies beschikbaar voor de review. Na het combineren van enkele van deze studies 
in een meta-analyse bleek er een reductie in recidiefkans te zijn van 59% na CHT in 
vergelijking met MMC. Het behoud van de blaas was 88% na CHT. Er waren vaker 
bijwerkingen na CHT dan na MMC maar het verschil was niet statisch significant. Kortom, 
CHT geeft veel belovende resultaten maar we konden geen harde aanbevelingen doen 
door het beperkte aantal studies en de variaties in studieopzet. 
Tot slot bespraken we de voorgaande hoofdstukken in een breder perspectief en de 
verwachtingen aangaande risico management en behandeling van NSIBK in Hoofdstuk 
IV.1. Samengevat zou er meer aandacht moeten zijn voor preventieve acties, zoals 
stimuleren van stoppen met roken, en voor het beter classificeren van patiënten om 
over- en onderbehandeling te voorkomen. Dit kan leiden tot betere uitkomsten voor 
patiënten met NSIBK tegen lagere kosten. 
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Promoveren doe je nooit alleen, en daarom wil ik in dit veelgelezen onderdeel graag 
iedereen bedanken die in wat voor vorm dan ook heeft geholpen aan de totstandkoming 
van dit proefschrift: veel dank! 
Er zijn een aantal mensen die ik in het bijzonder wil bedanken:
Allereerst mijn promotor prof. dr. J.A. Witjes, beste Fred. Tijdens mijn wetenschappelijke 
stage vroeg jij mij of ik jouw volgende promovenda op blaaskanker wilde worden. Jouw 
reputatie als (goede) begeleider was mij al bekend en ik hoefde dus ook niet lang na 
te denken. In maart 2010 begonnen we met een gesprek wat mij altijd is bij gebleven. 
Jouw instructies over hoe onderzoek te doen waren heel helder: hulp vragen is niet 
erg als je het maar op tijd doet, er kan veel maar je houdt niet van gemiep en gejank. 
Dat heb ik altijd goed in mijn oren geknoopt en volgens mij we hebben zo een hele 
fijne en vruchtbare onderzoeksperiode afgerond, waarbij ik alle kans heb gekregen mij 
te ontwikkelen op diverse onderwerpen die ik interessant vond. Daar ben ik je heel 
dankbaar voor! Ik hoop dat we in de toekomst ook nog kunnen samenwerken. 
Dan mijn andere steun en toeverlaat: mijn copromotor dr. W.P.J Witjes, beste Wim. We 
kunnen denk ik wel stellen dat de deal om jouw studies door mij en Fred (en de andere 
co-auteurs) te laten analyseren en publiceren goed heeft uitgepakt. De feedback van 
jou (en Fred) was altijd snel en zorgvuldig, en ik kon altijd heel goed met jou sparren. 
We hebben heel wat woensdagmiddagen samen gezeten op het trialbureau om 
resultaten door te spreken en samen tot mooie publicaties te komen. Dank je wel voor 
al je (praktische) steun en tips!
De leden van de manuscript commissie, prof. dr. W.R. Gerritsen, mw. prof. dr. M.M. 
Rovers en dr. B.W.G. van Rhijn wil ik bedanken voor hun tijd en bereidheid om mijn 
proefschrift te beoordelen. 
Wie ook zeker niet mogen ontbreken in deze lijst zijn mijn paranimfen Jos Falke en Max 
Bruins. Gedurende enkele jaren waren wij met z’n drieën ‘het blaaskankerteam’ van het 
Radboud. Daarom vind ik het ook superfijn dat jullie vandaag letterlijk naast mij staan, 
zoals dat tijdens mijn onderzoeksperiode ook het geval was. 
Jos, dankzij jouw creatieve out-of-the-box mentaliteit komen er regelmatig mooie 
(onderzoeks)ideeën naar boven, en als ik vast zat dan wist jij er altijd weer een 
interessante nieuwe draai aan te geven waardoor ik weer verder kon. Dat kon praktisch 
zijn maar ook in de vorm van afleiding door geinige nieuwe muziekjes, filmpjes op 
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Dumpers of lekker eten zoals je fabuleuze erwtensoep. Dank je wel!
Max, doordat jij net als ik veel statistisch onderzoek doet, kon ik altijd advies aan jou 
vragen hierover (en andersom). Ook jouw hulp bij het formuleren van Engelse zinnen 
was erg fijn. Ook jij heel erg bedankt voor al je hulp!
Prof. J. Palou Redorta, dr. O. Rodriquez, and other colleagues from Fundacio Puigvert. 
We started working together for the prediction model on recurrence outcome for 
intermediate risk bladder cancer patients, but since then we have done much more. 
I had the opportunity to visit you and your clinic several times, and we spent time on 
both research and clinical work. The differences between the Netherlands and Spain 
are many and large, but also very interesting. Muchos gracias por toda su ayuda!
Christina Caris en Ria Janzing-Pastors van CuraTrial voor het uitzoeken van extra 
gegevens en hulp bij extra analyses, dank! 
Vooral ook dank aan dr. J.C.M. Hendriks: uw kennis van (bio)statistiek is groot en ik ben 
u dan ook zeer dankbaar voor de vele uren die u heeft geholpen!
Also thanks for your help to all the co-authors: R.Colombo, Kees Hendricksen, B.A. 
Inman, M. Laufer, I. Leibovitch, C.T. Lee, O. Nativ, and R.J. Sylvester. 
Voor mijn onderzoek heb ik ook hulp gehad van vele anderen: 
Het team urologie van het UMC Radboud. Dank voor jullie interesse in mijn onderzoek 
en de hulp bij het includeren van patiënten. In het bijzonder dank hiervoor aan Inge 
van Oort, Michiel Sedelaar en Toine van der Heijden. Ook bedankt alle mensen van de 
polikliniek Urologie in het UMC Radboud voor de ondersteunende hulp en het geduld 
om alles te plannen, en Daniëlle Zaaijer-de Jong voor het zoeken van vele statussen in 
het pre-EPD-tijdperk. 
Annieke, Wendy, Moniek en Diana, de ´blaaskankerverpleegkundigen´ en dus steun- en 
toeverlaten op de Synergo poli, dank! 
De ‘nieuwe’ blaaskanker man, Tom Arends: superleuk dat jij het werk van mij (en Jos) 
kunt voortzetten met goed resultaat. Veel succes met je eigen studies en opleiding tot 
uroloog. 
Ondanks dat mijn onderzoek met name statistiek en klinische studies betrof, had ik 
een fantastische werkplek op het lab Experimentele Urologie. Daarom ook veel dank 
aan mijn roomies: Gisèle Leyten, Jos Falke, Siebren Dijkstra, Max Bruins, Else Bijker, 
Maurits van de Meer en Guido Bastiaens. Geen roomies maar wel vaak op de kamer: 
Dick Jansen, Ruben Cremers, Stijn Muselaers, Esther Hamoen, Boy Rozenberg, en Luc 
Roelofs. Samen hebben we mooie tijden beleeft! Ik heb van alles geleerd: onderzoek 
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maar vooral veel (niet-medische) terminologie, muziekjes en filmpjes. Ik zou er een 
boek over kunnen schrijven en we hebben al een cover ;-). Dank jullie wel!
Prof. dr.J.A. Schalken, beste Jack, jij ontvangt jouw (adoptie)onderzoekers graag en 
goed, zoals alleen een Brabander dat kan. Naast relax momenten met een kopje koffie 
in de centrale ruimte op ons lab, ook andere drankjes bij café Samson of bij jou thuis. 
Veel goede tips gekregen en vooral veel gelachen, dank je wel!
Dr. E. Oosterwijk, beste Egbert, jouw kennis van enorm veel onderzoekstechnieken 
bood mij de kans een soort externe feedback te krijgen, en daar heb ik dan ook 
regelmatig gebruik van gemaakt, dank je wel!
All the colleagues and students of the laboratory Experimental Urology of Radboud 
UMC, thank you!
Alle chirurgen en (oud) collega arts-assistenten uit het Jeroen Bosch Ziekenhuis: toen 
ik vanuit het urologische onderzoek begon aan mijn chirurgie vooropleiding was het 
op zijn zachtst gezegd even wennen maar dankzij jullie hulp en steun, in het bijzonder 
Walter Brokelman en Sander Romijn, heb ik een hele leuke en leerzame tijd gehad, 
dank!
Alle urologen en collega arts-assistenten van het UMC Utrecht. Ik ben nog niet zo lang 
bij jullie van de partij, maar ik vind het heel leuk dat jullie dit moment met mij kunnen 
delen. Ik kijk uit naar een leuke en leerzame tijd bij jullie!
Alle urologen en (oud) arts-assistenten van het Jeroen Bosch Ziekenhuis: na mijn 
seniorcoschap bij jullie wist ik zeker dat ik uroloog wilde worden. Dank jullie wel voor 
deze mooie periode en jullie hulp met het solliciteren naar een opleidingsplek. Ik ben 
heel blij dat ik in 2017 weer bij jullie mag komen om mijn opleiding tot uroloog af te 
ronden!
Tot slot wil ik mijn lieve vrienden en familie bedanken voor alle steun en interesse. 
Teske, Heleen en Lonneke: wij kennen elkaar nu al ruim 10 jaar en samen hebben we 
veel geleerd en gedaan. Later kwamen daar Marnix, Sander en Tarkan bij. Dank jullie 
wel voor jullie vriendschap, steun en interesse! Dat geldt ook zeker voor Esther, Sietske, 
en Mariëlle: bedankt! 
Last but zeker not least: mijn familie, in het bijzonder mijn ouders, Erwin en Karin, 
zonder jullie onvoorwaardelijke vertrouwen in mijn kunnen en het stimuleren tot eruit 
halen wat er in zit, was ik niet gekomen waar ik nu ben. Daarnaast altijd een nuchtere 
(Achterhoekse) 'kiek' op de zaak. Dank jullie wel hiervoor! 
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Janna Marie (Rianne) Lammers was born on Queensday (30 April) 1985 and was raised 
in the village Varsseveld, in the East part of the Netherlands. After graduating from 
the Ulenhof College (VWO) in Doetinchem in 1996, Rianne started to study Medicine 
at the Radboud University Nijmegen. During her internships she developed her 
interest in urology. In the summer of 2005 she worked at the Jeroen Bosch Hospital 
in ‘s-Hertogenbosch as a senior intern (supervisors: A. de Vylder and dr. H. Beerlage). 
Afterwards she participated in research on tissue engineering of the bladder during her 
scientific internship at the department of Pediatric Urology of the Radboud University 
Nijmegen (supervisors: prof. dr. W.F.J. Feitz and dr. P.J. Geutjes). She obtained her 
medical degree in May 2010. 
After finishing her internships (March 2010), she worked for almost three years as a 
PhD-candidate at the department of Urology of the Radboud University Nijmegen, 
under supervision of prof. dr. J.A. Witjes and dr. W.P.J. Witjes. The topic of her research 
was non-muscle-invasive bladder cancer, and the results of her research are presented 
in this manuscript. During her time as a PhD-candicate Rianne also was a member of, 
and later chairwomen of, the Clinical PhD council, which represented a part of the PhD-
candidates within the Medical Department of the Radboud University. Furthermore, 
she represented the PhD-candidates of the Medical Department at the Board of the 
University. 
In January 2013 she started the Urology residency training program. From 2013 until 
2014 she worked as a residence at the department of General Surgery of the Jeroen 
Bosch Hospital in ‘s-Hertogenbosch (supervisor: dr. K. Bosscha). Currently, she is 
working at the department of Urology at the UMC Utrecht in Utrecht, under supervision 
of prof. dr. J.L.H.R. Bosch. In 2017, she will start working at the department of Urology 
at the Jeroen Bosch Hospital in ‘s-Hertogenbosch (supervisor dr. H. Beerlage), where 
she will finish the last two years of her residency. 
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